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Abstract		Tuberculosis	(TB)	remains	a	global	health	challenge	due	to	limited	understanding	of	the	complex	host	immune	 responses	 required	 for	 the	 successful	 control	 and	 eradication	 of	 invading	Mycobacterium	
tuberculosis	(M.tb)	bacilli.	To	date,	T-cells	and	macrophages	have	been	regarded	as	the	principle	immune	cells	 responsibly	 for	 protective	 anti-TB	 immunity.	 However,	 emerging	 evidence	 has	 revealed	 a	fundamental	role	of	B-lymphocytes	(B-cells)	during	M.tb	infection;	although	the	function	of	B-cells	in	TB	disease	 incidence	and	progression	remains	 ill-defined.	We	hypothesize	that	B-cells	 influence	anti-TB	immune	responses	through	modulation	of	T-cell	activation,	and	that	the	microenvironment	in	which	these	interactions	occur	greatly	impacts	immune	cell	function,	with	an	emphasis	on	B-cells.				Healthy	participants	that	were	either	pre-exposed	or	unexposed	to	M.tb	were	recruited	for	the	study.	Within	 the	 pilot	 study	 investigating	 the	 effect	 of	 B-cells	 on	 T-cell	 function:	 peripheral	 blood	 was	collected,	and	B-	or	T-cell	enriched	using	magnetic-activated	cell	sorting	(MACS)	bead	technology	for	downstream	 analysis.	 Following	 sample	 collection,	 autologous	 T-cells	 were	 co-cultured	 with	H37Rv/BCG-stimulated	B-cells,	pulsed	with	or	without	cluster	of	differentiation	40	Ligand	(CD40L)	and	interleukin-5	 (IL5).	 The	 resulting	 B-	 and	 T-cell	 phenotypic	 frequencies	 and	 cytokine	 profiles	 were	subsequently	evaluated.		To	determine	the	effect	of	the	microenvironment	complexity	on	cell	function,	peripheral	 blood	was	 collected,	 and	B-cell	 frequency	 and	 function	 (immunoglobulin	 isotype	profile)	determined	in	whole	blood,	peripheral	blood	mononuclear	cells	(PBMCs)	and	untouched,	 isolated	B-cells	following	24-hour	stimulation	with	toll-like	receptor	9	agonist	(TLR9a)	or	H37Rv.		Our	results	demonstrate	that	B-cells	are	able	to	modulate	T-cell	activation	and	function.	We	found	that	Bacillus	Calmette-Guérin	(BCG)	and	H37RV	alike	are	able	to	induce	killer/regulatory	B-cell	phenotypes	in	QuantiFERON	positive	and	negative	participants.	Furthermore,	the	microenvironment	was	found	to	have	a	substantial	effect	on	B-cell	function	with	noticeable	changes	in	B-cell	development,	shown	by	a	decrease	 in	mature	B-cell	 frequencies	 following	 cellular	 isolation.	 Likewise,	 impairment	 of	 humoral	responses,	indicated	by	hampered	ability	to	produce	certain	immunoglobulin	isotypes	in	response	to	antigenic	stimulation,	were	observed	for	isolated	B-cells.	Collectively,	these	findings	indicate	the	potential	influence	B-cells	have	in	anti-TB	immune	responses	through	modulation	of	T-cell	behaviour,	underscoring	the	role	B-cells	may	play	in	initiating	and	guiding	the	immune	response	against	M.tb.	Our	study	highlights	the	need	to	further	study	B-cells	as	therapeutic	targets	 in	 novel	 TB	 prevention	 strategies.	 Additionally,	 our	 study	 identifies	 significant	 limitations	associated	with	the	use	of	cell	isolation	studies	for	inference	of	cell	function	during	health	and	disease.	Findings	 from	 these	 studies,	 while	 informative,	 should	 be	 interpreted	 carefully,	 as	 the	 in	 vitro	microenvironment	may	have	considerably	influenced	the	observed	results.		 	
Stellenbosch University  https://scholar.sun.ac.za
 iii 
Opsomming		Tuberkulose	(TB)	bly	 'n	wêreldwye	gesondheidsuitdaging	as	gevolg	van	die	beperkte	begrip	van	die	komplekse	gasheerimmuniteits	reaksies	wat	benodig	word	vir	die	suksesvolle	beheer	en	uitwissing	van	indringer	Mycobacterium	tuberculosis	 (M.tb)	bakteriee.	Tot	op	datum	is	T-selle	en	makrofages	as	die	primêre	 immuunselle	 verantwoordelik	 vir	 beskermende	 anti-TB	 immuniteit	 beskou.	 Opkomende	bewyse	 het	 egter	 'n	 fundamentele	 rol	 van	 B-limfosiete	 (B-selle)	 tydens	M.tb	 infeksie	 geopenbaar;	alhoewel	die	funksie	van	B-selle	 in	TB-siekte	voorkoms	en	progressie	steeds	ondefinieerbaar	 is.	Ons	vermoed	dat	B-selle	anti-TB	immuunresponse	beïnvloed	deur	modulasie	van	T-sel	aktivering,	en	dat	die	mikro-omgewing	waarin	hierdie	interaksies	voorkom	grootliks	die	immuunsel	funksie	beïnvloed,	met	die	klem	op	B-selle.	Gesonde	deelnemers	wie	blootgestel	was	aan	M.tb	is	vir	die	studie	gewerf.	Binne	die	loodsstudie	wat	die	effek	van	B-selle	op	T-selfunksie	ondersoek	het,	is	perifere	bloed	ingesamel,	en	B-	of	T-sel	verryk	met	behulp	 van	magnetiese-geaktiveerde	 sel	 sortering	 (MACS)	 kraal	 tegnologie	 vir	 stroomaf	 analise.	 Na	volgende	 monsterversameling,	 is	 autoloë	 T-selle	 gekweek	 met	 H37Rv/BCG-gestimuleerde	 B-selle,	gepulseer	met	of	sonder	groepering	van	differensiasie	40	Ligand	(CD40L)	en	Interleukine-5	(IL5).	Die	gevolglike	B-	en	T-sel	fenotipiese	frekwensies	en	sitokienprofiele	is	vervolgens	geëvalueer.	Om	die	effek	van	die	mikroomgewingskompleksiteit	op	 selfunksie	 te	bepaal,	 is	perifere	bloed	 ingesamel,	 en	B-sel	frekwensie	 en	 funksie	 (immunoglobulien	 isotipe	 profiel)	 is	 bepaal	 in	 volbloed,	 perifere	bloedmononukleêre	selle	(PBMCs)	en	onaangeraakte	geïsoleerde	B-selle	na	24	-uur	stimulasie	met	tol-like	receptor	9	agonist	(TLR9a)	of	H37Rv.	Ons	resultate	 toon	dat	B-selle	T-sel	aktivering	en	 funksie	kan	moduleer.	Ons	het	bevind	dat	Bacillus	Calmette-	Guérin	(BCG)	en	H37Rv	gelyk	is	aan	regulatoriese	B-sel	fenotipes	in	QuantiFERON	positiewe	en	negatiewe	deelnemers.	Verder	is	gevind	dat	die	mikro-omgewing	'n	wesenlike	effek	op	B-selfunksie	het	 met	 merkbare	 veranderinge	 in	 B-selontwikkeling,	 getoon	 deur	 'n	 afname	 in	 volwasse	 B-sel	frekwensies	na	sellulêre	isolasie.	Net	so	is	waargeneem	vir	die	geïsoleerde	B-selle	waardedaling	van	humorale	 response,	 aangedui	deur	die	belemmerde	vermoë	om	sekere	 immunoglobulien	 isotipes	 te	produseer	in	reaksie	op	antigeen	stimulasie.	Gesamentlik	dui	hierdie	bevindinge	op	die	moontlike	invloed	wat	B-selle	in	anti-TB	immuunresponse	het	deur	modulasie	van	T-selgedrag,	wat	die	rol	wat	B-selle	kan	speel	in	die	inisiatief	en	leiding	van	die	immuunrespons	teen	M.tb	beklemtoon.	Ons	studie	beklemtoon	die	noodsaaklikheid	om	B-selle	verder	as	terapeutiese	teikens	in	nuwe	TB-voorkomingstrategieë	te	bestudeer.	Daarbenewens	identifiseer	ons	studie	beduidende	beperkings	wat	verband	hou	met	die	gebruik	van	sel	isolasie	studies	vir	inferensie	van	selfunksie	tydens	gesondheid	en	siekte.	Bevindings	uit	hierdie	studies,	terwyl	insiggewend,	moet	versigtig	 geïnterpreteer	 word,	 aangesien	 die	 in	 vitro	 mikro-omgewing	 die	 waargenome	 resultate	aansienlik	beïnvloed	het.			 	
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	In	loving	memory	of	Stanley	John	Dechristie	Kenny	
	
	
“When	great	trees	fall,	
rocks	on	distant	hills	shudder,	
lions	hunker	down	in	tall	grasses,	
and	even	elephants	lumber	after	safety.	
	
When	great	trees	fall	in	forests,	
small	things	recoil	into	silence,	
their	senses	eroded	beyond	fear.	
	
When	great	souls	die,	
the	air	around	us	becomes	light,	rare,	sterile.	
We	breathe,	briefly.	
Our	eyes,	briefly,	see	with	a	hurtful	clarity.	
Our	memory,	suddenly	sharpened,		
examines,	gnaws	on	kind	words	unsaid,		
promised	walks	never	taken.	
	
Great	souls	die	and	our	reality,	
bound	to	them,	takes	leave	of	us.	
Our	souls,	dependent	upon	their	nurture,	
now	shrink,	wizened.	
Our	minds,	formed	and	informed		
by	their	radiance,	fall	away.	
We	are	not	so	much	maddened	
as	reduced	to	the	unutterable	ignorance	
of	dark,	cold	caves.	
	
And	when	great	souls	die,	
after	a	period	peace	blooms,	
slowly	and	always	irregularly.		
Spaces	fill	with	a	kind	of	
soothing	electric	vibration.	
Our	senses,	restored,	never	
to	be	the	same,	whisper	to	us.	
They	existed.	They	existed.	
We	can	be.	Be	and	be	
better.	For	they	existed.	
	
	- Maya	Angelou	
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Chapter	1:	Introduction		In	 2017,	 tuberculosis	 (TB)	was	 ranked	 the	 ninth	 leading	 causes	 of	 death	worldwide,	 causing	more	deaths	than	human	immunodeficiency	virus/acquired	immune	deficiency	syndrome	(HIV/AIDS).	The	World	 Health	 Organization	 (WHO)	 estimated	 10.4	 million	 new	 TB	 cases	 globally	 in	 2016,	 and	 the	existence	 of	 latent	 infection	 in	 nearly	 2	 billion	 individuals	 (World	 Health	 Organization,	 2017).	 The	etiological	agent	of	TB,	is	Mycobacterium	tuberculosis	(M.tb),	a	slow	growing	organism	with	a	doubling	time	of	12-24	hours	under	optimal	conditions	(Delogu	et	al.,	2013).	 	M.tb	 typically	 infects	 the	 lungs,	resulting	in	a	disease	formally	known	as	pulmonary	TB.	However,	M.tb	can	also	affect	other	sites	such	as	 the	brain,	eye	or	 lymph	nodes,	 in	which	case	 the	 infection	 is	known	as	extra	pulmonary	TB.	M.tb	transmission	occurs	when	an	individual	with	active	pulmonary	TB	coughs	or	sneezes,	expelling	tubercle	bacilli	 in	 droplets	 into	 the	 air,	 which	 are	 inhaled	 by	 the	 host.	 In	 the	 alveoli	 of	 the	 lungs,	 alveolar	macrophages	 phagocytose	 the	 bacteria,	 of	 which	most	 are	 eliminated	 by	 the	 host’s	 innate	 immune	response.	 In	 some	 cases,	 bacilli	 survive	 this	 initial	 defense	 and	 actively	 replicate	 within	 the	macrophages,	or	disperse	to	adjacent	cells	and	eventually	organs,	causing	active	disease	and	eliciting	an	adaptive	immune	response.			An	estimated	1.3	million	TB	deaths	occurred	among	HIV-negative	individuals	and	an	additional	374	000	deaths	among	HIV-positive	individuals	in	2016	(World	Health	Organization,	2017).	The	incidence	of	TB	on	the	WHO	African	region	continent	ranks	amongst	the	highest	globally,	and	accounts	for	25%	of	the	global	 total	 of	 TB	 cases	 (World	 Health	 Organization,	 2017).	 Importantly,	 the	 WHO	 African	 region	together	with	the	WHO	South-East	region	accounted	for	85%	of	the	total	TB	deaths	in	both	HIV-positive	and	HIV-negative	individuals.	The	WHO	proposed	a	strategy	in	2015	called	the	End	TB	Strategy,	in	which	it	sets	specific	targets	to	be	met	in	order	to	achieve	a	90%	reduction	in	TB	deaths	and	an	80%	reduction	in	 TB	 incidence	 by	 2030.	 Most	 TB	 deaths	 that	 occur	 could	 be	 prevented	 with	 early	 diagnosis	 and	appropriate	 treatment.	 However,	 most	 of	 the	 high	 TB	 burden	 areas	 include	 low	 to	 middle	 income	countries	who	lack	the	resources	needed	to	adequately	achieve	this.			Studies	 have	 projected	 an	 increase	 in	 the	 prevalence	 of	 TB	 worldwide,	 particularly	 in	 developing	countries,	 due	 to	 the	 introduction	 of	 agriculture,	 civilization,	 increased	 human	 population	 density,	inadequate	and	delayed	TB	diagnosis	and	unsuccessful	TB	treatment	(Albuquerque	et	al.,	2007;	Amante	and	Ahemed,	2015;	Dooley	et	al.,	2011;	Tachfouti	et	al.,	2011).	The	probability	of	contracting	TB	disease	is	much	higher	in	individuals	with	a	compromised	immune	system,	such	as	infection	with	HIV/AIDS,	as	well	as	in	individuals	exposed	to	high	risk	factors	for	TB	infection	which	include	malnutrition,	alcohol	abuse,	diabetes,	smoking	and	indoor	air-pollution	(Ismail	and	Bulgiba,	2013;	Tachfouti	et	al.,	2011;	Thuy	et	 al.,	 2007).	 These	 risk	 factors	 and	 co-infections	 are	 very	 typical	 in	 countries,	 where	 poverty,	insufficient	infrastructure	and	inadequate	access	to	health	facilities	are	common.	Currently,	the	African	health	care	system	is	insufficient,	and	has	led	to	selection	of	enhanced	virulent	strains,	which	persist	in	low	 density	 populations,	 causing	 TB	 disease	 reactivation	 following	 long	 periods	 of	 latent	 infection	
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(Comas	et	al.,	2013;	Gandhi	et	al.,	2006;	Pillay	and	Sturm,	2007;	Van	Soolingen	et	al.,	1997).	As	such	TB	poses	a	major	health,	social	and	economic	burden	on	low	and	middle-income	countries,	such	as	South	Africa,	due	to	the	high	costs	of	medical	care	and	poor	living	conditions.		The	ultimate	goal	for	the	WHO	End	TB	Strategy	and	researchers	in	health	and	medicine	is	to	improve	the	overall	health	and	well-being	of	the	country	to	ensure	a	bright	future	(World	Health	Organization,	2017).	In	order	for	these	targets	to	be	achieved,	provisions	for	TB	treatment	and	prevention	need	to	be	made,	and	investment	into	TB	research	and	translation	of	such	research	into	clinically	relevant	outputs	is	paramount.	Improvements	to	the	current	systems	used	to	diagnose	and	treat	TB	disease	form	part	of	this	much	needed	effective	change,	and	strategies	that	aim	at	increasing	TB	preventative	treatment	in	high	 risk	 population	 groups	 and	 developing	 effective,	 less	 harmful	 and	 timely	 treatments	will	 help	facilitate	this.			Research	into	the	mechanisms	by	which	the	host	adaptive	immune	system	responds	to	infection	with	
M.tb	have	indicated	T-cells	(Kaufmann,	2002;	Lalvani	et	al.,	1998;	Orme	et	al.,	1993;	Ribeiro-Rodrigues	et	al.,	2006)		and	macrophages	(Kamath	et	al.,	1999;	Kaufmann,	2002;	Sharma	et	al.,	2007)	as	the	main	line	of	defense	against	invading	pathogens.	Further	studies	revealed	the	ability	of	B-cells	to	modulate	T-cell	activation,	as	well	as	macrophage	and	T-cell	responses	and	function	(Bénard	et	al.,	2018;	Du	Plessis	et	al.,	2016).	As	such,	B-cell	function	may	directly	affect	the	immune	response	to	T-cell	driven	protection	and	macrophage	polarization	against	M.tb,	and	ultimately	play	a	key	role	in	disease	development	and	progression.	 Importantly,	 only	 approximately	 10%	 of	 individuals	 exposed	 to	 M.tb	 develop	 active	disease,	 while	 the	 remaining	 90%	 are	 able	 to	 effectively	 contain	 the	 bacteria	 (World	 Health	Organization,	2017).	This	is	believed	to	be	due	to	a	sufficient	balance	between	effector	and	regulatory	immune	 responses	 that	 are	 able	 to	 contain	 and	 eliminated	M.tb	 before	 infection	 is	 established	 (Du	Plessis,	 et	 al.	2016).	 Studies	 investigating	 the	 presence	 of	 B-cells	 during	 TB	 disease	 have	 indicated	dysfunction	 and	 decreased	 frequencies	 of	 B-cells	 following	 M.tb	 infection	 (Joosten	 et	 al.,	 2016).	Furthermore,	the	occurrence	of	regulatory	killer	B-cells	during	TB	illustrated	the	presence	of	this	cell	type	in	moderate	frequencies	in	healthy	individuals;	however	following	infection	with	M.tb	a	significant	decrease	in	this	population	was	observed	(van	Rensburg,	et	al.	2016).	In	accordance	with	successful	TB	treatment,	these	regulatory	killer	B-cell	frequencies	were	observed	to	increase	to	levels	similar	to	that	of	healthy	controls	 -	suggesting	a	protective	role	of	 this	cell	 type	 in	TB	disease	(van	Rensburg,	et	al.	2016).	It	is	thus	hypothesized	that	the	absence	of	regulatory	killer	B-cells	may	be	vital	in	TB	disease	onset	and	progression,	as	alterations	in	this	cell	population	frequency	and	function	has	been	associated	with	TB	disease	on	numerous	occasions.	The	exact	mechanisms	by	which	 regulatory	B-cells	 (CD19+	CD24++	CD38++)	and	more	specifically	the	regulatory	killer	B-cells	subtype	(CD19+	CD38+	CD178+)	may	modulate	the	immune	response	to	TB	is	undefined.	It	is	further	suggested	that	B-cell	derived	cytokines	and	cell	surface	factors	play	a	key	role	in	eliciting	the	postulated	protective	immune	responses.			
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Interestingly,	regulatory	killer	B-cells	have	been	shown	to	express	a	cell	surface	receptor	known	as	FasL	(CD178)	(van	Rensburg,	et	al.	2016;	Lundy,	et	al.	2015),	a	surface	protein	belonging	to	death	 ligand	family.	These	death	ligands	mediate	cell	death	through	cell-cell	contact	with	immune	cells	expressing	the	 co-receptor	 Fas	 (CD95),	 causing	 in	 the	 activation	 of	 an	 intracellular	 cascade	 that	 results	 in	 cell	apoptosis;	hence	the	name	“killer”	B-cells	(Lundy,	2009).	It	is	speculated	that	these	regulatory	killer	B-cells	provide	protection	against	M.tb	 infection	by:	1)	enhancing	M.tb	killing	capacity	of	macrophages	that	have	internalized	the	bacteria	into	a	phagosome	and	2)	control	the	spread	and	survival	of	the	bacilli	by	 inducing	 apoptosis	 of	 infected	 cells,	 thought	 to	 express	 the	 Fas	 co-receptor	 as	 a	 result	 of	 cell	activation	and	stress	due	to	M.tb	infection	(Lundy,	et	al.	2002).	This	induction	of	programmed	cell	death	facilitates	the	elimination	of	cellular	reservoirs,	responsible	for	harboring	the	bacteria	and	providing	a	niche	for	their	survival.			To	date,	there	is	limited	knowledge	as	to	the	exact	role	of	immune	cell	types	previously	thought	to	have	little	importance	during	M.tb	infection.	An	example	of	such	a	cell	type	is	B-cells.	The	primary	function	of	B-cells	 is	 antibody	 production	 and	 secretion;	 due	 to	 the	 intracellular	 nature	 of	 the	 pathogen,	many	researchers	believed	that	these	effector	cells	would	have	minimal	impact	on	the	survival	of	M.tb	and	thus	focused	their	efforts	elsewhere.	Studies	have	subsequently	identified	several	functions	of	B-cells	other	than	antibody	secretion,	including	antigen	presentation,	complement	activation	and	regulation	of	cellular	activation	and	function	of	additional	cells	types	via	cytokine	secretion	and	cell-cell	interactions	(Du	Plessis,	et	al.	2016;	Bénard,	et	al.	2017).	As	such,	the	purpose	of	this	project	was	to	investigate	the	modulatory	 effects	 of	 B-cells,	 whose	 role	 within	 TB	 disease	 incidence	 and	 progression	 remains	incompletely	defined.	Reports	have	suggested	a	clinically	relevant	role	of	regulatory	B-cells,	at	the	early	stages	 of	M.tb	 infection	 and	 have	 implied	 active	 interaction	with	T-cells	 and	macrophages	 -	 in	 turn	influencing	disease	outcome	(Rao,	et	al.	2015).	We	hypothesize	that	B-cells	have	the	ability	to	regulate	T-cell	 function,	 and	 that	 B-cell	 phenotype	 plays	 a	 key	 role	 in	 this	 interaction.	 Additionally,	 we	hypothesize	that	microenvironment	complexity	may	be	a	modulator	of	B-cell	population	distribution	and	could	contribute	to	B-cell	phenotype	and	function,	thereby	impacting	which	functional	markers	or	cell	surface	factors	are	expressed.			Accordingly,	 this	 research	 project	 aimed	 to	 study	 the	 interaction	 between	 B-	 and	 T-cells	 and	 the	resulting	effects	of	this	intercommunication	on	T-cell	function	in	order	to	understand	the	important	role	B-cells	may	play	in	the	immune	response	to	M.tb.	Apart	from	establishing	the	interaction	of	isolated	B-	and	T-cells	in	the	context	of	TB,	concerns	with	the	translation	of	the	observed	isolated	B-cell	response	to	events	in	whole	blood	and	in	vivo	remains.	As	such,	the	response	of	B-cells	to	a	particular	stimulus	in	various	compartments	of	isolation	(e.g.	whole	blood,	PBMC	fraction	and	pure	B-cells)	was	investigated	to	determine	whether	 in	 vitro	 study	observations,	made	 from	 cellular	 responses	within	 an	 artificial	microenvironment,	represent	viable	events	within	the	body.	Should	the	observed	responses	of	isolated	B-cells	prove	homogenous	to	those	within	whole	blood	ex	vivo,	identification	of	the	relevant	abundance	
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of	different	functional	immune	cell	subsets	during	various	stages	of	M.tb	infection/exposure	may	prove	useful	for	diagnosis,	disease	progression	and	treatment	monitoring.			To	achieve	our	aims,	we	evaluated	the	effect	of	M.tb	exposed	B-cells	on	the	T-cell	population	distribution	and	cytokine	secretion	by	assessing	the	cell	surface	receptor	expression	and	cytokine	production	of	T-cells	 using	 flow	 cytometry	 following	 stimulation.	 Different	 populations	 of	 cells	 can	 be	 readily	distinguished	by	 the	 expression	 of	 a	 unique	 combination	 of	 intracellular	molecules	 and	 cell	 surface	membrane	 receptors.	 As	 previously	 described,	 T-cells	 are	 regarded	 as	 the	 primary	 immune	 cells	responsible	 for	TB	disease	management,	as	such	modulation	of	 the	 function	of	 these	cells	may	have	direct	 implications	 on	 TB	 susceptibility.	 Many	 T-cell	 populations	 have	 been	 implicated	 in	 anti-TB	responses,	each	having	varied	effects	on	the	overall	outcome	of	infection.	Investigation	as	to	which	T-cell	population	M.tb	exposed	B-cells	induce	will	provide	insight	into	how	these	cells	contribute	to	the	host	defence	in	combating	M.tb	infection.	Additionally,	we	determined	the	effects	of	microenvironment	complexity	on	B-cell	function	by	stimulating	various	sample	fractions	obtained	throughout	isolation	of	B-cells	 from	whole	 blood.	 The	 cell	 surface	 receptor	 expression	 of	 B-cells	 in	 each	 fraction	was	 then	determined	using	flow	cytometry	and	the	type	and	magnitude	of	immunoglobulin	induced	and	secreted	under	each	condition	evaluated	using	multiplex	cytokine	analysis.			Targeting	of	B-cells	to	modulate	anti-TB	T-cell	responses	could	be	a	promising	host-based	treatment	strategy	to	combat	M.tb	infection	and	TB	disease,	should	B-cells	prove	efficient	in	directing	the	immune	response	 to	M.tb.	This	potential	prevention	 therapy	or	TB	 treatment	 strategy	may	confer	additional	protective	 immunity,	 resulting	 in	 better	 prognosis	 and	 successful	 treatment	 outcome;	 thereby	contributing	to	the	attainment	of	the	WHO	End	TB	Strategic	plan	(World	Health	Organization,	2017).	
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Chapter	2:				The	work	presented	in	this	chapter	has	been	formatted	in	the	style	of	Immunotherapy	journal	to	which	it	was	submitted	for	publication.			 	
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Abstract	The	role	of	B-cells	in	immunogenic	responses	has	become	increasingly	important	over	the	past	decade,	focusing	on	a	new	B-cell	subtype:	regulatory	B	(Breg)	cells.	These	Breg	cells	have	been	shown	to	possess	potent	immunosuppressive	activities	and	have	identified	as	key	players	in	disease	control	and	immune	tolerance.	 In	 this	 review	 the	 occurrence	 of	 this	 cell	 type	 in	 various	 conditions,	 along	with	 evidence	supporting	 discovered	 functions	 and	 proposed	 purposes	 will	 be	 explored.	 An	 example	 of	 such	regulatory	functions	includes	the	induction	or	suppression	of	various	T-cell	phenotypes	in	response	to	a	particular	stimulus.	Should	Breg	cells	prove	effective	in	mediating	immune	responses,	and	correlate	with	favourable	disease	outcome,	they	may	serve	as	a	novel	therapeutic	to	combat	disease	and	prevent	infection.	However,	the	induction,	functioning	and	stability	of	these	cells	remains	unclear	and	further	investigation	is	needed	to	better	understand	their	role	and	therapeutic	efficacy.	
	
1. Background	Immunity	refers	to	the	ability	of	an	organism	to	withstand	disease	and	is	conferred	by	cells,	tissues	and	molecules	 of	 the	 immune	 system	 (Paul,	 2013).	 These	 elements	 mediate	 illness	 by	 coordinating	 an	immune	response	to	prevent	disease	and	eradicate	established	infections.	The	importance	of	immunity	is	illustrated	by	individuals	with	compromised	immune	systems,	in	which	defective	immune	response	results	in	diminished	health	and	increased	susceptibility	to	life	threatening	conditions	(Lundy,	2009).	An	immune	response	occurs	when	infiltrating	foreign	microorganisms	are	encountered	by	immune	cells	within	 the	 body.	 Recognition	 of	 these	 foreign	 bodies	 by	 circulating	 immune	 cells	 results	 in	 their	subsequent	activation	and	initiation	of	a	cascade	of	events	to	control	infection	and	confer	protection	against	disease.		The	immune	system	can	be	divided	up	into	two	parts,	namely	innate	and	adaptive	immunity.	 Innate	immunity,	also	known	as	naïve	immunity	due	to	the	fact	that	it	is	encoded	within	the	genome	and	is	always	present,	provides	the	first	 line	of	defense	against	 invading	pathogens.	 It	 functions	to	prevent	entry	of	microbes	and	 facilitate	 rapid	elimination	of	microbes	 that	have	successfully	enter	 the	body	(Zabriskie,	2009).	Adaptive	immunity,	also	known	as	acquired	or	specific	immunity,	is	the	long-lasting	second	 line	 of	 defense	 that	 requires	 stimulation	 and	differentiation	 to	 activate	 and	 combat	 disease.	Adaptive	 immunity	 is	 less	 rapid	 in	 initial	 encounter	 of	 foreign	 substances,	 however	 once	 adaptive	immune	 cells	 have	 encountered	 a	 particular	 organism,	 they	 ‘remember’	 this	 organism	 through	development	of	memory	cells	which	remain	in	circulation	to	enable	faster	response	in	the	event	of	re-infection	(Abbas	et	al.,	2014).			Adaptive	immunity	can	be	further	divided	into	two	subsections,	namely	cell-mediated	immunity	and	humoral	immunity,	based	on	the	cell	types	and	molecules	they	produce	in	respond	to	invading	microbes.	Cell-mediated	immunity	is	facilitated	by	a	collection	of	cells	known	as	T	lymphocytes	(T-cells).	The	main	
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functions	 of	 these	 cells	 include	 elimination	 of	 intracellular	 microbes	 and	 stimulation	 of	 additional	immune	cells	to	combat	infection	(Abbas	et	al.,	2014;	Zabriskie,	2009).	Humoral	immunity	is	mediated	by	proteins	known	as	antibodies,	derived	from	B-lymphocytes	(B-cells).	These	antibodies	act	to	block	infection,	neutralise	foreign	substances	within	the	body,	activate	innate	immune	responses	(such	as	the	complement	system)	and	eliminate	microbes	(Capra	et	al.,	1999;	Slifka	et	al.,	1998).		Conventionally,	 B-cells	 have	 been	 regarded	 as	 positive	 regulators	 of	 the	 immune	 response	 and	 key	contributors	to	disease	pathology,	based	on	their	ability	to	produce	antibodies	(Abbas	et	al.,	2014;	Mauri	and	Bosma,	2012).	This	review	aims	to	consolidate	current	knowledge	of	effector	B-cell	 functioning,	with	newly	discovered	and	prospective	 functional	 roles	of	B-cells,	 in	order	 to	elucidate	 their	 role	 in	autoimmune	disease,	cancer	and	infection.	Understanding	how	and	why	these	effector	B-cells	mediate	the	 immune	 response	 by	 influencing	 the	 functioning	 of	 other	 immune	 cells,	 will	 better	 enable	researchers	to	harness	their	therapeutic	potential.		
	
2. B-cell	origin	and	development		B-lymphocytes	arise	from	a	stem	cell,	the	common	lymphoid	precursor,	within	the	bone	marrow	(Paul,	2013).	Immature	B-cells	go	through	a	process	of	selection	in	which	self-reactive	cells	are	destroyed.	B-cells	that	pass	the	selection	criteria	enter	into	circulation	and	peripheral	lymphoid	organs,	where	they	encounter	and	respond	to	foreign	antigens	(Abbas	et	al.,	2014;	Pier	et	al.,	2004).	When	naïve	B-cells	encounter	and	recognize	foreign	microbes,	antigen-specific	lymphocytes	are	activated,	proliferate	and	differentiate	into	effector	and	memory	cells	(Rosser	and	Mauri,	2015).	These	effector	cells	perform	key	immune	functions	that	prevent	infection	and	eliminate	microbes.	The	precise	phenotype,	and	in	turn	function,	of	these	effector	cells	depends	on	the	stimulus	encountered	and	the	surrounding	environment	(Baba	et	al.,	2015).		Over	 the	 past	 decade,	 a	 variety	 of	 newly	 discovered	 B	 subsets	 have	 arisen,	 collectively	 known	 as	regulatory	B-cells	 (Bregs)	 (Daien	et	 al.,	 2014;	Rosser	and	Mauri,	2015;	Shao	et	 al.,	 2014;	Siewe	et	al.,	2013).	Bregs	are	 immunosuppressive	cells	responsible	for	 immune	tolerance	and	modulation	through	the	expression	of	various	cytokines,	such	as	interleukin-10	(IL-10)	and	IL-35,	as	well	as	the	expression	of	 various	 cell	 surface	markers	 (Carter	 et	 al.,	 2012;	 Liu	 et	 al.,	 2016;	Matsumoto	 et	 al.,	 2014;	 Nova-Lamperti	 et	 al.,	 2016;	 Shen	 et	 al.,	 2014;	Wang	 et	 al.,	 2014).	 This	 Breg	 population	 is	 further	 divided,	depending	on	the	phenotype	of	the	cell,	the	molecules	secreted	and	the	predicted	function.	The	exact	origin	of	these	Bregs	are	still	unclear,	although	many	researchers	have	identified	pathways,	such	as	the	phosphoinositide	 3-kinase	 (PI3K)	 (Cantley,	 2002;	 Jellusova	 and	 Rickert,	 2016)	 and	 Bruton	 tyrosine	kinase	(BTK)	or	B-cell	receptor		(BCR)	pathway	(Petro	et	al.,	2000;	Takata	and	Kurosaki,	1996),	essential	for	the	development	and	functioning	of	these	cells.	As	such,	further	investigation	is	needed	to	determine	the	exact	molecular	changes	that	occur,	in	order	to	fully	characterise	these	cells.			
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It	was	initially	postulated	that	Bregs	originated	following	the	expression	of	a	Breg	-specific	lineage	factor	(Rosser	and	Mauri,	2015).	However,	this	theory	gives	little	explanation	as	to	observed	heterogenicity	of	phenotypes	within	 this	population.	Additionally,	 no	 study	 to	date	has	been	 successful	 in	 identifying	unique	transcription	factors	needed	for	Breg	development	(van	de	Veen	et	al.,	2013).	An	alternative,	and	widely	accepted	theory	states	that	under	certain	environmental	conditions,	this	regulatory	phenotype	can	be	induced	in	circulating	B-cell	of	any	type	(memory,	effector,	plasma)	(Matsumoto	et	al.,	2014;	Shen	et	 al.,	 2014).	 This	 alternative	 hypothesis	 supports	 the	 large	 phenotypic	 variance	 observed	 when	comparing	 Breg	 cell	 subsets	 from	 various	 immunological	 disorders.	 The	 observed	 plasticity	 of	 Breg	phenotypes	is	believed	to	arise	due	to	varying	environmental	conditions,	as	well	as	differential	time	of	stimulation	 (Mauri	 and	 Bosma,	 2012;	 van	 Rensburg	 et	 al.,	 2017).	 According	 to	 numerous	 studies,	inflammatory	 signals	 are	 essential	 for	Breg	 differentiation,	 and	different	 inflammatory	 environments	induce	distinct	Breg	populations	(Carter	et	al.,	2011,	2012;	Evans	et	al.,	2007;	Mizoguchi	et	al.,	2002).	Additionally,	Matsumoto	and	colleagues	(2014)	implicated	the	lymph	nodes,	in	addition	to	the	spleen,	as	 locations	 for	 Breg	 maturation,	 supporting	 the	 second	 theory	 of	 Breg	 development	 in	 which	 any	immature	B-cell	can	be	induced	into	a	regulatory	phenotype	(Matsumoto	et	al.,	2014).			Activation	of	naïve	B-cells	occurs	through	binding	of	microbial	antigens	in	circulation,	or	presented	by	CD4+	helper	T-cells/antigen	presenting	cells	(APCs),	to	the	B-cell	receptor	(Petro	et	al.,	2000;	Rao	et	al.,	2015;	 Takata	 and	 Kurosaki,	 1996).	 Importantly,	 in	 order	 for	 activation	 of	 B-cells	 to	 occur,	 a	costimulatory	signal	is	required.	This	takes	place	by	a	variety	of	surface	receptors,	including	Toll-like	receptors	 (TLRs),	 CD40	 and	 CD138	 (Mauri	 and	 Bosma,	 2012;	 Rosser	 and	Mauri,	 2015).	 Numerous	publications	 have	 indicated	 environmental	 stimuli	 required	 to	 introduce	 Breg	 development,	 namely	CD40L,	IL5,	TLR9	agonist	CpG	and	LPS	(Lundy	et	al.,	2015;	van	Rensburg	et	al.,	2017;	Rosser	and	Mauri,	2015;	Van	Rensburg	et	al.,	2017)	(see	Figure	2.1).	A	study	by	Lundy	and	Boros	(2002)	illustrated	the	induction	of	a	Breg	subset	in	response	to	schistosomal	infection	(Lundy	and	Boros,	2002).	Importantly,	induction	of	this	Breg	population,	in	response	to	schistosomal	egg	antigents	(SEA),	was	dependant	on	the	presence	 of	 IL-10	 and	 IL-4	 (Lundy	 and	Boros,	 2002).	 Furthermore,	 a	 study	 by	 Shao	 and	 colleagues	(2014)	 illustrated	 the	 importance	 of	 CD40	 in	 the	 differentiation	 of	 Bregs	 (Shao	 et	 al.,	 2014).	 This	highlights	the	necessity	of	co-stimulation	in	the	activation	and	differentiation	of	Bregs	(Abbas	et	al.,	2014;	Paul,	2013).	Additionally,	killer	Breg	functioning	was	found	to	be	dependent	on	CD4+	T-cell-derived	IL-10,	creating	a	negative	feedback	loop	to	reduce	apoptosis	following	down	modulation	once	decreased	inflammation	is	achieved	(Lundy	and	Boros,	2002).	 Inhibitors	also	play	a	key	role	 in	modulating	the	functioning	of	B-cells,	in	which	substances	such	as	BTK	inhibitors	(Advani	et	al.,	2013),	NF-κB	inhibitors	(Wu	et	al.,	1996)	and	Stat3	inhibitors	(Zhang	et	al.,	2016)	have	been	found	to	impact	B-cell	activation,	differentiation	 and	 functioning.	 Investigation	 into	 the	 effect	 these	 inhibitors	 have	 on	 immune	modulation	by	B-cells	has	provided	great	insight	into	molecular	pathways	essential	to	their	functioning.			 	
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Figure	2.1.	Proposed	Developmental	Pathways	for	regulatory	B	(Breg)	Cell	Differentiation.	During	 development,	 immature	 B-cells	 can	 be	 activated	 by	 a	 variety	 of	 stimuli,	 depending	 on	 the	microenvironment	to	which	they	are	exposed.	After	activation,	immature	B-cells	can	differentiate	into	either	 regulatory	 B-cells	 (Bregs)	 or	 mature	 B-cells.	 It	 is	 probable	 that	 these	 Bregs	 can	 mature	 into	multifunctional	immune	cells,	in	which	they	are	able	to	secrete	antibodies,	as	well	as	produce	regulatory	cytokines	and	perform	B-cell	effector	functions	such	as	antigen	presentation.	In	accordance	with	the	large	heterogenicity	found	in	the	Breg	population,	it	is	postulated	that	Bregs	can	also	differentiate	from	mature	B-cells	with	during	or	after	terminal	effector	function	differentiation.	Adapted	from	(Rosser	and	Mauri,	2015)			 	
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3. Functional	role	of	B-cell	subsets	The	commonly	known	effector	cells	in	the	B-lymphocyte	lineage	are	antibody-producing	cells,	known	as	plasma	cells	(Abbas	et	al.,	2014;	Capra	et	al.,	1999;	Paul,	2013;	Pier	et	al.,	2004).	These	plasma	cells	secrete	 antibodies	 during	 and	 long	 after	 infection	 to	 confer	 protection	 against	 infiltrating	microbes	(Slifka	et	al.,	1998).	Antibodies	are	able	to	bind	a	wide	variety	of	targets	with	a	complementary	epitope,	depending	on	their	class,	and	mediate	their	effector	functions	(Abbas	et	al.,	2014;	Slifka	et	al.,	1998;	van	de	Veen	et	al.,	2013).	These	include	opsonization	of	bacterial	cells,	neutralization	of	secreted	bacterial	proteins	and	antibody-dependant	cellular	toxicity	(Achkar	et	al.,	2015;	Rao	et	al.,	2015).	Naïve	B-cells	express	either	membrane	bound	IgM	or	IgD.	Upon	activation	these	effector	cells	are	able	to	undergo	a	process	known	as	 isotype	switching	 in	which	they	are	able	 to	produce	antibodies	with	other	heavy-chain	classes	(Abbas	et	al.,	2014;	Paul,	2013;	Pier	et	al.,	2004).			Over	the	past	two	decades,	researchers	have	attributed	several	additional	functions	of	effector	B-cells	apart	 from	 antibody	 production.	 These	 include	 opsonization,	 complement	 activation,	 antigen	presentation,	cytokine	production	and	most	recently	suppressive	capacity	(Abbas	et	al.,	2014;	Du	Plessis	et	al.,	2016;	Mauri	and	Bosma,	2012;	Rao	et	al.,	2015;	Rosser	and	Mauri,	2015;	Zabriskie,	2009).		Antigen	presentation	by	B-cells	occurs	via	the	MHC	class	II	pathway	which	is	recognised	and	bound	by	antigen-specific	CD4+	T-cells,	 resulting	 in	 the	 induction	of	effective	T-cell	 immune	responses	during	disease,	contributing	to	early	protection	(Abbas	et	al.,	2014;	Capra	et	al.,	1999;	Paul,	2013;	Pier	et	al.,	2004;	Rao	et	al.,	2015).	The	suppressive	activity	of	B-cells	has	been	attributed	to	a	variety	of	molecules,	found	to	modulate	immune	responses	and	immune	cell	frequencies	(Blair	et	al.,	2010;	Carter	et	al.,	2012;	Liu	et	al.,	 2016;	 Lundy,	 2009;	 Lundy	 et	 al.,	 2015;	Matsumoto	 et	 al.,	 2014;	Nova-Lamperti	 et	 al.,	 2016;	 van	Rensburg	et	al.,	2017;	Shen	et	al.,	2014;	Wang	et	al.,	2014).	 	The	relevance	of	this	recently	attributed	function	will	be	discussed	in	more	detail	below.	Depicted	in	the	table	2.1	is	a	list	of	Bregs	markers	that	have	been	identified	in	literature,	as	well	as	their	proposed	and/or	documented	function(s).		
4. Evidence	for	the	modulation	of	immune	responses	by	B-cell	during	disease	The	 importance	 of	 B-cells	 have	 been	 shown	 in	 numerous	 diseases,	 such	 as	 rheumatoid	 arthritis	(Edwards	and	Cambridge,	2006;	Hirano	et	al.,	1988),	cancer	(Berntsson	et	al.,	2016;	Lee-Chang	et	al.,	2013;	Lundgren	et	al.,	2016;	Mor	et	al.,	2000;	Ou	et	al.,	2015;	Shao	et	al.,	2014;	Tadmor	et	al.,	2011;	Zhou	et	 al.,	 2014)	 ,	 systemic	 lupus	 erythematosus	 (Blair	 et	 al.,	 2010),	 inflammatory	 bowel	 syndrome	(Defendenti	et	al.,	2011)	and	others,	in	which	absence	or	impaired	functioning	of	these	immune	cells	has	 been	 associated	 with	 immune	 complications	 and	 poor	 prognosis.	 Studies	 investigating	 the	dysfunction	and	decreased	frequencies	of	IL-10	producing	B-cells	have	implicated	their	significant	role	in	immune	balance	within	the	body	(Carter	et	al.,	2012;	Liu	et	al.,	2016;	Matsumoto	et	al.,	2014;	Nova-Lamperti	et	al.,	2016).	Numerous	murine	models	involving	IL-10	deficient	B-cells	illustrated	a	skewed	proinflammatory	response,	by	an	increase	in	Th17	and	Th1	responses,	and	a	decrease	in	Treg		
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Table	 2.1.	 Regulatory	 B-cell	 (Breg)	 subsets	 and	 their	 proposed	 functions.	 Depicted	 is	 a	comprehensive	list	of	the	phenotypic	descriptions	used	within	current	literature	to	describe	regulatory	B-cell	subsets,	along	with	the	suggested	immune	function	of	these	cell	populations.	 	
Breg	Marker	 Phenotype	 Proposed	Function	 Reference	
CD138,	IgM	 CD19+CD24hi	CD38hi	CD138+	IgM+	 Plasma	Breg	 (Lundy	and	Boros,	2002;	Mauri	and	Bosma,	2012;	Shen	et	al.,	2014;	Van	Rensburg	et	al.,	2017)	
CD27	 CD19+	 CD24hi	CD27+	 Memory	Breg	 (Mauri	and	Bosma,	2012)	
IL-10	 CD19+	 CD24hi	CD38hi	IL10+	 Decrease	Th1/Th17;	increase	Treg	
(Carter	 et	 al.,	 2012;	 Flores-Borja	 et	al.,	 2013;	 Lundy,	 2009;	 Nova-Lamperti	et	al.,	2016;	van	Rensburg	et	al.,	2017)	
FasL	(CD178)	 CD19+	 CD24hi	CD38hi	CD178+	CD5+	 Induction	of	T-cell	apoptosis	 via	binding	to	Fas	
(Lundy,	 2009;	 Lundy	 and	 Boros,	2002;	Lundy	and	Fox,	2009;	Lundy	et	al.,	 2015;	 Mor	 et	 al.,	 2000;	 van	Rensburg	 and	 Loxton,	 2018a;	 van	Rensburg	et	al.,	2017)	
IL-35	 CD19+	 CD24hi	CD38hi	IL35+	
Decrease	Th1/Th17;	increase	 Treg	immune	cells	
(Mauri	and	Bosma,	2012;	Shen	et	al.,	2014;	Wang	et	al.,	2014)	
TGF-B	 CD19+	 CD24hi	CD38hi	TGF-b+	 Induction	of	Tregs	 4,	12,	13,	17(Carter	et	al.,	2012;	Liu	et	al.,	2016;	Lundy	et	al.,	2015;	Mauri	and	Bosma,	2012;	Rosser	and	Mauri,	2015;	Tadmor	et	al.,	2011)	
Stat3	 CD19+	CD5+	IL10+	 Induction	of	Tregs	 (Evans	 et	 al.,	 2007;	 Zhang	 et	 al.,	2016)	
TNFa	 	 Induction	 of	 IL-10	producing	Bregs	 (Carter	et	al.,	2012;	Lundy	and	Boros,	2002;	 Sedger	 et	 al.,	 2002;	 Van	Rensburg	et	al.,	2017)	
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development	(Carter	et	al.,	2012;	Lee-Chang	et	al.,	2013;	Liu	et	al.,	2016;	Nova-Lamperti	et	al.,	2016).	The	requirement	of	Bregs	in	immunosuppressive	activities	and	immune	modulation	is	further	illustrated	in	work	by	Wang	and	colleagues	(2014),	who	stated	that	Bregs	negatively	regulate	monocyte	cytokine	production	 through	 IL-10	 dependant	mechanisms	 (Wang	 et	 al.,	 2014).	 These	 findings	 illustrate	 the	capacity	of	B-cells	 in	controlling	regulatory	hierarchy,	there	by	controlling	the	 immune	responses	to	maintain	homeostasis	(see	Figure	2.2).	This	balance	between	immune	suppression	and	activation	is	key	in	preventing	autoimmunity	and	maintaining	immune	tolerance	(Abbas	et	al.,	2014;	Carter	et	al.,	2012;	Evans	et	al.,	2007;	Mauri	and	Bosma,	2012;	Rao	et	al.,	2015).		Additional	studies	have	identified	a	Breg	phenotype	commonly	referred	to	as	killer	Bregs	(Lundy,	2009;	Lundy	and	Boros,	2002;	Lundy	et	al.,	2015;	Mor	et	al.,	2000;	van	Rensburg	et	al.,	2017;	Van	Rensburg	et	al.,	2017).	These	killer	Bregs	express	death-inducing	 ligand	Fas	 ligand	(FasL),	known	to	 induce	apoptosis	of	activated	CD4+	T-cells	(Lundy	et	al.,	2015;	 van	 Rensburg	 et	 al.,	 2017).	 It	 is	 believed	 that	 these	 cells	mediate	 inflammation	 and	 immune	responsiveness	through	Fas-mediated	mechanisms	(Lundy,	2009;	Lundy	and	Boros,	2002;	Lundy	et	al.,	2015).		
	
4.1	B-cells	in	cancer	An	 example	 of	 the	 importance	 of	 immune	 balance	 has	 been	 illustrated	 in	 multiple	 tumor	 studies	(Berntsson	et	al.,	2016;	Lee-Chang	et	al.,	2013;	Lundgren	et	al.,	2016;	Mor	et	al.,	2000;	Shao	et	al.,	2014;	Tadmor	et	al.,	2011;	Zhou	et	al.,	2014),	in	which	an	increase	in	Breg	cells	frequency	corresponds	to	poor	disease	 outcome.	 During	 these	 investigations,	 Bregs	 were	 found	 to	 suppress	 anti-tumor	 activity	 of	pathogenic	immune	cells,	resulting	in	tumor	growth	and	metastasis	(Berntsson	et	al.,	2016;	Lee-Chang	et	al.,	2013;	Lundgren	et	al.,	2016;	Ou	et	al.,	2015;	Schwartz	et	al.,	2016;	Tadmor	et	al.,	2011)	.	In	such	cases,	 suppression	 of	 the	 immune	 system	 is	 disadvantageous	 and	 ultimately	 contributes	 to	 disease	pathology.	Studies	have	found	a	significant	positive	correlation	between	Treg	(CD4+	CD25+	CD127low)	and	MDSC	 (CD14+	 HLA-DR-)	 frequencies	 with	 Breg	 (CD19+	 CD24hi	 CD38hi	 IL10+)	 frequencies	 in	 cancer	patients	 (Carter	 et	 al.,	 2012;	 Flores-Borja	 et	 al.,	 2013;	 Liu	 et	 al.,	 2016;	 Nova-Lamperti	 et	 al.,	 2016;	Schwartz	et	al.,	2016).	Various	investigations	proposed	that	these	tumor-evoked	Bregs	(tBres)	induce	a	TGF-β-dependant	conversion	of	FoxP3+	regulatory	T-cells	(Tregs)	from	non-Treg	CD4+	cells	(Flores-Borja	et	al.,	2013;	Kessel	et	al.,	2012;	Liu	et	al.,	2016),	which	suppressing	anti-tumor	activity	of	CD8+	T-cells	and	NK	cells,	in	turn	protect	cancer	cells	(Kessel	et	al.,	2012;	Lee-Chang	et	al.,	2013;	Rao	et	al.,	2015).	Studies	have	also	identified	the	occurrence	of	killer	Bregs	in	various	cancer	models	(Lundy	et	al.,	2015;	Mor	et	al.,	2000).	In	these	models,	killer	Bregs	promote	tumor	survival	and	suppress	anti-tumor	activities	through	 Fas-dependant	 mechanisms,	 to	 induce	 apoptosis	 of	 activated	 CD4+	 T-cells,	 preventing	activation	and	functioning	of	cytotoxic	T-cells.	 In	certain	cancer	cases,	anti-CD20	antibody	treatment	results	 in	 depletion	 of	 CD20+	 B-cells,	 impeding	 primary	 tumour	metastasize,	 facilitating	 favourable	prognosis	 (Lee-Chang	 et	 al.,	 2013;	 Schwartz	 et	 al.,	 2016b).	 However,	 in	 other	 instances	 anti-CD20	antibody	treatment	has	been	found	to	enrich	CD20-	tBregs	which	are	potent	anti-tumor	effector	cells,		
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Figure	2.2.	Functional	Properties	of	 regulatory	B-cells	 (Bregs).	Through	 the	expression	of	various	cell	surface	markers	and	soluble	factors,	Breg	cells	are	capable	of	modulating	the	differentiation	and	function	of	several	immune	cells,	including	monocytes,	dendritic	cells	and	T-cells.	The	influence	of	Breg	 cells	 on	 other	 immune	 cells,	 and	 in	 turn	 the	 effect	 of	 the	 elicited	 response,	 depends	 on	 the	environment	in	which	they	are	found.	As	such,	Breg	occurrence	could	be	beneficial	or	detrimental	to	the	overall	outcome	of	a	condition.		Adapted	from	(Rosser	and	Mauri,	2015)		 	
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leading	to	enhanced	tumor	growth	and	metastasis	(Lee-Chang	et	al.,	2013).	To	date,	no	simple	or	specific	method	exists	 to	 inactivate	Bregs.	Although,	 some	promise	has	been	 shown	with	 various	 compounds	including	resveratrol	(RSV)	(Lee-Chang	et	al.,	2013;	Wang	et	al.,	2017),		ibrutinib	(Advani	et	al.,	2013;	Castillo	et	al.,	2016)	and	Idelalisib	(Brown	et	al.,	2014;	Lannutti	et	al.,	2011).	Low,	noncytotoxic	doses	of	RSV	have	been	shown	to	inactivate	Stat3	phosphorylation	and	acetylation,	a	constitutively	expressed	pathway	involved	in	TGF-β	generation,	and	thus	tBreg	functioning	(Lee-Chang	et	al.,	2013).	Idelalisib	is	a	potent	inhibitor	of	the	PI3K	pathway,	which	has	been	shown	to	be	vital	for	proper	B-cell	activation	and	functioning	 (Lannutti	 et	 al.,	 2011).	 Zhang	 and	 colleagues	 (2016)	 also	 showed	 a	 strong	 positive	correlation	between	CD5+	CD19+	cells	with	Stat3	expression	levels	in	patients	with	lung	and	prostate	cancer	(Zhang	et	al.,	2016).	In	a	study	by	Chang,	C.L.	and	colleagues	(2013),	RSV-treated	mice	were	found	to	have	significantly	 lower	 tBreg	and	Tregs,	and	 that	 their	 tBregs	had	 lost	all	 suppressive	activity,	when	compared	to	untreated	mice	(Lee-Chang	et	al.,	2013).	RSV	relieved	the	immunosuppressive	effects	of	tBregs	 by	 blocking	 the	 generation	 of	 Tregs,	 providing	 evidence	 of	 the	 relevance	 of	 Bregs	 in	 immune	regulation	and	disease	outcome	(Wang	et	al.,	2017).		
4.2	B-cells	in	autoimmunity	Breg	cells	have	also	been	shown	to	play	key	roles	in	autoimmunity	(Edwards	and	Cambridge,	2006;	Firl	et	al.,	2017;	Lundy	et	al.,	2015;	Matsumoto	et	al.,	2014;	Wang	et	al.,	2014),	in	which	deficiency	of	IL-10	producing	Bregs	have	been	associated	with	autoimmunity	(Liu	et	al.,	2016;	Mauri	and	Bosma,	2012;	Mauri	and	Menon,	2015;	Ray	and	Dittel,	2017).	It	has	been	suggested	that	these	cells	mediate	their	effector	function	via	passive	or	active	immune	suppressive	mechanisms	(Lundy,	2009).	During	passive	immune	suppression,	 deactivation	 or	 decreased	 functioning	 of	 effector	 cells	 is	 observed,	 including	 cytokine	withdrawal,	 antigen	 clearance	 and	 T-cell	 anergy	 (Lundy,	 2009).	 It	 is	 speculated	 that	 Bregs	 suppress	autoimmune	pathogenic	T-cell	activity	through	antigen-specific	MHCII	mechanisms	(Lundy	et	al.,	2015).		In	 contrast,	 active	 immune	 suppression	 involves	 cytokine	 secretion	or	 activation-induced	 cell	 death	(AICD)	(Alderson	and	Lynch,	1998;	Anel	et	al.,	2007;	Sharpe	et	al.,	2007).	Increasing	amounts	of	evidence	support	the	hypothesis	of	AICD	as	a	mechanism	by	which	Bregs	inflict	their	suppressive	activity	(Sedger	et	al.,	2002;	Takahashi	et	al.,	1994).	The	occurrence	of	killer	Bregs	has	been	shown	in	an	autoimmune	model,	following	stimulation	with	LPS	or	PMA/ionomycin	(Lundy	and	Boros,	2002;	Lundy	et	al.,	2015;	Mauri	and	Bosma,	2012;	Van	Rensburg	et	al.,	2017).	Importantly,	studies	investigating	the	role	of	B-cells	in	 autoimmunity	 have	 focused	mainly	 on	 IL-10	 production	 (Carter	 et	 al.,	 2011;	 Lundy	 et	 al.,	 2015;	Matsumoto	et	al.,	2014;	Mauri	and	Bosma,	2012),	and	not	FasL	expression.	Adoptive	transfer	of	killer	Bregs	 from	 FasL-deficient	 mice	 have	 been	 shown	 to	 induce	 immune	 tolerance,	 providing	 probable	evidence	of	key	FasL	mechanisms	needed	(Lundy	et	al.,	2015).	Mixed	results	have	been	shown	regarding	B-cell-deficiency	models,	 in	which	 the	presence	of	Bregs	during	disease	have	conflicting	outcomes.	 In	some	cases,	Breg	frequencies	were	associated	with	decreased	inflammatory	conditions	and	favourable	disease	 outcome	 (Carter	 et	 al.,	 2012;	 Lundy	 and	 Fox,	 2009;	 Lundy	 et	 al.,	 2005);	 while	 other	 cases	
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indicated	 an	 exacerbated	 disease	 condition,	 correlating	 with	 Breg	 frequencies	 (Daien	 et	 al.,	 2014;	Johansson	et	al.,	2001;	Matsushita	et	al.,	2008;	Svensson	et	al.,	1998).		In	some	instances,	self-reactive	B-cells	are	believed	 to	revert	 to	a	 regulatory	phenotype	 in	an	attempt	 to	eliminate	or	 inactivate	other	autoreactive	cells,	conferring	protection	against	autoimmunity	(Lundy	et	al.,	2015).	Alternatively,	self-reactive	B-cells	 could	 contribute	 to	 inflammation	 and	 autoimmunity	 by	 chronic	 humoral	 responses,	thereby	contributing	to	immune	pathology	(Carter	et	al.,	2011;	Johansson	et	al.,	2001).	This	potentially	harmful	 self-reactive	 B-cell	 responses	 could	 account	 for	 instances	where	 B-cell	 depletion	 results	 in	better	disease	prognosis.		
	
4.3	B-cells	in	transplantation	Following	transplantation,	innate	immune	cells	distinguish	between	self	and	donor	antigens,	resulting	in	immune	stimulation	(Abbas	et	al.,	2014;	Capra	et	al.,	1999;	Zabriskie,	2009).	As	expected,	T-cells	are	mainly	responsible	for	allograft	rejection	(Firl	et	al.,	2017;	Ingulli,	2010).	However,	in	order	for	these	T-cells	to	function,	they	require	activation	from	other	immune	cells	(Benichou	and	Thomson,	2009;	Felix	and	Allen,	2007;	Ng	et	al.,	2010).	B-cells	are	responsible	for	allopeptide	presentation	to	T-cells,	providing	co-stimulation	essential	for	activation	and	differentiation	of	memory	T-cells	(Bharat	and	Mohanakumar,	2007;	Leddon	and	Sant,	2010).	As	such	alloresponsiveness	is	dependent	on	this	B--T-cell	 interaction	(Benichou	and	Thomson,	2009;	Ng	et	al.,	2010;	Vongwiwatana	et	al.,	2003;	Whitmire	et	al.,	2009).	A	study	by	Firl	and	colleagues	(2017)	showed	that	B-cell	depletion	correlated	with	 increased	allograft	rejection	due	to	increased	alloreactivity	(Firl	et	al.,	2017).	During	chronic	inflammation,	Bregs	skew	T-cells	development	to	a	regulatory	phenotype	(Tregs)	and	maintain	this	population	to	 impose	 immune	tolerance	(Adams	and	Newell,	2012;	Bharat	and	Mohanakumar,	2007;	Matsumoto	et	al.,	2014;	Rosser	and	Mauri,	2015).	Therefore,	Bregs	could	promote	tolerance	of	mismatched	MHC	transplants	by	inducing	Tregs	suppression	and	inflammatory	alloreactivity	(Adams	and	Newell,	2012;	Chesneau	et	al.,	2013;	Firl	et	al.,	2017;	Flores-Borja	et	al.,	2013;	Vongwiwatana	et	al.,	2003).	Another	theory	is	the	induction	of	apoptosis	 of	 self-reactive	 T-cells	 by	 killer	 Bregs	 (Alderson	 and	 Lynch,	 1998;	 Sharpe	 et	 al.,	 2007).	Importantly,	B-cells	do	not	always	foster	tolerance;	In	acute	and	chronic	allograft	rejection,	plasma	cells	secrete	donor-specific	antibodies	responsible	 for	complement	 fixation	and	antibody-dependanT-cell-mediated	cytotoxicity,	resulting	in	allograft	rejection	(Adams	and	Newell,	2012;	Chesneau	et	al.,	2013;	Matsumoto	 et	 al.,	 2014,	 2014;	 Ray	 and	 Dittel,	 2017).	 Henceforth,	 understanding	 the	 complex	mechanisms	involved	in	alloresponses,	and	conditions	needed	to	induce	regulatory	B-cell	phenotypes	to	increase	immune	tolerance,	are	key	to	achieving	beneficial	outcomes	in	transplantation	procedures.		
4.4	B-cells	during	infectious	disease	Inflammation	is	the	primary	immune	response	to	infection,	resulting	in	effective	pathogenic	clearance	and	activation	of	the	wound	healing	cascade	(Abbas	et	al.,	2014;	Medzhitov,	2008).	Innate	effector	B-cells	have	been	shown	to	promote	Th1	and	Th17	development	 through	B-effector	1	(Be-1)	cytokine	
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production	(e.g.	IFN-γ),	important	for	antimicrobial	immune	responses	(Baba	et	al.,	2015;	Du	Plessis	et	al.,	2016;	Lundy	and	Boros,	2002;	Mauri	and	Bosma,	2012).	However	if	unresolved	could	result	in	injury	to	the	host	(Rao	et	al.,	2015;	Rosser	and	Mauri,	2015).	As	such,	anti-inflammatory	regulatory	mediators,	such	as	Bregs,	are	needed	to	suppress	the	immune	response,	via	production	of	Be-2	cytokines	(e.g.	IL-4)	and	prevent	tissue	damage	by	subverting	the	Th1	and	Th17	response	(Achkar	et	al.,	2015;	Carter	et	al.,	2012;	Kessel	et	al.,	2012;	Shen	et	al.,	2014).	A	study	by	van	Rensburg	and	colleagues	(2017)	investigated	the	role	of	B-cells	 in	the	context	of	Mycobacterium	tuberculosis	 infection	(van	Rensburg	et	al.,	2017).	Stimulation	 of	 isolated	 B-cells	 with	 BCG,	 and	 co-stimulatory	 molecules	 (CD40L),	 resulted	 in	 the	induction	 of	 Bregs	 expressing	 FasL	 (unpublished	 results).	 Additionally,	 van	 Rensburg	 and	 colleagues	(2017)	detected	the	induction	of	Bregs,	expressing		FasL,	following	successful	anti-tuberculosis	treatment	(van	Rensburg	et	al.,	2017;	Van	Rensburg	et	al.,	2017).	In	these	studies,	higher	phenotypic	frequencies	of	FasL+	IL5RA+	CD40+	PD-1+	CD38+	Bregs	cells,	although	not	significant,	were	found	in	healthy	controls	compared	 to	 TB	 patients	 (van	Rensburg	 et	 al.,	 2017;	 Van	Rensburg	 et	 al.,	 2017).	 Following	 anti-TB	treatment,	phenotypic	expression	levels	of	these	markers	increased.			Gene	 expression	 analysis	 revealed	 significant	 increases	 in	 FasL,	 CD19,	 APRIL	 and	 IL5RA	 31(Van	Rensburg	et	al.,	2017),	while	cytokine	expression	analysis	revealed	significant	increases	in	sFasL	levels	(Du	Plessis	et	al.,	2016;	van	Rensburg	et	al.,	2017),	following	anti-TB	treatment.	This	implies	that	an	increase	in	B-cell	activation	(killer	Breg	activity)	during	TB	disease	corresponds	to	reversion	towards	a	healthy	state.	A	study	by	Lundy	and	colleagues	(2015)	illustrated	that	T-cell	surface	expression	of	FasL	represents	just	a	fraction	of	the	total	FasL	protein	produced	by	activated	killer	Bregs	(Lundy	et	al.,	2015).	These	 findings	 explain	 the	 variations	 of	 significance	 in	 van	 Rensburg	 and	 colleagues’	 investigation.	Collectively,	these	results	suggest	that	the	killer	Breg	cell	population	are	crucial	in	the	immune	response	and	confer	a	protective	role	during	infection.	According	to	Rao	and	colleagues	(2015),	this	suggested	protection	 is	as	a	 result	of	B-cell-induced	apoptosis	of	Mtb	 reservoirs,	decreasing	 the	bacterial	 load,	associated	cytokine	profiles	and	interaction	with	T-cells	during	disease	(Rao	et	al.,	2015).	These	results	are	 in	 agreement	 with	 others	 involving	 parasitic	 infection	 (e.g.	 schistisomal	 infection)	 in	 which	 an	increase	 in	 the	killer	Breg	 subset,	 response	 to	SEA	exposure,	was	 found	to	correlate	with	CD4+	T-cell	apoptosis,	decreased	granuloma	size	and	better	treatment	outcome	(Lundy	and	Boros,	2002;	Lundy	et	al.,	2015).	Interestingly,	B-cells	from	uninfected	mice,	exposed	to	SEA,	showed	potent	killing	functioning,	while	B-cells	from	infected	mice	showed	enhanced	killing	capacity,	indicating	that	primed	B-cells	have	heightened	FasL	expression	and	advanced	function	(Lundy	and	Boros,	2002).	Comprehensively,	results	for	 each	 of	 the	 studies	 suggest	 that	 killer	 Bregs	may	 possess	 a	 constitutive	 effector	 function	 in	 non-diseased	conditions,	linking	with	van	Rensburg	and	colleagues’	findings	that	increased	Breg	frequencies	in	 infected	patients	corresponds	 to	a	healthy	state.	Nevertheless,	Breg	presence	during	disease	 is	not	always	favourable.	To	date,	a	limited	number	of	studies	have	focused	on	the	immunomodulatory	role	of	Bregs	 in	 intracellular	 infection.	 Investigation	 of	 Breg	 function	 during	HIV	 infection	 has	 associated	Breg	
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functioning	 with	 immune	 dysfunction	 and	 poor	 disease	 outcome	 (Siewe	 et	 al.,	 2013).	 Accordingly,	further	research	is	required	in	order	to	characterize	the	role	of	these	killer	Bregs	in	disease.		
5. Future	Advances	Current	literature	indicates	vast	functional	roles	of	B-cells	in	immune	modulation,	in	which	evidence	of	the	regulatory	role	of	B-cells	has	been	shown	in	numerous	diseases.	However,	in	order	to	fully	elucidate	the	role	of	these	Bregs,	additional	functional	and	transcriptional	studies	are	required	to	uncover	the	basic	operation	of	 these	cells	and	how	they	elicit	 their	control.	Remarkably,	Lundy	and	colleagues	 (2015)	investigated	 the	potential	 uses	of	 killer	Bregs	 in	mediating	peripheral	 immune	 tolerance	 through	 the	induction	and	use	of	killer	Breg-derived	FasL	expressing	exosomes	(Lundy	et	al.,	2015).	Self-reacting	B-cells	have	been	shown	to	express	FasL	(Firl	et	al.,	2017),	 thus	 it	 is	hypothesized	that	 these	cells	can	synthesize	and	secrete	FasL	expressing	exosomes,	with	 incorporated	MHC	II	self-Ag	presentation,	 to	induce	 apoptosis	 of	 other	 self-reactive	 cells	 throughout	 the	 body,	 implementing	 immune	 tolerance	(Alderson	and	Lynch,	1998;	Firl	et	al.,	2017;	Sharpe	et	al.,	2007).	Currently,	cellular	immunity	mediated	by	adoptive	transfer	of	regulatory	lymphocytes	is	used	to	treat	autoimmunity	and	allergic	responses,	however	this	procedure	has	many	drawbacks	(Chesneau	et	al.,	2013;	Firl	et	al.,	2017;	Leddon	and	Sant,	2010;	Lundy	and	Boros,	2002;	Shen	et	al.,	2014).			A	newly	developed,	robust	method	for	experimentally	producing	human	B-cell	derived	FasL+	MHCII+	exosomes	provides	therapeutic	potential	for	patient-customized	treatment,	with	many	benefits	and	far	less	shortcomings	(Lundy	et	al.,	2015).	However,	investigation	into	the	safety	and	efficacy	of	this	method	remains	unknown.	Studies	 involving	various	stimuli	and	 inhibitors	have	begun	uncovering	essential	pathways	needed	for	Breg	generation	and	functioning	(Advani	et	al.,	2013;	Brown	et	al.,	2014;	Lannutti	et	al.,	2011;	Lee-Chang	et	al.,	2013;	Takata	and	Kurosaki,	1996),	however	these	only	touch	the	surface	with	regards	to	the	mechanisms	Bregs	employ.	The	relative	importance	of	each	molecule	expressed	or	secreted	by	Bregs	 in	 immune	modulation	would	enable	better	understanding	of	potential	 interactions	with	other	immune	cells.	Determination	of	the	contribution	of	each	cell	subset,	 in	this	case	Bregs,	and	their	 impact	 on	disease	occurrence	 and	progression	 could	have	vast	 implications	 for	 future	 vaccine	development	and	treatment	regimens	(Du	Plessis	et	al.,	2016;	Lundy,	2009;	Van	Rensburg	et	al.,	2017).	Moreover,	 identification	 of	 a	 unique	 Breg	 cell-surface	 marker	 could	 permit	 its	 potential	 use	 as	 a	biomarker,	to	diagnose	disease	occurrence	and	monitor	treatment	response	to	treatment.	The	potential	of	Bregs	remains	infinite,	while	our	knowledge	is	limiting.	
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Chapter	3:				The	work	presented	in	this	chapter	has	been	formatted	in	the	style	of	PLoS	ONE	journal	to	which	it	was	submitted	for	publication	and	is	currently	under	review.			 	
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Abstract	This	article	describes	the	procedures	used	to	isolate	pure	B-cell	populations	from	whole	blood	using	various	Miltenyi	magnetic-activated	cell	sorting	(MACS)	bead	Isolation	kits.	Such	populations	are	vital	for	studies	investigating	the	functional	capacity	of	B-cells,	as	the	presence	of	other	cell	types	may	have	indirect	 effects	 on	 B-cell	 function	 through	 cell-cell	 interactions	 or	 by	 secretion	 of	 several	 soluble	molecules.	 B-cells	 can	be	 isolated	by	 two	main	 approaches:	 1)	Negative	 selection	 -	 in	which	B-cells	remain	 “untouched”	 in	 their	 native	 state;	 this	 is	 advantageous	 as	 it	 is	 likely	 that	 B-cells	 remain	functionally	unaltered	by	this	process.	2)	Positive	selection	–	in	which	B-cells	are	labelled	and	actively	removed	 from	the	sample.	We	used	 three	Negative	B-cell	 isolation	kits	as	well	as	 the	Positive	B-cell	isolation	 kit	 from	 Miltenyi	 and	 compared	 the	 purity	 of	 each	 of	 the	 resulting	 B-cells	 fractions.	Contamination	of	isolated	B-cell	fractions	with	platelets	was	the	conclusive	finding	for	all	of	the	isolation	techniques	tested.	These	results	illustrate	the	inefficiency	of	current	available	MACS	B-cell	isolation	kits	to	produce	pure	B-cell	populations,	from	which	concrete	findings	can	be	made.	As	such	we	suggest	cell	sorting	as	the	preferred	method	for	isolating	pure	B-cells	to	be	used	for	downstream	functional	assays.		
1. Background	The	 immune	 system	 consists	 of	 a	 collection	 of	 cell	 types	 responsible	 for	maintaining	 our	 health	 by	fighting	off	infection,	eradicating	foreign	materials	and	battling	disease	(Abbas	et	al.,	2014;	Capra	et	al.,	1999;	Lundy,	2009;	Slifka	et	al.,	1998;	Zabriskie,	2009).	B-lymphocytes	(B-cells),	an	immune	cell	type	that	 forms	part	of	 the	adaptive	 immune	response,	 contribute	 fundamentally	 to	 the	balance	between	health	and	disease.	B-cells	perform	a	multitude	of	effector	 functions,	 including	antigen	presentation,	antibody	production,	cytokine	secretion,	opsonization,	complement	activation	and	immune	modulation	(Abbas	et	al.,	2014;	Capra	et	al.,	1999;	Du	Plessis	et	al.,	2016b;	Mauri	and	Bosma,	2012;	Paul,	2013;	Pier	et	al.,	2004;	Rao	et	al.,	2015;	Rosser	and	Mauri,	2015;	Zabriskie,	2009).		The	activation	state	of	B-cells	influences	the	effect	they	have	on	the	immune	response	and	ultimately	determines	whether	or	not	their	presence	is	beneficial	or	harmful	to	the	host.			B-cells	 interact	 directly	with	 other	 immunes	 cells,	 such	 as	macrophages,	 T-cells	 and	 dendritic	 cells,	through	 receptor-mediated	 mechanisms	 as	 well	 as	 indirectly	 through	 the	 secretion	 of	 various	molecules.	For	instance,	B-cells	present	a	captured	antigen	via	major	histocompatibility	complex	(MHC)	to	a	T-cell	clone	within	a	secondary	lymphoid	organ	resulting	in	cellular	activation,	clonal	expansion	and	elicitation	of	an	immune	response.	This	is	an	example	of	cell-contact	immune	modulation.	Moreover,	B-cells	 may	 enhance	 the	 function	 of	 already	 activated	 immune	 cells	 through	 indirect	 means.	 For	example,	 antibody	 secretion	 by	 plasma	 cells	 (differentiated	 effector	 B-cells)	 enables	 microbe	opsonization	which	targets	foreign	material	for	phagocytosis	by	circulating	macrophages	by	increasing	binding	affinity	and	uptake	by	endocytosis.			
Stellenbosch University  https://scholar.sun.ac.za
 36 
Similarly,	B-cell	function	is	influenced	by	the	presence	and	interaction	with	other	cells	types.	Several	studies	have	illustrated	the	necessity		of	co-stimulation	by	other	cell	types	via	MHC	presentation,	co-receptor	engagement	and	cytokine	encounter	 for	B-cell	activation	and	differentiation	(Breloer	et	al.,	2007;	Cazac	and	Roes,	2000;	Chambers	and	Allison,	1997;	Chen	and	Flies,	2013;	Elgueta	et	al.,	2009;	Jang	et	al.,	2015;	Kretschmer	et	al.,	2007;	McKenzie	et	al.,	1993;	Müller	et	al.,	1991;	Takatsu,	1997).		An	example	of	receptor-mediated	mechanisms	that	influence	B-cell	function	is	the	CD40-CD40L	interaction	that	occurs	between	B-cells	and	T-cells,	required	for	cellular	maturation	and	survival	(Chambers	and	Allison,	1997;	Chen	and	Flies,	2013;	Elgueta	et	al.,	2009).	Additionally,	cytokines	such	as	interleukin-	2,4,	6,	21,	transforming-growth	factor	beta	(TGF-b)	and	interferons	(IFNs)	(Cazac	and	Roes,	2000;	Chen	and	Flies,	2013;	McKenzie	et	al.,	1993;	Sowa	et	al.,	2009;	Takatsu,	1997)	produced	by	activated	immune	cells	bind	to	various	receptors	on	the	B-cell	surface,	such	as	the	B-cell	receptor,	CD21,	membrane-bound	immunoglobulin	and	toll-like	receptors	(TLRs),	initiating	intracellular	signalling	pathways	that	regulate	B-cell	 differentiation	 and	 activation.	 Dysregulation	 or	 impaired	 function	 of	 B-cells	 can	 result	 in	detrimental	consequences	for	the	host;	therefore,	studies	investigating	the	behavior	of	B-cells	and	their	contribution	to	observed	immune	response	are	of	great	importance.		The	study	of	human	B-cell	populations	for	functional	and/or	mechanistic	purposes	are	best	performed	in	the	absence	of	other	cell	types.	The	presence	of	these	other	cell	types	may	alter	B-cell	function,	either	through	direct	contact	or	 indirectly	by	the	production	and	secretion	of	soluble	factors	 like	cytokines	(Igaz	et	al.,	2001;	McKenzie	et	al.,	1993;	Wrenshall	et	al.,	1999).	B-cells	constitute	roughly	10-20%	of	the	total	lymphocytes	population	within	whole	blood	(Autissier	et	al.,	2010;	Corkum	et	al.,	2015;	Kleiveland,	2015),	as	such	studies	on	whole	blood,	or	isolated	peripheral	blood	mononuclear	cells	(PBMCs)	are	not	suitable	 for	 investigating	 in-depth	 B-cell	 specific	 function.	 It	 is	 thus	 important	 to	 validate	 isolation	procedures	that	are	used	to	obtain	these	desirable	pure	B-cell	populations,	as	they	ultimately	determine	the	reliability	and	accuracy	of	such	studies.			Currently,	a	range	of	B-cell	isolation	kits	from	various	companies	are	available.	Miltenyi	B-cell	isolation	kits	 are	 among	 the	most	popular	 to	be	used	 for	 obtaining	pure	B-cell	 populations	 from	human	 (Du	Plessis	et	al.,	2016;	 Joosten	et	al.,	2016;	Lundy	and	Boros,	2002;	Qiu	et	al.,	2016;	van	Rensburg	and	Loxton,	2018;	Xu	et	al.,	2008;	Yanaba	et	al.,	2008;	Yoshizaki	et	al.,	2012)	and	animal	samples	(Jang	et	al.,	2015;	Martinez-Martin	et	al.,	2017;	Tsui	et	al.,	2018;	Yanaba	et	al.,	2008).	As	such,	a	large	proportion	of	the	 research	 currently	 inferring	 conclusions	 regarding	B-cell	 function	 rely	heavily	on	 the	efficacy	of	these	kits	to	isolate	B-cells	from	whole	blood.	This	paper	reviews	the	ability	of	various	B-cell	isolation	kits	available	from	Miltenyi	to	isolate	pure	B-cell	populations	from	human	blood,	based	on	the	purity	of	the	obtained	sample	fractions.	
	
	 	
Stellenbosch University  https://scholar.sun.ac.za
 37 
2. Methods	2.1	Participant	Recruitment	and	Sample	collection/preparation	Ethical	approval	was	obtained	from	the	ethics	committee	of	Stellenbosch	University	(N16/05/070)	and	the	City	of	Cape	Town	City	Health.	The	study	was	conducted	according	to	the	Helsinki	Declaration	and	International	 Conference	 of	 Harmonisation	 guidelines.	 For	 this	 study,	 we	 recruited	 27	 healthy	individuals.	On	several	occasions,	varying	amounts	of	peripheral	blood	was	collected	in	Sodium	Heparin	tubes	and	processed	as	described	below.	Each	blood	draw,	and	subsequent	cell	isolation	procedure,	was	recorded	as	a	separate	event	(amounting	to	a	total	of	68	cell	isolation	procedures).	Written	informed	consent	was	obtained	from	all	study	participants.	
	2.2	Isolation	of	peripheral	blood	mononuclear	cells	(PBMC)	from	whole	blood	In	 this	 section,	 the	 various	 protocols	 amendments	 used	 to	 isolate	 B-cells	 from	 whole	 blood	 are	described.	It	should	be	noted	that	Miltenyi	 isolation	kits	used	to	obtain	enriched	pure	B	populations	required	a	pre-isolation	of	PBMCs	from	whole	blood.	As	such	the	protocol	for	PBMC	isolation	refers	to	the	initial	processing	of	blood	samples,	before	the	use	of	either	of	the	Miltenyi	isolation	kits.			
2.2.1	Isolation	of	mononuclear	cells	from	peripheral	blood	using	the	Ficoll-density	Gradient	method	
Materials	9mL	Sodium	Heparin	(NaHep)	tubes	(Lasec)	 	 	 Disposable	Pipettes	Phosphate-buffered	saline	(PBS;	Lonza)		 	 	 Trypan	Blue	(Sigma)	50mL	Falcon	centrifugation	tubes		 	 	 	 Heamocytometer	Ficoll-Histoplaque	Plus	Media	(GE	Healthcare)	 	 Microscope	Centrifuge	Note:	Unless	otherwise	notes,	performed	all	steps	in	biosafety	cabinet	under	sterile	conditions.	
Methods	1. Collect	peripheral	blood	from	donor	in	NaHep	tubes	–	This	step	is	done	by	a	professional	healthcare	worker	in	a	medical	examination	room.	Blood	was	processed	within	two	hours	of	blood	draw.	2. In	50mL	Falcon	tube,	add	15mL	of	Ficoll-Histoplaque	Plus	media	3. In	separate	50mL	Flacon	tube,	dilute	peripheral	blood	in	1:1	ratio	with	PBS	(to	a	max	volume	of	35mL)	4. Gently	layer	the	diluted	blood	from	step	3	onto	the	Ficoll	from	step	2	5. Centrifuge	at	400xg	for	25	min	at	room	temperature	with	the	accelerator	and	brake	off.		6. Use	a	sterile	Pasteur	pipette	to	carefully	remove	the	upper	plasma	layer.	In	a	circular	motion,	collect	the	opaque	PBMC	band	at	the	Ficoll	interface	and	transfer	into	a	new	50mL	Falcon	tube	7. Wash	the	PBMCs	twice	in	50mL	of	PBS,	centrifuge	at	400xg	for	10	min	at	room	temperature	with	the	brake	and	accelerator	set	to	max.	8. Count	the	cells	to	determine	cell	number	and	viability.	
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2.2.2	Additions	and	Alterations	to	PBMC	isolation	protocol	
A.	Addition	of	Platelet	wash	step	to	PBMC	isolation	procedure	The	alteration	steps	listed	replace	step	7	in	the	PBMC	isolation	method	described	in	section	1	above.	This	was	done	to	decrease	the	debris/platelet	population	found	in	the	PBMC	sample.	This	was	done	by	altering	the	speed	at	which	the	isolated	PBMC’s	were	washed,	in	an	attempt	to	prevent	pelleting	and	retention	 of	 the	 platelets	 during	 the	 washing	 steps.	 It	 is	 assumed	 that	 the	 degree	 of	 platelet	contamination	within	the	PBMC	fraction	is	likely	to	affect	the	purity	of	the	isolated	B-cell	fraction,	and	thus	 should	 be	 limited.	 Three	 different	 approaches	 were	 used,	 each	 tested	 in	 a	 separate	 set	 of	experiments	multiple	times	by	various	lab	technicians:		1. Wash	the	PBMCs	twice	in	50mL	of	PBS,	centrifuge	at	300xg	for	10	min	at	room	temperature	2. Wash	the	PBMCs	twice	in	50mL	of	PBS,	centrifuge	at	200xg	for	10	min	at	room	temperature	3. Wash	the	PBMCs	twice	in	50mL	of	PBS,	centrifuge	at	120xg	for	15	min	at	room	temperature		2.3	Isolation	of	B-cells	from	mononuclear	cells	using	the	Miltenyi	B-cell	Isolation	kits	Miltenyi	 isolation	 kits	 are	 based	 on	 a	 simple	 process,	 in	which	 biotin	 conjugated	 antibody-labelled	mononuclear	cells	are	separated	from	unlabeled	cells	via	a	column	in	the	presence	of	a	magnetic	field.	During	negative	selection,	the	cell	type	of	interest	(in	this	case	B-cells)	remains	unlabeled/“untouched”	and	in	its	native	state,	while	the	remaining	unwanted	mononuclear	cells	(in	this	case	T-cells,	NK	cells	and	monocytes)	are	targeted	via	biotin	labelled-antibodies	specific	for	cell	surface	receptor(s)	of	those	cell	types.	During	positive	selection,	the	cell	type	of	interest	(in	this	case	B-cells)	are	specifically	targeted,	labelled	and	actively	magnetically	removed	from	the	sample	by	retention	in	the	column	in	the	presence	of	a	magnetic	field.	These	cells	are	then	retrieved	by	plunging	the	column	in	the	absence	of	a	magnetic	field.			
2.3.1	Isolation	of	B-cells	from	mononuclear	cells	by	negative	selection	using	the	Miltenyi	B-cell	Isolation	kit	
II	
Materials	Miltenyi	B-cell	Isolation	Kit	II	(For	detailed	description	of	kit	components	see	supplementary	3.1)	MACS	buffer	(PBS)	containing	0.5%	(v/v)	fetal	bovine	serum	(FBS,	heat-inactivated,	Hyclone)	and	2mM	EDTA	Standard	MACS	Isolation	materials:	 MACS	Magnet	and	magnet	stand	LS	Columns	15mL	Falcon	centrifugation	tubes	 	Centrifuge	Note:	Unless	otherwise	noted,	all	steps	were	performed	in	biosafety	cabinet	under	sterile	conditions,	at	4oC	on	ice	in	the	dark.	LS	columns	and	MACS	buffer	were	stored	are	at	4oC	prior	to	procedure	while	MACS	magnet	and	magnet	stand	were	stored	at	-20oC.		
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Methods	The	kit	was	operated	according	 to	 the	manufacturer’s	 instructions;	For	detailed	 information	on	 this	procedure	see	supplementary	3.1.			
2.3.2	Additions	and	Alterations	to	original	protocol	
A.	Addition	of	Miltenyi	Dead	cell	removal	kit	to	isolation	protocol	The	addition	of	this	isolation	kit	was	done	in	attempt	to	decrease	the	“cell	debris/platelet”	population	found	 within	 isolated	 B-cell	 fractions.	 This	 kit	 was	 used	 according	 to	 the	 manufacturer’s	recommendations	(For	detailed	description	of	kit	components	see	supplementary	3.2)	and	integrated	into	the	isolation	procedure	described	in	section	2.3.1	was	done	using	three	different	approached:		1. Perform	dead	cell	removal	procedure	before	B-cells	isolation	procedure	2. Perform	 dead	 cell	 removal	 procedure	 simultaneously	 to	 B-cell	 isolation	 (Addition	 of	 dead	 cell	staining	 buffer	 together	 with	 negative	 isolation	 kit	 buffers	 –	 MACS	 buffer	 volumes	 altered	 to	maintain	stipulated	staining	volume	of	B-cell	isolation	kit	II)	3. Perform	dead	cell	removal	procedure	after	B-cells	isolation	procedure		
B.	Addition	of	Miltenyi	CD61	platelet	removal	kit	to	isolation	protocol	The	addition	of	this	isolation	kit	was	done	in	attempt	to	decrease	the	“cell	debris/platelet”	population	found	 within	 isolated	 B-cell	 fractions.	 This	 kit	 was	 used	 according	 to	 the	 manufacturer’s	recommendations	(For	detailed	description	of	kit	components	see	supplementary	3.3)	and	integrated	into	the	isolation	procedure	described	in	section	2.3.1	was	done	using	three	different	approached:		1. Perform	CD61	platelet	removal	procedure	before	B-cells	isolation	procedure	2. Perform	 CD61	 platelet	 removal	 procedure	 simultaneously	 to	 B-cell	 isolation	 (Addition	 of	 CD61	staining	 buffers	 together	 with	 negative	 isolation	 kit	 buffers	 -	 MACS	 buffer	 volumes	 altered	 to	maintain	stipulated	staining	volume	of	B-cell	isolation	kit	II)	3. Perform	CD61	platelet	removal	procedure	after	B-cells	isolation	procedure		
2.3.3.	 Isolation	 of	 B-cells	 from	mononuclear	 cells	 by	 negative	 selection	 using	 the	Miltenyi	 Naïve	 B-cell	
Isolation	kit	
Materials	Miltenyi	Naïve	B-cell	Isolation	Kit	(For	detailed	description	of	kit	components	see	supplementary	3.4)	Standard	MACS	Isolation	materials	(listed	in	methods	section	2.3.1)	
Methods	The	kit	was	operated	according	 to	 the	manufacturer’s	 instructions;	For	detailed	 information	on	 this	procedure	see	supplementary	3.4.			
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2.3.4.	Isolation	of	B-cells	from	mononuclear	cells	by	negative	selection	using	the	Miltenyi	CD43	Microbeads	
kit	
Materials	Miltenyi	CD43	Microbeads	Kit	(For	detailed	description	of	kit	components	see	supplementary	3.5)	MACS	buffer	(PBS	containing	5%	fetal	bovine	serum)	Standard	MACS	Isolation	materials	(listed	in	methods	section	2.3.1)	
Methods	The	kit	was	operated	according	 to	 the	manufacturer’s	 instructions;	For	detailed	 information	on	 this	procedure	see	supplementary	3.5.			
2.3.5.	 Isolation	of	B-cells	 from	mononuclear	 cells	 by	positive	 selection	using	 the	Miltenyi	CD19	positive	
Isolation	kit	
Materials	Miltenyi	CD19	positive	Isolation	Kit	(For	detailed	description	of	kit	components	see	supplementary	3.6)	Standard	MACS	Isolation	materials	(listed	in	methods	section	2.3.1)	
Methods	The	kit	was	operated	according	 to	 the	manufacturer’s	 instructions;	For	detailed	 information	on	 this	procedure	see	supplementary	3.6)			2.4.	 Isolation	 of	 T-cells	 from	mononuclear	 cells	 by	 negative	 selection	 using	 the	Miltenyi	 Pan	 T-cell	Isolation	kit	
Materials	Miltenyi	Pan	T-cell	Isolation	Kit	(For	detailed	description	of	kit	components	see	supplementary	3.7)	Standard	MACS	Isolation	materials	(listed	in	methods	section	2.3.1)	
Methods	The	kit	was	operated	according	 to	 the	manufacturer’s	 instructions;	For	detailed	 information	on	 this	procedure	see	supplementary	3.7)		2.5	Fluorescent-activated	cell	sorting	(FACS)	of	isolated	B-cell	from	samples	pre-processed	using	the	Miltenyi	B-cell	isolation	kit	II	Lymphocytes	were	FACS	sorted	from	biological	samples,	that	had	already	undergone	MACS	isolation	sample	using	the	B-cell	isolation	kit	II,	based	on	their	forward-scatter	area	(FSC)	and	side-scatter	area	(SSC)	properties.	In	theory,	B-cells	should	account	for	the	majority	(above	90%)	of	the	cells	within	the	lymphocyte	population.	Therefore,	this	additional	separation	process	should	remove	particles	within	the	sample	that	do	not	form	part	of	the	lymphocyte	population,	essentially	purifying	the	sample.	Sorting	based	 on	 size	 and	 cellular	 complexity	 rather	 than	 fluorescence	 was	 done	 to	 limit	 the	 level	 of	manipulation	 and	 processing	 that	 the	 cells	 were	 exposed	 to,	 as	 this	 may	 have	 negative	 effects	 on	
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downstream	processes	 as	 previously	mentioned.	 Prior	 to	 sorting	 the	 cell	 suspensions	were	 filtered	through	0.35µm	filter	to	remove	any	cell	aggregates	that	could	block	the	fluidics	lines	within	the	FACS	instrument.	Samples	underwent	two	sorting	steps:	1)	an	enrichment	sort	-	to	remove	excessive	debris	without	compromising	the	cell	numbers	by	sorting	all	cells	of	interest,	and	2)	a	pure	sort	-	to	completely	eliminate	cell	debris	while	sacrificing	cell	yield	by	only	sorting	the	cells	of	interest	that	were	not	flanked	by	contaminating	cells.		2.6	 Immunofluorescence	 staining	 and	 flow	 cytometric	 analysis	 of	 various	 cell	 fractions	 to	 confirm	determine	the	purity	of	isolated	samples	Sample	purity	is	of	vital	importance;	this	purity	check	validates	the	isolation	technique	as	sufficient	in	isolating	 the	 cell	 type	 of	 interest	 and	 that	 conclusions	 drawn	 from	 downstream	 experiments	 are	conclusive	 based	 on	 the	 measured	 cellular	 responses	 of	 the	 isolated	 cells	 and	 not	 by	 the	presence/influence	of	other	cell	types.			The	isolated	fraction	was	stained	with	anti-human	mAb	specific	for	CD19	(to	determine	the	proportion	of	 isolated	B-cells	 in	 the	 lymphocyte	population	 i.e	 “B-cell	purity”)	and	anti-human	mAb	specific	 for	CD36	 (to	 determine	 the	 proportion	 of	 platelets	 making	 up	 the	 cell	 debris	 population	 i.e.	 “Platelet	Contamination”).	The	differentiation	of	cell	debris	 from	 lymphocytes	was	determined	using	FSC	and	SSC,	 a	due	 to	 the	 fact	 that	 cell	debris,	dead	cells	 and	platelets	are	of	 a	 smaller	 size	and	 less	 cellular	complexity	compared	to	lymphocytes.	The	gating	strategy	used	to	evaluate	sample	purity	of	isolated	B-cells	(see	Suppl	Figure	3.1	and	3.2.)	and	T-cells	(see	Supp	Figure	3.3)	is	displayed	in	Supplementary	data.	The	resulting	data	was	analyzed	using	FlowJo	v10	software	(Oregon,	USA).			2.7	Statistical	Analysis		Data	analysis	of	the	flow	cytometry	plots	was	done	using	FlowJo	V10	(Treestar,	USA)	and	the	resulting	stats	 analyzed	 using	 Prism	 7	 Software	 (San	 Diego,	 CA).	 Statistical	 differences	 between	 groups	 was	calculated	 using	 a	 non-parametric	 Kruskal-Wallis	 test	 with	 a	 Dunn’s	 multiple	 comparisons	 test.	Alternatively,	when	applicable	a	multiple	non-parametric	unpaired	student	t-test	was	used	to	calculate	statistical	differences	between	groups	for	a	list	of	independent	variables.	Linear	regression	analysis	was	performed	using	Prism	7	Software.	A	two-way	step-up	Benjamini,	Krieger	and	Yekutieli	False	Discovery	rate	(FDR)	approach,	with	an	FDR	of	1%,	was	used	to	correct	for	multiple	testing.	Statistical	significance	is	indicated	by	an	asterisk,	in	which	the	p	<	0.05	(*),	p<.	0.01	(**),	p<0.001(***)	and	p<0.0001(****)	or	by	letters	in	which	data	points	with	different	letters	indicated	statistical	differences.		
	
									
	 	
Stellenbosch University  https://scholar.sun.ac.za
 42 
3.			Results	and	Discussion	The	purpose	of	cell	isolation	methods	is	to	obtain	a	pure	cell	population	of	interest,	that	can	be	used	to	investigate	cell	structure	and	function	without	the	influence	of	other	cell	types.	As	such,	the	presence	of	contaminants	in	an	isolated	sample	are	undesirable	and	defeat	the	objective	of	 isolation	procedures.	The	 methods	 described	 in	 this	 paper	 using	 various	 Miltenyi	 B-cell	 isolation	 kits	 result	 in	 such	 a	phenomenon.	The	desired	purity	of	a	cell-type	within	an	isolated	sample	equates	to	90%	or	more	of	the	total	cell	population.	Key	factors	used	to	assess	the	purity	of	isolated	samples	within	this	study	included:	1)	lymphocyte	population	frequency	-	the	proportion	(%)	of	lymphocytes	within	the	sample,	2)	debris	population	frequency	-	the	proportion	(%)	of	cell	debris	within	the	sample,	3)	Platelet	frequency	–	the	proportion	(%)	of	CD36+	within	the	debris	population	and	4)	B-cell	purity	–the	proportion	(%)	of	CD19+	within	the	lymphocyte	population.	It	should	be	highlighted	that	the	acceptable	>	90%	isolated	cell	purity	stated	in	the	data	sheet	of	the	tested	isolation	kits	is	only	achieved	when	examining	the	cellular	content	of	the	lymphocyte	population,	while	excluding	all	cell	debris	from	analysis	(Figure	3.1a).	This	type	of	analysis	is	termed	“gated	purity”	and	overlooks	the	composition	of	the	isolated	sample	as	a	whole.		This	isolation	method	is	sufficient	for	studies	only	focusing	on	cell	surface	receptor	expression	analysis	but	not	functional	downstream	experiments,	due	to	the	presence	of	cellular	contaminants	within	the	final	sample	 fraction.	 Thus	 “gated	 purity”	 should	 not	 be	 the	 only	 purity	 of	 concern	 when	 assessing	 the	efficiency	of	isolation	procedures.		In	almost	all	instances,	with	the	exception	of	the	MACS	CD19	positive	isolation	kit,	platelets	were	found	to	be	a	large	contaminant	within	the	isolated	samples,	making	up	a	large	portion	of	the	total	cell	content	within	the	isolated	fraction	(Table	3.1).	Platelets	were	identified	using	flow	cytometry	based	on	their	size,	cellular	complexity	and	expression	of	the	cell	surface	marker	CD36	(Oquendo	et	al.,	1989;	Silverstein,	2009).	This	large	variation	of	platelet	contamination	may	be	as	a	result	of	individual	sample	variation	in	the	number	of	platelets	per	liter	of	human	peripheral	blood	–	the		reference	range	has	been	reported	as	150-450	x	109	per	liter	(Brecher	and	Cronkite,	1950;	Bull	et	al.,	1965;	Lozano	et	al.,	1998).			Consequently,	the	volume	of	peripheral	blood	used	for	the	isolation	procedure,	and	in	turn	the	number	of	platelets	comprised	within	the	whole	blood	sample,	had	a	significant	effect	on	the	obtained	sample	purity	 (Figure	3.1b).	A	 significant	difference	was	observed	between	 the	 investigated	blood	volumes	when	 investigating	 it’s	 the	 effect	 on	 each	 of	 the	 factors	 used	 to	 assess	 sample	 purity	 following	 the	isolation	process.	Upon	further	analysis	it	was	found	that	a	positive	relationship	exists	between	whole	blood	volume	and	the	frequency	of	the	debris	population	(Figure	3.2a),	as	well	as	platelet	contamination	(Figure	3.2b).	Conversely,	a	negative	relationship	exists	between	whole	blood	volume	and	the	frequency	of	the	lymphocyte	population	(Figure	3.2c).	Notably,	the	frequency	of	CD19+	cells	within	the	lymphocyte	population	remained	unaffected	by	whole	blood	volume	(Figure	3.2d).	
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Table	3.1.	Summary	of	B-cell	isolation	kits	tested.	This	table	includes	the	various	parameters	used	to	evaluate	the	efficiency	of	each	of	the	Miltenyi	B-cell	isolation	kits	tested.	The	statistical	comparison	between	the	various	parameters	listed	above	is	graphically	illustrated	in	Figure	3.1.			
	
	
	
	
	
	
	
Figure	3.1.	Analysis	of	isolated	B-cell	sample	purity	obtained	using	commercially	available	MACS	B-cell	isolation	kit	II	(n	=68).	(a)	Sample	purity	following	negative	MACS	bead	isolation	using	B-cell	Isolation	Kit	II	only.	The	left	axis	illustrates	total	lymphocytes	as	a	percentage	of	all	cellular	content	within	 the	 isolated	 sample,	 while	 the	 right	 axis	 illustrates	 B-cell	 purity	 as	 a	 percentage	 of	 the	 lymphocyte	 population	 (b)	 Effect	 of	 blood	 volume	 on	effectiveness	of	MACS	B-cell	Isolation	Kit	II.	Statistical	differences	between	blood	volumes	was	calculated	using	a	non-parametric	Kruskal-Wallis	test	with	a	Dunn’s	multiple	comparisons	test.	A	two-way	step-up	Benjamini,	Krieger	and	Yekutieli	False	Discovery	rate	(FDR)	approach,	with	a	FDR	of	1%,	was	used	to	correct	for	multiple	testing.	Statistical	significance	is	indicated	by	an	asterisk,	in	which	the	p	<	0.05	(*),	p<.	0.01	(**),	p<0.001(***)	and	p<0.0001(****).	
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Figure	3.2.	Relationship	between	B-cell	isolation	quality	and	sample	volume	for	all	B-cell	
isolation	kits	 tested	 (n=79).	(a)	 Linear	 regression	between	blood	 volume	 and	 frequency	of	 debris	population	 (b)	Linear	 regression	between	blood	volume	and	 total	 lymphocyte	population	 (c)	Linear	regression	between	blood	volume	and	frequency	of	CD36+	platelets	within	debris	population	(d)	Linear	regression	between	blood	volume	and	frequency	of	CD19+	cells	in	lymphocyte	population.	
Figure	 3.3.	 Analysis	 of	 isolated	 B-cell	 sample	 purity	 obtained	 using	 the	 MACS	 B-cell	
isolation	kit	II	with	the	addition	of	a	CD61	platelet	removal	kit.	The	implementation	of	the	CD63	platelet	removal	kit	was	done	in	three	different	ways,	namely	before	isolation	with	MACS	B-cell	isolation	kit	II	(Procedure	1,	n=1),	simultaneously	with	MACS	B-cell	isolation	kit	II	(Procedure	2,	n=1)	and	after	isolation	with	MACS	B-cell	isolation	kit	II	(Procedure	3,	n=1).		
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As	previously	stated,	significantly	less	platelet	contamination	was	observed	in	samples	isolated	with	the	MACS	CD19	positive	 isolation	 kit,	when	 compared	 to	 the	 negative	B-cell	 isolation	 kit	 II	 (Table	 3.1).	However,	the	obtained	isolated	sample	comprised	of	a	large	proportion	of	‘cell	debris’	(range	30-70%).	Characteristically,	dead	cells	are	identified	in	flow	cytometry	by	changes	in	their	light	scatter;	generally	they	exhibit	decreased	FSC	and	increased	in	SSC	properties	(Muirhead	et	al.,	1985;	Penttila	et	al.,	1975;	Schmid	 et	 al.,	 2001,	 1992),	 hence	 are	 suspected	 to	make	up	 this	 debris	 population.	During	 positive	selection	surface	receptors	on	the	cell	type	of	interest	are	targeted	for	labeling.	Theoretically,	positive	selection	should	result	in	highly	pure	cell	populations	to	be	obtained,	as	all	non-labelled	cells	(including	cell	debris)	should	simple	elute	from	the	column	leaving	only	the	labeled	cell	type	of	interest.	However,	non-specific	binding	may	occur	resulting	in	unwanted	cell	types	contaminating	the	final	sample.	Dead	cells	have	been	known	to	bind	non-specifically	to	antibodies	(Schmid	et	al.,	2001,	1992)	and	could	thus	be	the	major	source	of	the	observed	contamination.	Nevertheless,	further	investigation	is	required	in	order	to	determine	the	source	of	this	‘contamination’.	Ideally,	negative	isolation	would	be	the	method	of	choice	as	the	cell	type	of	interest	surface	receptors	remain	unbound	and	thus	functionally	unaltered	by	this	process,	where	as	positive	selection	introduces	the	risk	of	possible	cell	activation	and	ultimately	functional	alteration	of	 the	cell,	which	may	complicate	downstream	processes.	Possible	downstream	processes	include	but	is	not	limited	to	investigating	cellular	activation	following	exposure	to	a	particular	molecule/drug.	This	ex	vivo	manipulation	could	result	 in	altered	B-cell	 function	to	either	enhance	or	diminish	the	measured	B-cell	response	resulting	in	artefactual	observations.		Of	 the	 three	 negative	B-cell	 isolation	 kits	 investigated,	 one	 of	 the	 kits,	 namely	 the	 CD43	microbead	isolation	kit,	did	not	contain	any	anti-biotin	CD36+	monoclonal	antibody	(mAb),	which	would	explain	the	large	degree	of	platelet	contamination	within	these	samples	(Table	3.1,	Suppl	Figure	3.1a).	However,	a	large	population	of	CD36+	platelets	were	identified	within	isolated	samples	that	underwent	processing	using	either	of	the	other	two	negative	B-cells	isolation	kits	that	contain	an	anti-biotin	CD36	mAb	(Table	3.1),	namely	the	B-cell	isolation	kit	II	(Suppl	Figure	3.2a	and	b)	or	the	Naïve	B-cell	isolation	kit	(Suppl	Figure	3.1b),	for	effectively	removal	of	CD36	positive	cells	(including	platelets).	A	possible	reason	for	the	observed	phenomenon	 is	 inadequate	 concentration	of	 this	 cell	 surface	 receptor	mAb	within	 the	antibody	cocktail	solution,	thereby	influencing	the	obtained	sample	purity.	This	supports	the	observed	effects	of	whole	blood	volume	of	the	overall	effectiveness	of	the	isolation	process,	in	which	an	increase	in	the	volume	of	starting	sample,	hence	platelet	numbers,	resulting	in	decreased	efficiency	in	removal	of	CD36+	platelets.	Due	to	the	large	individual	variability	of	platelet	counts	per	participant,	it	is	difficult	to	determine	how	much	anti-biotin	CD36	mAb	is	adequate.			Various	procedures	were	implemented	into	the	isolation	procedure	utilizing	the	MACS	negative	B-cell	isolation	kit	II	in	an	attempt	to	decrease	the	platelet	contamination	and	‘cell	debris’	population	found	within	isolated	samples.	These	modifications	including	the	addition	of	a	MACS	CD61	platelet	removal	kit	to	determine	whether	or	not	this	would	improve	the	resulting	sample	purity	(Suppl	Figure	3.2c).	
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While	a	general	improvement	in	the	obtained	sample	quality	was	observed	as	seen	by	a	reduction	in	the	frequency	 of	 the	 debris	 population	 within	 the	 isolated	 sample,	 these	 results	 were	 not	 statistically	significant	 from	 either	 of	 the	 other	 isolation	 methods	 (Table	 3.1).	 It	 should	 be	 noted	 that	 when	comparing	the	effectiveness	of	the	addition	of	the	MACS	CD61	microbead	kit	to	other	isolation	methods,	the	 results	 from	 procedure	 I,	 II	 and	 III	 were	 pooled.	 When	 subjectively	 relating	 each	 of	 the	implementation	 methods	 separately,	 no	 methods	 was	 perceived	 to	 be	 superior	 (Figure	 3.3).	Furthermore,	the	addition	of	a	MACS	dead	cell	removal	kit	was	implemented	to	determine	whether	this	would	improve	sample	quality	in	cases	where	platelet	contamination	within	the	“cell	debris”	population	was	 infrequent	 (Suppl	 Figure	 3.2d).	 No	 improvement	 in	 the	 resulting	 sample	 quality	was	 observed	(Table	3.1).	It	should	be	noted	that	when	comparing	the	effectiveness	of	the	addition	of	the	MACS	dead	cell	removal	kit	to	other	isolation	methods,	the	results	from	procedure	I,	II	and	III	were	pooled.	Notable,	when	subjectively	relating	each	of	the	implementation	methods	separately,	procedure	II	was	perceived	to	yield	sample	purity	of	a	superior	quality	(Figure	3.4).	As	such,	further	investigation	utilizing	method	II	should	be	performed	in	order	to	better	evaluate	the	usefulness	of	this	kit	in	improving	B-cell	isolation.		Additionally,	the	effectiveness	of	this	MACS	dead	cell	removal	kit	was	not	investigated	in	combination	with	the	MACS	CD19	positive	isolation	kit,	in	which	dead	cells	are	the	suspected	cause	of	contamination	within	isolated	samples	(Suppl	Figure	3.1c).	Accordingly,	additional	investigation	is	required	before	a	conclusive	 decision	 can	 be	 made	 with	 regards	 to	 the	 efficiency	 of	 the	 modification	 in	 refining	 the	isolation	process.		Interestingly,	when	performing	T	cell	isolations	using	the	MACS	Pan	T	cell	negative	isolation	kit	available	from	Miltenyi,	limited	debris/platelet	contamination	within	the	resulting	isolated	fraction	was	observed	(Figure	3.5a).	Additionally,	sample	volume	was	observed	to	have	no	confounding	effect	on	the	resulting	sample	purity	 (Figure	3.5b).	These	 results	 thereby	 illustrate	 that	our	PBMC	 isolation	 technique	and	MACS	isolation	methods	are	up	to	standard	and	are	not	the	cause	of	this	recurring	contamination	issue.	Instead,	these	results	emphasize	the	inefficiency	of	current	B-cell	isolation	kits	available	from	Miltenyi	to	produce	pure	B-cell	populations	from	which	concrete	findings	can	be	made.	Given	that	it	is	standard	practice	for	immunology	research	to	be	conducted	on	immune	cells	in	isolation	ex	vivo	(Du	Plessis	et	al.,	2016;	Jang	et	al.,	2015;	Joosten	et	al.,	2016;	Lundy	and	Boros,	2002;	Martinez-Martin	et	al.,	2017;	Qiu	et	al.,	2016;	Tsui	et	al.,	2018;	van	Rensburg	and	Loxton,	2018;	Xu	et	al.,	2008;	Yanaba	et	al.,	2008,	2008;	Yoshizaki	et	al.,	2012),	it	is	crucial	that	any	external	influences,	such	as	the	presence	of	contaminating	cells	within	 an	 isolated	 sample,	 be	 acknowledged	 as	 these	 factors	may	 contribute	 to	 the	measured	physiological	responses,	resulting	in	artefactual	observations.	It	is	thus	proposed	that	the	Miltenyi	B-cell	 isolation	kits	 are	 suboptimal	 and	need	 further	optimization	 in	order	 to	 achieve	 the	desired	 cell	isolation	results	for	which	these	kits	are	intended.	The	presence	of	platelets	and	cell	debris	within	isolate	cell	 samples	 to	 be	 used	 for	 downstream	 functional	 assays	 is	 a	 significant	 drawback	 -	 as	 these	“contaminants”	may	influence	the	function	of	cells	under	investigation.	Platelets	and	cell	debris		 	
Stellenbosch University  https://scholar.sun.ac.za
 47 
Figure	 3.4.	 Analysis	 of	 isolated	 B-cell	 sample	 purity	 obtained	 using	 the	 MACS	 B-cell	
isolation	kit	II	with	the	addition	of	the	dead	cell	removal	kit.	The	implementation	of	the	dead	cell	removal	kit	was	done	in	three	different	ways,	namely	before	isolation	with	MACS	B-cell	isolation	kit	II	(Procedure	 1,	 n=1),	 simultaneously	 with	 MACS	 B-cell	 isolation	 kit	 II	 (Procedure	 2,	 n=1)	 and	 after	isolation	with	MACS	B-cell	isolation	kit	II	(Procedure	3,	n=1).		
	
	
	
	
	
	
	
	
	
	
Figure	3.5.	Analysis	of	isolated	T	cell	sample	purity	obtained	using	the	MACS	Pan	T	cell	
isolation	kit	(n=11).	(a)	Sample	purity	following	negative	MACS	bead	isolation.	The	left	axis	illustrates	total	lymphocytes	as	a	percentage	of	all	cellular	content	within	the	isolated	sample,	while	the	right	axis	illustrates	T-cell	purity	as	a	percentage	of	the	lymphocyte	population.	As	illustrated,	platelet/cell	debris	was	successfully	removed,	and	a	pure	T	cell	population	obtained,	as	shown	by	CD3+	cells	 (b)	Linear	regression	 between	 blood	 volume	 and	 efficiency	 of	MACS	 Pan	 T-cell	 isolation	 kit	with	 reference	 to	frequency	of	lymphocyte	population	and	frequency	of	CD3+	cells	within	lymphocyte	population	(T-cell	Purity).		 	
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contribute	to	the	microenvironment,	that	is	the	in	vitro	setting,	in	which	these	cells	are	investigate	as	they	secrete	various	substances	such	as	cytokines	(in	the	case	of	platelets)	or	cellular	content	(in	the	case	of	dead	cells)		known	to	have	an	effect	on	the	activation	and	function	of	surrounding	immune	cells	(Elzey	et	al.,	2005;	Kral	et	al.,	2016).	Thus,	the	observed	immune	response	of	investigate	cells	may	not	be	 identical	 to	 those	where	pure	 sample	 isolates	were	used	 as	 the	 cellular	 function	may	have	been	altered	by	the	substances	released	from	these	contaminating	cells.	Evidence	has	illustrated	that	platelets	have	the	capacity	to	modulate	B	and	T	cell	function	-	and	potentially	drive	their	operation	(Sowa	et	al.,	2009).	One	 such	way	 in	which	platelets	may	achieve	 this	 is	 through	 the	expression	of	mRNA	 found	within	their	cytoplasm	(Denis	et	al.,	2005;	Power	et	al.,	1995;	Soslau	et	al.,	1997).	The	resulting	proteins	include	a	variety	of	molecules	known	to	influence	cell	function,	including	cell	surface	receptors	involved	in	cellular	activation	and	various	cytokines	(Elzey	et	al.,	2005;	Kral	et	al.,	2016;	Sowa	et	al.,	2009).	These	findings	are	of	huge	concern,	as	several	studies	inferring	B-cell	function	downstream	utilizing	these	kits	to	obtain	“pure”	B-cell	populations,	have	not	acknowledged	the	presence	of	these	platelets	within	their	isolated	samples.	Therefore,	any	conclusions	made	from	isolated	cell	studies	that	utilized	these	B-cell	isolation	kits,	need	to	consider	the	presence	of	these	platelets	within	the	sample,	and	note	the	limitations	when	reporting	their	findings	contributing	to	B-cell	function.			Lastly,	the	addition	of	a	fluorescent-activated	cell	sorting	(FACS)	step,	following	B-cell	isolation	with	the	Miltenyi	B-cell	isolation	kit	II,	was	investigated	to	determine	whether	this	could	improve	sample	purity.	The	resulting	sample	 fraction	was	 found	 to	have	significantly	 improved	sample	purity,	however	cell	number	was	compromised	using	this	method	(Figure	3.6).	The	gating	strategy	used	to	evaluate	sample	purity	of	FACS	B-cells	is	displayed	in	Suppl	Figure	4.	Based	on	the	findings	of	this	paper,	the	addition	of	FACS	sorting	to	this	isolation	procedure	for	obtaining	pure	B-cell	populations	is	recommended,	as	this	technique	 was	 found	 to	 significantly	 reduce	 the	 platelet	 contamination	 within	 the	 isolated	 sample	fractions.	Consequently,	 the	 tested	B-cell	 isolation	kits	would	better	 serve	as	 a	pre-enrichment	 step	prior	to	cell	sorting	rather	than	an	isolation	technique	alone.	This	is	highly	beneficial	in	comparison	to	traditional	cell	sorting	as	it	allows	for	the	isolation	of	naïve	B-cells,	whereas	B-cells	sorted	directly	from	whole	blood	or	PBMC	samples	requires	labeling	of	the	cells	of	interest	with	a	fluorescent	tag	for	removal	from	cell	suspension.	This	is	disadvantageous	as	it	may	result	in	cell	activation	through	engagement	of	the	B-cell	receptor	(CD19)	resulting	in	altered	immune	function,	as	well	as	the	increased	amount	of	time	needed	to	sort	the	B-cells	out	of	these	dense	cell	populations,	resulting	in	excessive	costs.	As	such,	the	use	of	the	commercially	available	MACS	isolation	kits	is	not	discouraged	but	rather	recommended	as	an	additional	pre-step	to	cell	sorting	procedures.				
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Various	FACS	sorting	platforms	exist	(eg.	BD,	SONY,	Beckman	Coulter)	including	the	MACSQuant-Tyto	(Miltenyi	Germany)	 and	use	of	 the	 services	offered	 should	be	 to	 achieve	 the	desired	 sample	purity.	However,	 in	 terms	of	 the	research	cost,	processing	time	and	the	volume	of	blood	required	to	obtain	sufficient	B-cell	numbers	for	functional	assays	downstream,	this	method	may	not	be	feasible	for	most	laboratories.	A	possible	improvement	to	reduce	the	loss	in	cell	number	could	be	to	label	the	sample	with	a	CD36	mAb	and	actively	sort	the	platelets	within	the	debris	population,	using	the	pure	sort	method,	based	on	their	FSC	and	SSC	properties	as	well	as	fluorescence;	followed	by	a	pure	sort	of	the	lymphocyte	population	based	on	FSC	and	SSC,	with	less	abort	rates	as	the	sample	will	comprise	of	significantly	less	cell	debris.	Importantly,	B-cell	isolation	kits	from	additional	companies	was	not	investigated	within	this	study.	 Therefore,	 the	 results	 depicted	within	 this	 paper	 do	not	 dissuade	 the	 efficacy	 of	 other	B-cell	isolation	kits.	However,	it	would	be	advisable	to	do	a	comparative	study	to	determine	the	efficacy	of	the	kits	not	tested.	 	
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Figure	 3.6.	 Analysis	 of	 isolated	 B-cell	 sample	 purity	 obtained	 using	 the	 MACS	 B-cell	
isolation	kit	II,	followed	by	cell	sorting	based	on	FSC	and	SSC	(n=2).	Statistical	differences	between	sorting	conditions	was	calculated	using	multiple	non-parametric	unpaired	student	t-tests.	A	two-way	step-up	Benjamini,	Krieger	and	Yekutieli	False	Discovery	rate	(FDR)	approach,	with	a	FDR	of	1%,	was	used	to	correct	for	multiple	testing.	Statistical	significance	is	indicated	by	an	asterisk,	in	which	the	p	<	0.05	(*),	p<.	0.01	(**)	and	p<0.001(***)				
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Components 1 mL B Cell Biotin-Antibody Cocktail, human: 
Cocktail of biotin-conjugated monoclonal 
antibodies against CD2, CD14, CD16, CD36, 
CD43, and CD235a (Glycophorin A).
 2 mL Anti-Biotin MicroBeads:  
MicroBeads conjugated to monoclonal anti-
biotin antibodies (isotype: mouse IgG1).
Capacity For 109 total cells.
Product format All components are supplied in buffer 
containing stabilizer and 0.05% sodium azide.
Storage Store protected from light at 2 − 8 °C. Do not 
freeze. The expiration date is indicated on the 
vial labels.
Safety information
For research use only. Not intended for any animal or human 
therapeutic or diagnostic use.
Before use, please consult the Safety Data Sheet for information 
regarding hazards and safe handling practices.
Cell separation protocols
Fully automated cell labeling and separation  
using the autoMACS® Pro Separator
Alternatively:
Manual magnetic labeling
Subsequent 
manual 
separation
or
Subsequent automated 
cell separation  
using the autoMACS® 
Pro Separator 
General notes
▲ For tips concerning sample preparation, magnetic labeling 
and separation, visit www.miltenyibiotec.com/faq and 
www.miltenyibiotec.com/protocols.
▲ For product-specific background information and applications 
of this product, refer to the respective product page at 
www.miltenybiotec.com/130-091-151.
Reagent and instrument requirements
● Buffer: Prepare a solution containing phosphate-buffered saline 
(PBS), pH 7.2, 0.5% bovine serum albumin (BSA), and 2 mM 
EDTA by diluting MACS® BSA Stock Solution (# 130-091-376) 
1:20 with autoMACS® Rinsing Solution (# 130-091-222). Degas 
buffer before use, as air bubbles could block the column.
● (Optional) Pre-Separation Filters (30 µm) (# 130-041-407) to 
remove cell clumps.
● Choose the appropriate MACS Separator and MACS Columns:
Column  Max. number 
of labeled cells
Max. number 
of total cells
Separator
MS 107 2×108 MiniMACS, OctoMACS
LS 108 2 ×109 MidiMACS, QuadroMACS 
autoMACS 2×108 4 ×109 autoMACS Pro
 ▲ Note: When using this kit the unwanted cell fraction is labeled and the target 
cells remain unlabeled. Depending on the target cell frequency, the labeled 
fraction can therefore represent the majority of the total cells. 
 To avoid blocking of the column, do not exceed the max. number of labeled cells 
per column. Estimate the number of labeled cells in the sample, split the sample 
if necessary and use the appropriate number of separation columns.
Fully automated cell labeling and separation 
using the autoMACS® Pro Separator
▲ Refer to the user manual for instructions on how to use the 
autoMACS® Pro Separator.
▲ All buffer temperatures should be ≥10 °C.  
▲ Place tubes in the following Chill Rack positions:
position A = sample, position B = negative fraction,  
position C = positive fraction.
1. For appropriate resuspension volumes and cell concentrations, 
please visit www.automacspro.com/autolabeling.
2. Switch on the instrument for automatic initialization.
3. Go to the Reagent menu and select Read Reagent. Scan the 
2D barcode of each reagent vial with the barcode scanner 
on the autoMACS Pro Separator. Place the reagent into the 
appropriate position on the reagent rack.
4. Place sample and collection tubes into the Chill Rack. 
5. Go to the Separation menu and select the reagent name for 
each sample from the Labeling submenu (the correct labeling, 
separation, and wash protocols will be selected automatically).
6. Enter sample volume into the Volume submenu. Press Enter.
7. Select Run.
8. Collect enriched B cell fraction at position B = negative fraction.
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Components of MACS® Dead Cell Removal Kit
- MACS® colloidal super-paramagnetic Dead Cell Removal 
MicroBeads. The product is supplied as a suspension containing 
stabilizer. 
- MACS 20× Binding Buffer stock solution. The buffer has to be 
diluted 20-fold with sterile,  double distilled water prior to use 
(see Preparation of 1× Binding Buffer).
These MACS products are susceptible to bacterial contamination. 
Handle under sterile conditions!
Storage Conditions
Store protected from light at 4 °C. Do not freeze.
Instruments Required
Magnetic cell separators MiniMACS™, MidiMACS™, VarioMACS™ 
or SuperMACS™.
MACS Column(s) MS or LS (plus MS or LS adapter for use in 
combination with VarioMACS or SuperMACS).
Protocol for Dead Cell Removal
Preparation of 1× Binding Buffer 
Per 107 total cells, dilute 0.25 mL of 20× Binding Buffer Stock 
Solution with 4.75 mL of sterile, double distilled water. Alternatively, 
the total amount of 25 mL of 20× Binding Buffer Stock Solution can 
be diluted with 475 mL of sterile, double distilled water. Store at 4 °C. 
Important: Handle under sterile conditions!
Magnetic labeling
Collect cells e.g. from cell culture. 
Centrifuge cells at 300×g. Remove supernatant completely and 
resuspend cell pellet in 100 µL of Dead Cell Removal MicroBeads 
per approximately 107 total cells (e.g. petri dish Ø 9 cm: about 1×107 
cells, one mouse spleen: about 1×108 cells). For fewer cells, use same 
volume. Mix well and incubate for 15 minutes at room temperature 
(20–25 °C). 
Preparation of MACS® Column
Choose a positive selection column type MS (for up to 107 dead cells 
and up to 2 ×108 total cells) or LS (for up to 108 dead cells and up 
to 2 ×109 total cells) and place the column in the magnetic field of a 
suitable MACS® Separator (see “Column Data Sheets”).
Prepare column by rinsing with 1× Binding Buffer (MS: 500 µL; 
LS: 3 mL; for details, see “Column Data Sheets”).
Magnetic separation 
Apply cell suspension in suitable amount of 1× Binding Buffer 
onto the column (MS: 500-1000 µL; LS: 1–10 mL; see ”Important 
Notes”). Let the negative cells pass through. Rinse with appropriate 
amount of 1× Binding Buffer (MS: 4 × 500 µL; LS: 4 × 3 mL). 
Collect effluent as live cell fraction.
 How to eliminate dead cells using 
Dead Cell Removal Kit
6.  Collect effluent as live cell fraction.
1.  Prepare 1× Binding Buffer by dilution of 
20× Binding Buffer Stock Solution.
2. Collect cells, centrifuge at 300×g and 
remove supernatant completely.
3. Resuspend cells in Dead Cell Removal 
MicroBeads. Mix well and incubate for 
15 min at room temperature.
4.  Place column in MACS Separator, prepare by 
rinsing with 1× Binding Buffer.
5.  Apply cell suspension onto the column. 
Rinse with 1× Binding Buffer.

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Miltenyi Biotec GmbH 
Friedrich-Ebert-Straße 68, 51429 Bergisch Gladbach, Germany
Phone +49 2204 8306-0, Fax +49 2204 85197
macs@miltenyibiotec.de 
www.miltenyibiotec.com 
Miltenyi Biotec Inc. 
2303 Lindbergh Street, Auburn, CA 95602, USA
Phone 800 FOR MACS, +1 530 888 8871, Fax +1 877 591 1060
macs@miltenyibiotec.com 
page 1/2
14
0-
00
0-
87
1.
07
Components 1 mL Naive B Cell Biotin-Antibody Cocktail, 
human: Cocktail of biotin-conjugated 
monoclonal antibodies against CD2, CD14, 
CD16, CD27, CD36, CD43 and CD235a 
(Glycophorin A).
 2 mL Anti-Biotin MicroBeads:  
MicroBeads conjugated to monoclonal anti-
biotin antibodies (isotype: mouse IgG1).
Capacity For 109 total cells.
Product format All components are supplied in buffer 
containing stabilizer and 0.05% sodium azide.
Storage Store protected from light at 2 − 8 °C. Do not 
freeze. The expiration date is indicated on the 
vial labels.
Safety information
For research use only. Not intended for any animal or human 
therapeutic or diagnostic use.
Before use, please consult the Safety Data Sheet for information 
regarding hazards and safe handling practices.
Cell separation protocols
Fully automated cell labeling and separation  
using the autoMACS® Pro Separator
Alternatively:
Manual magnetic labeling
Subsequent 
manual 
separation
or
Subsequent automated 
cell separation  
using the autoMACS® 
Pro Separator 
General notes
▲ For tips concerning sample preparation, magnetic labeling 
and separation, visit www.miltenyibiotec.com/faq and 
www.miltenyibiotec.com/protocols.
▲ For product-specific background information and applications 
of this product, refer to the respective product page at 
www.miltenybiotec.com/130-091-150.
Reagent and instrument requirements
● Buffer: Prepare a solution containing phosphate-buffered saline 
(PBS), pH 7.2, 0.5% bovine serum albumin (BSA), and 2 mM 
EDTA by diluting MACS® BSA Stock Solution (# 130-091-376) 
1:20 with autoMACS® Rinsing Solution (# 130-091-222). Degas 
buffer before use, as air bubbles could block the column.
● (Optional) Pre-Separation Filters (30 µm) (# 130-041-407) to 
remove cell clumps.
● Choose the appropriate MACS Separator and MACS Columns:
Column  Max. number 
of labeled cells
Max. number 
of total cells
Separator
MS 107 2×108 MiniMACS, OctoMACS
LS 108 2 ×109 MidiMACS, QuadroMACS 
autoMACS 2×108 4 ×109 autoMACS Pro
 ▲ Note: When using this kit the unwanted cell fraction is labeled and the target 
cells remain unlabeled. Depending on the target cell frequency, the labeled 
fraction can therefore represent the majority of the total cells. 
 To avoid blocking of the column, do not exceed the max. number of labeled cells 
per column. Estimate the number of labeled cells in the sample, split the sample 
if necessary and use the appropriate number of separation columns.
Fully automated cell labeling and separation 
using the autoMACS® Pro Separator
▲ Refer to the user manual for instructions on how to use the 
autoMACS® Pro Separator.
▲ All buffer temperatures should be ≥10 °C.  
▲ Place tubes in the following Chill Rack positions:
position A = sample, position B = negative fraction,  
position C = positive fraction.
1. For appropriate resuspension volumes and cell concentrations, 
please visit www.automacspro.com/autolabeling.
2. Switch on the instrument for automatic initialization.
3. Go to the Reagent menu and select Read Reagent. Scan the 
2D barcode of each reagent vial with the barcode scanner 
on the autoMACS Pro Separator. Place the reagent into the 
appropriate position on the reagent rack.
4. Place sample and collection tubes into the Chill Rack. 
5. Go to the Separation menu and select the reagent name for 
each sample from the Labeling submenu (the correct labeling, 
separation, and wash protocols will be selected automatically).
6. Enter sample volume into the Volume submenu. Press Enter.
7. Select Run.
8. Collect enriched naive B cell fraction at position B = negative 
fraction.
 
Naive B Cell Isolation Kit II
human
Order no. 130-091-150
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Miltenyi Biotec GmbH 
Friedrich-Ebert-Straße 68, 51429 Bergisch Gladbach, Germany
Phone +49 2204 8306-0, Fax +49 2204 85197
macs@miltenyibiotec.de 
www.miltenyibiotec.com 
Miltenyi Biotec Inc. 
2303 Lindbergh Street, Auburn, CA 95602, USA
Phone 800 FOR MACS, +1 530 888 8871, Fax +1 877 591 1060
macs@miltenyibiotec.com 
page 1/2
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Components 1 mL Pan T Cell Biotin-Antibody Cocktail, 
human: Cocktail of biotin-conjugated 
monoclonal antibodies against CD14, CD15, 
CD16, CD19, CD34, CD36, CD56, CD123, and 
CD235a (GlycophorinA).
 2 mL Pan T Cell MicroBead Cocktail, human: 
MicroBeads conjugated to monoclonal anti-
biotin antibody (isotype: mouse IgG1) and 
monoclonal anti-CD61 antibody (isotype: 
mouse IgG1).
Capacity For 109 total cells.
Product format All components are supplied in buffer 
containing stabilizer and 0.05% sodium azide.
Storage Store protected from light at 2 − 8 °C. Do not 
freeze. The expiration date is indicated on the 
vial labels.
Safety information
For research use only. Not intended for any animal or human 
therapeutic or diagnostic use.
Before use, please consult the Safety Data Sheet for information 
regarding hazards and safe handling practices.
Cell separation protocols
Fully automated cell labeling and separation  
using the autoMACS® Pro Separator
Alternatively:
Manual magnetic labeling
Subsequent 
manual 
separation
or
Subsequent automated 
cell separation  
using the autoMACS® 
Pro Separator 
General notes
▲ For tips concerning sample preparation, magnetic labeling 
and separation, visit www.miltenyibiotec.com/faq and 
www.miltenyibiotec.com/protocols.
▲ For product-specific background information and applications 
of this product, refer to the respective product page at 
www.miltenybiotec.com/130-096-535.
Reagent and instrument requirements
● Buffer: Prepare a solution containing phosphate-buffered saline 
(PBS), pH 7.2, 0.5% bovine serum albumin (BSA), and 2 mM 
EDTA by diluting MACS® BSA Stock Solution (# 130-091-376) 
1:20 with autoMACS® Rinsing Solution (# 130-091-222). Degas 
buffer before use, as air bubbles could block the column.
● (Optional) Pre-Separation Filters (30 µm) (# 130-041-407) to 
remove cell clumps.
● Choose the appropriate MACS Separator and MACS Columns:
Column  Max. number 
of labeled cells
Max. number 
of total cells
Separator
LS 108 2 ×109 MidiMACS, QuadroMACS 
autoMACS 2×108 4 ×109 autoMACS Pro
 ▲ Note: When using this kit the unwanted cell fraction is labeled and the target 
cells remain unlabeled. Depending on the target cell frequency, the labeled 
fraction can therefore represent the majority of the total cells. 
 To avoid blocking of the column, do not exceed the max. number of labeled cells 
per column. Estimate the number of labeled cells in the sample, split the sample 
if necessary and use the appropriate number of separation columns.
Fully automated cell labeling and separation 
using the autoMACS® Pro Separator
▲ Refer to the user manual for instructions on how to use the 
autoMACS® Pro Separator.
▲ All buffer temperatures should be ≥10 °C.  
▲ Place tubes in the following Chill Rack positions:
position A = sample, position B = negative fraction,  
position C = positive fraction.
1. For appropriate resuspension volumes and cell concentrations, 
please visit www.automacspro.com/autolabeling.
2. Switch on the instrument for automatic initialization.
3. Go to the Reagent menu and select Read Reagent. Scan the 
2D barcode of each reagent vial with the barcode scanner 
on the autoMACS Pro Separator. Place the reagent into the 
appropriate position on the reagent rack.
4. Place sample and collection tubes into the Chill Rack. 
5. Go to the Separation menu and select the reagent name for 
each sample from the Labeling submenu (the correct labeling, 
separation, and wash protocols will be selected automatically).
6. Enter sample volume into the Volume submenu. Press Enter.
7. Select Run.
8. Collect enriched T cell fraction at position B = negative fraction.
 
Pan T Cell Isolation Kit 
human
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Suppl	Figure	3.1.	Flow	cytometric	analysis	of	isolated	B-cell	sample	purity	obtained	using	
the	naive	MACS	isolation	kits.	(a)	CD43	microbeads	kit	(n	=	1)	(b)	Naïve	B-cell	Isolation	kit	(n	=	1)	(c)	CD19	 positive	 Isolation	 kit	 (n	 =	 3).	 These	 sample	 were	 not	 stained	 with	 CD36	 mAb	 and	 thus	 the	proportion	of	platelets	that	make	up	the	‘Debris’	population	cannot	be	confirmed.		
	 	
    a)                                   b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     c)      
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Suppl	Figure	3.2.	Flow	cytometric	analysis	of	isolated	B-cell	sample	purity	obtained	using	
the	MACS	B-cell	 isolation	kit	 II.	 (a)	Using	the	normal	PBMC	method	(n	=	16)	(b)	Using	the	altered	platelet	wash	method	(n=	4)	(c)	Addition	of	CD61	platelet	removal	kit	(n	=	3)	(d)	Addition	of	dead	cell	removal	kit	(n	=	3).			
	
	 	
a)                                   b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
c)       d) 
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Suppl	Figure	3.3.	Flow	cytometric	analysis	of	isolated	T	cell	sample	purity	obtained	using	
the	MACS	Pan	T	cell	 isolation	kit.	Sample	purity	 following	negative	MACS	bead	 isolation	 in	which	platelet/cell	debris	was	successfully	removed,	as	shown	in	SSC-A	vs	FSC-A,	and	a	pure	T	cell	population	obtained,	as	shown	by	CD3+	cells	(n	=	11).				
	
	
Suppl	Figure	3.4.	Flow	cytometric	analysis	of	isolated	B-cell	sample	purity	obtained	using	
the	MACS	B-cell	isolation	kit	II,	followed	by	cell	sorting	based	on	FSC	and	SSC.	(a)	Sample	purity	of	MACS	bead	isolated	B-cell	sample	(b)	Sample	purity	of	MACS	bead	isolated	B-cell	sample	followed	by	two	cell	sorting	steps,	resulting	in	successfully	removal	of	undesirable	platelet	contamination	(n=2).				 	
      a)                                             b) 
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Chapter	4:				The	work	presented	in	this	chapter	has	been	formatted	in	the	style	of	a	manuscript	for	submission	to	an	immunology	journal.					
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Abstract	
Rationale:	 Emerging	 evidence	 implicate	 B-cells	 as	 important	 players	 in	 the	 defense	 against	
Mycobacterium	tuberculosis	(M.tb).	This	study	aimed	to	identify	potential	mechanisms	by	which	B-cells	modulate	T-cell	function,	the	cells	regarded	as	the	principle	immune	cells	involved	in	eradicating	TB	disease.		
Method:	Autologous	T-cells	were	 co-cultured	with	H37Rv/BCG-stimulated	or	naive	B-cells	 that	had	been	pulsed	with	or	without	CD40L	and	IL5,	to	induce	a	regulatory	killer	B-cell	subtype.	The	resulting	B-	and	T-cell	phenotypic	frequencies	and	cytokine	profiles	were	evaluated	by	multiparameter	analysis.		
Results:	Killer	(FasL+)	B-cell	frequencies	were	elevated	in	M.tb	healthy,	QuantiFERON	(QFN)	negative	individuals	when	compared	to	healthy	QFN	positive	individuals.	Elevated	levels	of	Fas-expressing	T-cells	was	 observed	 in	QFN	positive	 individuals	 compared	 to	QFN	negative	 individuals	 following	 co-culture	 of	 autologous	 T-cells	 with	 H37Rv-stimulated	 B-cells.	 Additionally,	 B-cells,	 naïve	 or	 pre-stimulated,	were	observed	to	induce	alterations	in	effector	T-cell	(TE)	and	Treg	frequencies.	Wherein,	a	decrease	in	TE	and	Treg	frequencies	for	QFN	positive	and	negative	participants	was	observed	following	co-culture	of	T-cells	with	pre-stimulated	B-cells.	 Interestingly,	 an	 increase	 in	TE	 frequencies	of	QFN	negative	 individuals	was	 observed	 following	 co-culture	with	H37Rv-stimulated	B-cells	 compared	 to	naïve	 B-cells.	 Similarly,	 enhanced	 Treg	 frequencies	 were	 observed,	 for	 QFN	 positive	 and	 negative,	following	co-culture	with	H37Rv-stimulated	B-cells	 compared	 to	naïve	B-cells.	Finally,	 alterations	 in	cytokine	production	by	CD4+	and	CD8+	T-cells	was	observed,	such	as	the	induction	of	bi-functional	and	multifunctional	 T-cells,	 of	 both	 QFN	 positive	 and	 negative	 individuals	 following	 co-culture	 with	unstimulated	of	H37Rv/BCG	stimulated	B-cells.	
Conclusion:	Naïve	B-cells,	as	well	as	killer	B-cells,	are	able	to	influence	T-cell	behavior	by	modulating	phenotype	development	and	cytokine	secretion,	emphasizing	the	potential	important	involvement	of	B-cells	in	initiating	and	guiding	the	immune	response	against	M.tb.
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1.	Introduction	Tuberculosis	(TB)	remains	the	leading	cause	of	death	from	a	single	infectious	agent	worldwide,	with	approximately	10.4	million	active	TB	cases,	resulting	in	an	estimated	1.67	million	TB	deaths	in	2016	(World	Health	Organization,	2017).	The	etiological	agent	of	TB	disease	is	Mycobacterium	tuberculosis	
(M.tb)	 (Delogu	et	al.,	2013),	an	air-borne	pathogen	easily	spread	 in	over-populated	areas	amid	poor	living	conditions	-	where	lack	of	hygiene	and	poor-ventilation	contribute	to	the	unsuccessful	eradication	of	 this	bacillus	 (Schwander	and	Dheda,	2011;	World	Health	Organization,	2017).	Currently,	 the	only	vaccine	 available	 for	 TB	 prevention	 is	 the	 Bacillus	 Calmette-Guérin	 (BCG)	 vaccine,	 which	 has	 been	shown	to	have	variable	efficacy	(Colditz	et	al.,	1994;	Romano	and	Huygen,	2012;	Sepulveda	et	al.,	1992),	offering	reasonable	protection	against	disseminated	TB	in	infants,	while	providing	minimal	protection	against	the	primary	form	of	the	disease,	pulmonary	TB,	which	predominantly	affects	adolescents	and	adults	 (Kaufmann	 and	 Gengenbacher,	 2012;	 Li	 et	 al.,	 2017).	 Partial	 understanding	 of	 the	 complex	interplay	 between	 immune	 cells	 and	 the	 cellular	 responses	 required	 for	 successful	 control	 and	eradication	of	M.tb	infection,	has	resulted	in	poor	vaccine	design	(Andersen,	2001).	Consequently,	novel	vaccine	 candidates	 fail	 to	 elicit	 an	 immune	 response	 superior	 or	 equivalent	 to	 that	 of	BCG,	 and	 are	unsuccessful	 in	 improving	 TB	 prevention	 therapies	 (Andersen	 and	Kaufmann,	 2014;	 Baldwin	 et	 al.,	2009;	 Gupta	 et	 al.,	 2007;	 Kaufmann,	 2006,	 2000;	Williams	 et	 al.,	 2005).	 This	 has	 resulted	 in	 poor	development	and	progression	of	innovative	therapeutics	against	TB	disease	(Cliff	et	al.,	2015;	Ottenhoff	and	Kaufmann,	2012).	As	such,	a	re-evaluation	of	the	importance	of	other	cell	types	previously	thought	to	have	minor	influence	on	the	effectiveness	of	anti-TB	response	has	followed	(Achkar	and	Casadevall,	2013;	Balu	et	al.,	2011).				Increasing	evidence	suggests	that	B-cells	and	immunoglobulins	play	a	significant	role	in	modulating	the	immune	response	to	M.tb	(Chan	et	al.,	2014;	Li	et	al.,	2017).	For	decades,	it	was	assumed	that	B-cells	had	minimal	influence	on	the	survival	of	M.tb	due	to	the	fact	that	antibody	production	was	considered	to	be	the	primary	function	of	B-cells.	Multiple	studies	involving	several	other	intracellular	pathogens	have	shown	great	promise	with	antibody-mediated	immunity	(Achkar	and	Casadevall,	2013;	Balu	et	al.,	2011;	Buccheri	et	al.,	2009;	Chan	et	al.,	2014;	Hamasur	et	al.,	2004;	Teitelbaum	et	al.,	1998),	underscoring	the	possibility	that	protective	humoral	immune	responses	may	exist	for	TB.	In	addition,	recent	findings	have	revealed	 non-humoral	 functions	 of	 B-cells,	 including	 immune	modulation	 and	 cytokine	 production,	which		contribute	to	the	successful	suppression	of	M.tb	infection	(Bao	and	Cao,	2014;	Bénard	et	al.,	2018;	Blair	et	al.,	2010;	Carter	et	al.,	2012,	2011;	Chesneau	et	al.,	2013;	Du	Plessis	et	al.,	2016b;	Elgueta	et	al.,	2009;	Kurt-Jones	et	al.,	1988a;	León	et	al.,	2014;	Matsumoto	et	al.,	2014;	Nova-Lamperti	et	al.,	2016;	Schwartz	et	al.,	2016;	Whitmire	et	al.,	2009;	Yoshizaki	et	al.,	2012).	Thus	far,	it	is	unclear	whether	or	not	B-cell	 derived	 antibodies	 directly	 target	 mycobacterial	 antigens	 or	 if	 they	 stimulate	 a	 general	immunomodulatory	effect	 to	target	the	 inflammatory	response	to	TB	disease,	resulting	 in	protective	immune	function	(Li	et	al.,	2017).	Furthermore,	mouse	models	have	shown	that	mice	with	dysfunctional	
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B-cells,	or	depleted	B-cells,	tend	to	have	increased	bacterial	burdens	(Maglione	et	al.,	2007),	illustrating	a	key	role	of	B-cells	in	immunity.	As	such,	deeper	insight	into	the	function	of	B-cells	and	their	role	in	inducing	protective	immune	responses	against	TB	disease	is	required.		T-cells,		together	with	macrophages,	are	regarded	as	the	central	immune	cells	responsible	for	TB	disease	management	(Cliff	et	al.,	2015;	Kaufmann,	2002;	Lalvani	et	al.,	1998;	McKenzie	et	al.,	1993;	Orme	et	al.,	1993;	Ribeiro-Rodrigues	et	al.,	2006;	Schwander	and	Dheda,	2011;	Scriba	et	al.,	2016;	Sharma	et	al.,	2007;	 Stevens	 et	 al.,	 1988).	 The	modulation	 of	 T	 cell	 function	 is	 largely	 associated	with	TB	disease	outcome.	 Thus,	 the	 objective	 of	 this	 study	 was	 to	 elucidate	 the	 influence	 B-cells	 have	 on	 T-cell	polarisation,	phenotype	development	and	function	-	in	the	context	of	M.tb	infection.	This	was	achieved	by	co-culture	of	isolated	T-cells	with	autologous	M.tb-stimulated	B-cells	and	comparing	the	resulting	T-cell	population	 to	determine	whether	any	variations	occurred.	A	subpopulation	of	B-cells,	known	as	killer	B-cells	was	recently	discovered	(Lundy,	2009;	Lundy	et	al.,	2015;	van	Rensburg	et	al.,	2017;	Van	Rensburg	et	al.,	2017;	van	Rensburg	and	Loxton,	2018a).	The	frequency	and	function	of	these	killer	B-cells	during	TB	disease	has	been	investigated,	in	which	decreased	levels	of	killer	B-cells	were	observed	in	 TB-infected	 individuals	 compared	 to	 healthy	 controls	 and	 successfully	 treated	 TB	 patients	 (Van	Rensburg	et	al.,	2017),	suggesting	an	essential	role	of	killer	B-cells	in	effective	anti-TB	immunity.	In	light	of	the	above,	changes	in	T-cell	activation	and	function	following	killer	B-cell	induction	were	investigated,	to	afford	deeper	insight	into	possible	mechanisms	by	which	these	cells	exert	their	therapeutic	effects.		
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2.	Methods	
2.1	Ethics	Statement	
The	current	study	consists	of	two	parts:	BCG	Pilot	study	and	H37Rv	Pilot	study	Ethical	approval	was	obtained	from	the	health	research	ethics	committee	of	Stellenbosch	University	for	the	BCG	pilot	(N10/01/013)	and	H37Rv	pilot	(N16/05/070)	and	from	the	City	of	Cape	Town	City	Health.	The	 study	 was	 conducted	 according	 to	 the	 Helsinki	 Declaration	 and	 International	 Conference	 of	Harmonisation	guidelines.	Written	informed	consent	was	obtained	from	all	study	participants.	
	
2.2	Study	Participants	For	both	studies,	10	healthy	participants	were	recruited	(5	individuals	with	a	positive	QuantiFERON	(QFN)	status	and	5	individuals	with	a	QFN	negative	status)	–	BCG	pilot	in	the	year	2016	and	H37Rv	pilot	during	2017.	The	QFN	status	was	suggestive	of	exposure	to	M.tb,	and	participants	with	a	positive	status	were	considered	latently	infected.	Recruited	participants	did	not	present	any	clinical	symptoms	of	TB,	with	no	previous	record	of	active	disease.	All	participants	for	this	study	were	HIV	negative.	QFN	positive	and	negative	participants	were	matched	according	 to	socio-economic	background.	The	studies	were	performed	in	Cape	Town,	South	Africa.	
	
2.3	B-cell	Isolation	Heparinized	peripheral	blood	(80ml)	was	collected	and	peripheral	blood	mononuclear	cells	(PBMCs)	isolated	 using	 the	 ficoll-histopaque	 (GE	 Healthcare	 Life	 Sciences,	 USA)	 density	 gradient	 method.	Subsequently,	B-cells	were	negatively	isolated	from	PBMCs	using	MACS	bead	technology,	according	to	the	manufacturer’s	instructions,	with	the	B-cell	isolation	kit	II	(Miltenyi	Biotec,	South	Africa).	Enriched	B-cells	were	then	cryopreserved	(90%	Fetal	Calf	Serum	(FCS),	Lonza,	South	Africa	and	10%	Dimethyl	sulfoxide	(DMSO),	Sigma-Aldrich,	St,	Louis,	MO)	and	stored	in	liquid	nitrogen	for	future	use.	Purity	of	the	enriched	B-cell	samples	was	confirmed	by	flow	cytometry	using	anti-human	CD19	mAb.	All	samples	had	a	 gated	B-cell	purity	 (%	CD19+	 cells	within	 lymphocyte	population	–	 exclude	debris	population	portion	of	sample)	above	90%.	
	
2.4	T-cell	Isolation	On	a	separate	occasion,	heparinized	peripheral	blood	(20ml)	was	collected	to	obtain	autologous	T-cells	for	co-culture.	PBMCs	were	isolated	as	described	above,	and	T-cells	subsequently	isolated	from	PBMCs	using	MACS	bead	technology	with	the	Pan	T-cell	isolation	kit	(Miltenyi	Biotec,	South	Africa).	Enriched	T-cells	were	cryopreserved	 (90%	FCS	and	10%	DMSO)	and	stored	 in	 liquid	nitrogen	 for	 future	use.	Purity	of	the	enriched	T-cell	samples	was	confirmed	by	flow	cytometry	using	anti-human	CD3	mAb.	All	samples	had	a	T-cell	purity	(%	CD3+	cells	within	sample	–	including	lymphocyte	and	debris	population)	above	90%.	
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2.5	Co-culture	Stimulation	Isolated	B-cells	(250	000	cells/well)	were	cultured	in	96-well	round	bottom	plates,	in	a	total	of	200uL	complete	media	(RPMI	plus	L/Glutamine	(Sigma,	USA)	supplemented	with	10%	FCS)	at	37oC	and	5%	CO2.	B-cells	were	stimulated	with	BCG	Danish	1331	(1.25	x	106	CFU/mL),	or	H37Rv	at	a	MOI	of	10:1,	for	3	hours.	Where	applicable,	IL-5	(Sigma,	USA)	was	added	at	50	ng/ml	and	CD40L	(Sigma,	USA)	at	2ug/ml	(for	 BCG	 pilot	 study)	 or	 1ug/ml	 (for	 H37Rv	 pilot	 study).	 A	 detailed	 description	 of	 the	 stimulatory	conditions	can	be	found	in	Suppl	Table	4.1.			
BCG	Pilot	study	Following	the	above	mentioned	3-hour	incubation,	culture	supernatants	were	removed,	and	isolated	T	cells	added	(500	000	cells/well)	to	the	respective	wells	containing	activated	B-cells	(2:1	ratio).	These	cells	were	co-cultured	in	the	presence	of	brefeldin	A	(Sigma,	USA)	at	5ug/mL,	immediately,	for	20	hours.	Following	stimulation,	culture	supernatant	was	removed,	and	the	cells	cryopreserved	(90%	FCS	and	10%	DMSO)	for	phenotypic	receptor	analysis	by	flow	cytometry	at	a	later	time.	
	
H37Rv	Pilot	study	Following	the	3-hour	incubation,	culture	supernatants	were	harvested,	filtered	and	stored	at	-80oC	for	“early”	B-cell	cytokine	immune	response	evaluation	(pre-co-culture	=	time	point	1).	Isolated	T	cells	were	added	(500	000	cells/well)	to	the	respective	wells	containing	activated	B-cells	(2:1	ratio).	These	cells	were	co-cultured	for	3	hours	prior	to	the	addition	of	brefeldin	A	(Sigma,	USA)	at	5ug/mL	followed	by	incubation	 for	 an	 additional	 16	 hours’	 stimulation.	 Following	 this	 19-hour	 incubation,	 culture	supernatants	were	harvested,	 passed	 through	a	 filter	 of	 0.22µm	(to	 remove	any	bacilli	 that	may	be	contained	within	the	sample)	and	stored	at	-80oC	for	analysis	of	‘late’	B-cell	cytokine	immune	response	(post-co-culture	=	time	point	2).	Cells	were	fixed	in	fixation	buffer	(Biolegend,	California)	for	30	min	at	37oC	and	immediately	stained	for	phenotypic	receptor	analysis	by	flow	cytometry.	
	
2.6	Cytokine	Analysis	by	Luminex	
H37Rv	Pilot	study	Quantification	of	soluble	factors	within	cell	culture	supernatant,	was	determined	using	the	MAGPix	and	Bioplex	 platforms	 (Bio-rad	 Laboratories,	 California,	 USA).	 The	 analytes	 of	 interest	 included	 APRIL,	BAFF,	FasL,	ICAM-1,	IFN-β,	IFN-γ,	IL-1β,	IL-2,	IL-4,	IL-6,	IL-10,	IL-12p70,	IL-17A,	IL-21,	TNF-α,	TGF-β1,	TGF-β2	and	TGF-β3,	assayed	according	to	the	manufacturer’s	recommendations.		
2.7	Phenotype	Analysis	by	Flow	Cytometry	For	culture	conditions	to	which	no	T	cells	were	added,	a	B-cell	specific	antibody	panel	was	used,	whereas	culture	 conditions	 in	which	T	 cells	were	present,	 a	T	 cell	 specific	 antibody	panel	was	used.	 For	 the	purpose	of	intracellular	staining,	all	cells	were	cultured	with	Brefeldin	A	as	previously	described.	The	gating	strategies	used	for	each	of	the	panels	can	be	found	in	Suppl	Figures	4.1	to	4.5.	 	
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BCG	Pilot	study	The	T-cell	antibody	panel	consisted	of	CD3-FITC,	CD4-HV500,	CD8-APC-Cy7,	CD25-PE,	IFN-γ-	PE/Cy7,	TNF-α-	APC	and	IL-2-PerCP-Cy5.5	(All	from	Beckton	Dickenson	(BD),	Germany).	Cells	were	stained	in	1x	permeabilization	buffer	 (Biolegend,	California)	 for	30min	at	 room	 temperature	 in	 the	dark	after,	which	the	cells	were	washed	and	acquired	on	a	BD	LSR	II	(BD	Biosciences).	 	The	resulting	data	was	analyzed	using	FlowJo	v10	software	(Treestar,	USA).	
	
H37Rv	Pilot	study	The	B-cell	antibody	panel	consisted	of	IgM-FITC,	CD24-BV510,	CD38-PE/Cy7,	CD5-PerCP/Cy5.5,	CD125	(IL5RA)-PE	 (All	 from	BD,	Germany),	CD19-BV605,	 IL-10-BV421	 (All	 from	Biolegend,	California)	 and	CD178	 (FASL)-APC	 (Miltenyi	 Biotec,	 South	 Africa).	 The	 T-cell	 panel	 consisted	 of	 CD3-PerCP,	 CD95-APC/Fire750,	 IL-2-BV421	 (All	 from	 Biolegend,	 California),	 CD4-BV510,	 CD8-FITC,	 CD25-PE,	 IFN-γ-	PE/Cy7	and	TNF-α-	APC	and	(All	from	BD,	Germany).	Cells	were	stained	in	1x	permeabilization	buffer	(Biolegend,	California)	for	1	hour	at	room	temperature	in	the	dark	with	the	respective	antibody	panels,	after	which	the	cells	were	washed,	individual	participant	samples	pooled	(according	to	QFN	status	and	stimulation	condition)	and	acquired	on	a	BD	LSR	II	(BD	Biosciences).	The	resulting	data	was	analyzed	using	FlowJo	v10	software	(Treestar,	USA).	
	
2.8	Statistical	Analysis		
BCG	Pilot	study	The	exported	frequencies	of	the	flow	cytometry	plots	analyzed	using	FlowJo	V10	(Treestar,	USA),	were	analyzed	using	Prism	7	Software	(San	Diego,	CA).	Comparisons	between	groups	was	calculated	using	the	Mann	Whitney	U-test,	and	differences	within	groups	was	calculated	using	the	Kruskal-Wallis	with	Dunns	multiple	comparisons	post-hoc	test.	Statistical	significance	is	indicated	by	an	asterisk,	in	which	the	p	<	0.05	(*),	p<.	0.01	(**)	and	p<0.001(***).	
	
H37Rv	Pilot	study	Data	analysis	for	all	Luminex	results	was	performed	using	Statistica	12	software	(Statsoft,	Ohio,	USA)	and	 Prism	 7	 Software	 (San	 Diego,	 CA).	 Raw	 data	was	 checked	 for	 normality	 using	 normality	 plots.	Statistical	differences	between	culture	conditions	was	calculated	using	a	three-way	or	four-way	mixed	model	ANOVA.	Comparisons	within	groups	was	calculated	using	the	Fishers	LSD	post-hoc	test.	A	two-way	step-up	Benjamini,	Krieger	and	Yekutieli	False	Discovery	rate	(FDR)	approach,	with	a	FDR	of	1%,	was	used	to	correct	for	multiple	testing.	Statistical	significance	is	indicated	by	an	asterisk,	in	which	the	p	<	0.05	(*),	p<.	0.01	(**)	and	p<0.001(***)	or	by	letters,	in	which	groups	denoted	with	different	letters	indicate	statistical	differences.	Data	analysis	of	 the	 flow	cytometry	plots	was	done	using	FlowJo	V10	(Treestar,	USA)	and	the	resulting	frequencies	of	pooled	cells	plotted	using	Prism	7	Software	(San	Diego,	CA).	Note:	isolated	B-cell	samples	were	pooled	prior	to	flow	cytometry	analysis,	due	to	inadequate	cell	
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numbers	 compromising	 acquisition	 event	 rate,	 thereby	 prohibiting	 the	 performance	 of	 statistical	analysis.			
3.	Results		3.1	Regulatory	B-cell	(Breg)	frequencies	The	frequency	of	Breg	in	response	to	immune	stimulation	and	M.tb	challenge	was	investigated.	Bregs	were	defined	by	 the	phenotype	CD19+CD24hiCD38hi.	For	each	of	 the	 investigated	stimulation	conditions,	a	general	pattern	of	elevated	mean	Bregs	frequencies	was	observed	for	the	QFN	negative	group	compared	to	 the	QFN	positive	 group	 (Figure	 4.1).	 However,	 the	 significance	 of	 these	 differences	 could	 not	 be	investigated	due	to	the	samples	being	pooled.	 Interestingly,	CD40L/IL5	stimulation	was	observed	to	have	varying	effects	on	Breg	frequencies	depending	on	QFN	status	of	the	participants.	A	minor	increase	in	 measured	 mean	 Breg	 frequencies	 was	 observed	 for	 the	 QFN	 positive	 group	 following	 antigenic	stimulation	of	B-cells	(CD40L+IL5	3.70%;	H37Rv+CD40L+IL5	3.87%	vs	Unstimulated	3.63%),	whereas	a	decrease	in	mean	Breg	frequencies	was	observed	for	the	QFN	negative	group	in	response	to	antigenic	stimulation	 (CD40L+IL5	 6.36%;	 H37Rv+CD40L+IL5	 4.54%	 vs	 Unstimulated	 6.74%).	 Notably,	 the	implication	of	these	differences	could	not	be	determined,	due	to	lack	of	insight	into	individual	sample	variation	as	previously	stated.				 	
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Figure	 4.1.	 Evaluation	 of	 regulatory	 B-cell	 (Breg)	 frequencies	 following	 antigenic	
stimulation	for	the	H37Rv	pilot	study.		The	frequency	of	Bregs	was	expressed	as	a	percentage	of	CD19+	B-cells,	in	which	Bregs	were	defined	by	the	phenotype	CD19+CD24hiCD38hi.	Differences	in	the	mean	Bregs	frequencies	 between	 the	 QFN	 positive	 and	 negative	 group	 were	 investigated	 for	 the	 relevant	stimulatory	conditions.	Samples	were	pooled	according	to	QFN	status	and	stimulation	condition	prior	to	flow	cytometry	analysis,	prohibiting	the	performance	of	statistical	analysis.		 	
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3.2	FasL-expressing/Killer	B-cell	frequencies	Isolated	B-cells	were	pulsed	with	CD40L	and	IL5,	in	combination	with	H37Rv	infection,	to	evaluate	the	relative	expression	of	FasL	by	B-cells	following	M.tb	infection.	Following	stimulation,	the	frequency	of	killer	B-cells	in	response	to	the	various	culture	conditions	was	investigated.	The	expression	of	CD178	(FasL)	was	evaluated	in	association	with	CD125	(IL5Ra),	as	signalling	via	this	cell	surface	receptor	has	been	 implicated	 in	 killer	 B-cell	 development.	 Killer	 B-cells	 were	 defined	 by	 the	 phenotype	CD19+CD5+IgM+CD38+CD178+.	 A	 pattern	 of	 increased	 mean	 killer	 B-cells	 (CD178+)	 frequencies,	regardless	of	IL5Ra	expression,	was	observed	for	the	QFN	positive	group	(Figure	4.2a,	H37Rv	0.25%;	CD40L+IL5	0.34%;	H37Rv+CD40L+IL5	0.23%	vs	Unstimulated	0.21%;	and	Figure	4.2b,	H37Rv	0.074%;	CH37Rv+D40+IL5	0.059	vs	Unstimulated	0.039%)	 in	response	 to	antigenic	stimulation	compared	to	unstimulated	 B-cells.	 Similarly,	 a	 pattern	 of	 increased	 mean	 killer	 B-cells	 (CD178+)	 frequencies,	regardless	of	IL5Ra	expression,	was	observed	for	the	QFN	negative	group	(Figure	4.2a,	H37Rv	0.022%;	CD40L+IL5	 0.098%;	 H37Rv+CD40L+IL5	 0.083%	 vs	 Unstimulated	 0.011%;	 and	 Figure	 4.2b,	 H37Rv	0.029%;	 CD40L+IL5	 0.049%;	 H37Rv+CD40L+IL5	 0.006%	 vs	 Unstimulated	 0.000%)	 in	 response	 to	stimulation	with	either	H37Rv	or	CD40L	and	IL5Ra	compared	to	unstimulated	B-cells.		Furthermore,	a	pattern	of	increased	mean	IL5Ra	expression	by	B-cells,	regardless	of	FasL	expression,	was	observed	for	the	QFN	positive	group	(Figure	4.2a;	Figure	4.2c,	H37Rv	0.089%;	CD40L+IL5	0.100%;	H37Rv+CD40L+IL5	 0.044%	 vs	 Unstimulated	 0.052%)	 following	 stimulation	 with	 either	 H37Rv	 or	CD40L	 and	 IL5Ra	 compared	 to	 unstimulated	 B-cells.	 Likewise,	 a	 pattern	 of	 increased	mean	 IL5Ra	expression	by	B-cells,	 regardless	of	FasL	expression,	was	observed	 for	both	 the	QFN	negative	group	(Figure	 4.2a;	 Figure	 4.2c,	 H37Rv	 0.037%;	 CD40L+IL5	 0.029%;	 H37Rv+CD40L+IL5	 0.026%	 vs	Unstimulated	 0.011%)	 following	 stimulation	 with	 either	 H37Rv	 or	 CD40L	 and	 IL5Ra	 compared	 to	unstimulated	B-cells.		In	 all	 instances,	 a	higher	 incidence	of	 killer-B	 frequencies	was	observed	 for	 the	QFN	positive	 group	compared	to	the	QFN	negative	group	(Figure	4.2),	with	the	exception	of	FasL+IL5Ra-	killer	B-cells	 in	response	to	CD40L	and	IL5	stimulation	(Figure	4.2b).	Notably,	the	significance	of	these	differences	could	not	be	investigated	due	to	the	pooling	of	samples	as	previously	described.	As	such,	the	implication	of	these	differences	could	not	be	determined,	due	to	lack	of	insight	into	individual	sample	variation.			 	
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Figure	4.2.	Evaluation	of	Killer	(FasL-expressing)	B-cell	frequencies	following	antigenic	
stimulation	for	the	H37Rv	Pilot	study.		The	frequency	of	killer	B-cells	was	expressed	as	a	percentage	of	 CD19+IgM+	 B-cells,	 in	 which	 killer	 B-cells	 were	 defined	 by	 the	 phenotype	CD19+CD5+IgM+CD38+CD178+.	 Additionally,	 expression	 of	 interleukin-5	 receptor	 alpha	 (IL5Ra)	 was	investigated	 as	 engagement	 of	 this	 receptor	 with	 IL5	 is	 associated	 with	 killer	 B-cell	 development.	Differences	in	the	mean	frequencies	between	the	QFN	positive	and	negative	group	were	investigated	for	the	relevant	stimulatory	conditions.	(a)	IL5Ra-expressing	killer	B-cell	frequencies	(CD125+CD178+)	for	the	 various	 stimulatory	 conditions.	 (b)	 Killer	 B-cell	 frequencies	 (CD125-CD178+)	 for	 the	 various	stimulatory	 conditions.	 (c)	 IL5Ra-expressing	 B-cell	 frequencies	 (CD125+CD178-)	 for	 the	 various	stimulatory	conditions.	Samples	were	pooled	according	to	QFN	status	and	stimulation	condition	prior	to	flow	cytometry	analysis,	prohibiting	the	performance	of	statistical	analysis.		 	
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3.3	Fas-expressing	T-cell	frequencies	A	subtle	increase	in	mean	Fas	expression	levels	by	CD4+	(Figure	4.3a,	15.1%	vs	10.6%)	and	CD8+	(Figure	4.3b,	 13,3%	 vs	 11.6%)	 T-cells	 was	 observed	 for	 the	 QFN	 positive	 group	 following	 co-culture	 with	unstimulated	B-cells.	In	contrast,	co-culture	of	T-cells	with	unstimulated	B-cells	for	the	QFN	negative	group	resulted	in	a	decrease	in	Fas	expression	by	CD4+	(Figure	4.3a,	3.67%	vs	6.74%)	and	CD8+	(Figure	4.3b,	3.94%	vs	8.03%)	T-cells.	However,	the	inference	of	these	differences	could	not	be	determined,	due	to	 pooling	 of	 samples	 prior	 to	 flow	 cytometry	 analysis,	 prohibiting	 insight	 into	 individual	 sample	variation.		Remarkably,	co-culture	of	T-cells	with	autologous	pre-stimulated	B-cells	resulted	in	decreased	mean	frequencies	of	CD4+Fas+	(8.36-10.7%	vs	15.1%)	and	CD8+Fas+	T-cells	(9.39-11.9%	vs	13.3%)	for	the	QFN	positive	group,	whilst	increased	the	mean	frequencies	of	CD4+Fas	+	(4.66-5.21%	vs	3.67%)	and	CD8+Fas+	T-cells	 (5.23-6.29%	vs	3.94)	was	 observed	 for	 the	QFN	negative	 group	under	 the	 same	 stimulatory	conditions	(Figure	4.3).	As	previously	alluded	to,	the	statistical	significance	of	these	differences	could	not	be	determined	due	to	pooling	of	samples.			 	
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Figure	 4.3.	 Evaluation	 of	 Fas-expressing	 T-cell	 frequencies	 following	 co-culture	 with	
autologous	pre-stimulated	B-cells	for	the	H37Rv	Pilot	study.		The	frequency	of	Fas+	(CD95+)	for	each	of	the	investigated	T-cells	populations	was	expressed	as	a	percentage	of	CD4+	and	CD8+	T-cells,	in	(a)	and	(b)	respectively.	A	control	condition,	in	which	T-cells	were	cultured	in	the	absence	of	pre-stimulated	B-cells,	was	used	as	the	reference	of	basal	T-cell	phenotypic	frequencies.	Differences	in	the	mean	Fas-expression	between	the	QFN	positive	and	negative	group	were	investigated	for	the	relevant	stimulatory	conditions.	 (a)	 CD4+Fas+(CD95+)	 T-cell	 frequencies	 for	 the	 various	 stimulatory	 conditions	 (b)	CD8+Fas+(CD95+)	 T-cell	 frequencies	 for	 the	 various	 stimulatory	 conditions.	 Samples	 were	 pooled	according	 to	QFN	 status	 and	 stimulation	 condition	prior	 to	 flow	cytometry	 analysis,	 prohibiting	 the	performance	of	statistical	analysis		 	
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3.4	Effector	T-cell	and	Regulatory	T-cell	frequencies	The	ability	of	B-cells	to	alter	T-cell	 function	was	evaluated,	by	assessing	alterations	in	effector	T-cell	(TE)	phenotypic	frequencies	following	co-culture	with	autologous,	pre-stimulated	B-cells.	Effector	T-cells	 were	 defined	 by	 the	 phenotype	 CD3+CD4+CD25+.	 Within	 the	 H37Rv	 Pilot	 study,	 a	 pattern	 of	decreased	mean	TE	frequencies	was	observed	for	both	the	QFN	positive	(6.49-7.00%	vs	8.22%)	and	negative	group	(1.63-4.16%	vs	9.60%)	for	all	culture	conditions	in	which	autologous	T-cells	were	co-cultured	 with	 pre-stimulated	 B-cells,	 compared	 to	 the	 control	 condition	 consisting	 of	 T-cells	 only	(Figure	4.4a).	Paradoxically,	an	increase	in	mean	TE	frequencies	were	observed	following	co-culture	of	T-cells	with	unstimulated	B-cells	for	the	QFN	positive	group	(Figure	4a,	9.94%	vs	8.22%).	Markedly,	the	implication	 of	 these	 differences	 could	 not	 be	 determined,	 due	 to	 pooling	 of	 samples	 prior	 to	 flow	cytometry	analysis,	prohibiting	insight	into	individual	sample	variation.			Within	the	BCG	pilot	study,	a	similar	pattern	of	decreased	TE	frequency	was	observed,	although	not	significant	in	all	cases,	for	both	QFN	positive	and	negative	individuals,	for	all	culture	conditions	where	pre-stimulated	 B-cells	 were	 present	 compared	 to	 T-cells	 only	 (Figure	 4.4b).	 Notably,	 a	 significant	decrease	 in	 TE	 frequencies	 was	 observed	 for	 QFN	 negative	 individuals	 following	 coculture	 with	BCG+CD40L+IL5	stimulated	B-cells	compared	to	T-cells	only	(p=0.01,	Figure	4.4b).	Following	culture	of	T-cells	with	unstimulated	B-cells,	a	non-significant	increase	in	TE	frequencies	was	observed	for	QFN	positive	individuals.		Interestingly,	elevated	mean	frequencies	of	TE	were	observed	for	the	QFN	positive	group	in	all	instances	where	T-cells	were	 cultured	 in	 combination	with	autologous	B-cells,	 compared	 to	 the	QFN	negative	group.	However,	in	the	case	of	the	BCG	pilot	study,	no	significant	differences	were	observed.			 	
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Figure	 4.4.	 Evaluation	 of	 effector	 T-cell	 (TE)	 frequencies	 following	 co-culture	 with	
autologous	pre-stimulated	B-cells.	 	The	frequency	of	TE	was	expressed	as	a	percentage	of	CD3+	T-cells,	in	which	TEs	were	defined	by	the	phenotype	CD3+CD4+CD25+.	A	control	condition,	in	which	T-cells	were	 cultured	 in	 the	 absence	 of	 pre-stimulated	 B-cells,	 was	 used	 as	 the	 reference	 for	 basal	 T-cell	phenotypic	 frequencies.	Differences	 in	mean	TE	 frequencies	between	 the	QFN	positive	and	negative	groups	were	 investigated	 for	 the	relevant	stimulatory	conditions.	 (a)	TE	 frequencies	 for	 the	various	stimulatory	conditions	observed	for	H37Rv	Pilot	study.	Samples	were	pooled	according	to	QFN	status	and	stimulation	condition	prior	to	flow	cytometry	analysis,	prohibiting	the	performance	of	statistical	analysis	(b)	TE	frequencies	for	the	various	stimulatory	conditions	observed	for	BCG	pilot	study.	Whisker	denote	min	and	max.	Comparisons	between	groups	was	calculated	using	the	Mann	Whitney	U-test,	and	differences	within	groups	was	calculated	using	the	Kruskal-Wallis	with	Dunns	multiple	comparisons	post-hoc	test.	Statistical	significance	is	indicated	by	an	asterisk	(*),	where	the	p	<	0.05.			 	
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Additionally,	the	ability	of	B-cells	to	modulate	regulatory	T-cell	(Treg)	phenotypic	frequencies	following	co-culture	 was	 investigated.	 Regulatory	 T-cells	 were	 defined	 by	 the	 phenotype	 CD3+CD4+CD25hi.	Additional	Treg	markers	such	as	CD127	and	FoxP3	were	not	included	in	this	analysis,	limiting	the	validity	of	 the	 defined	 cell	 population	 as	 true	 Tregs.	 Within	 the	 H37Tv	 pilot	 study,	 a	 decrease	 in	 mean	 Treg	frequencies	was	observed	for	both	the	QFN	positive	(0.28%	vs	0.41%)	and	negative	group	(0.048%	vs	0.41%)	following	co-culture	of	autologous	T-cells	with	unstimulated	B-cells	(Figure	4.5a).	Likewise,	a	pattern	 of	 decreased	mean	Treg	 frequencies	were	 observed,	 for	 the	QFN	positive	 (Figure	 4.5a,	 0.29-0.37%	vs	0.41%)	and	negative	group	(Figure	4.5a,	0.037-0.092%	vs	0.41%),	for	all	culture	conditions	where	pre-stimulated	B-cells	were	present	 compared	 to	T-cells	only.	Cell	 viability	was	not	assessed	post-co-culture,	hence	the	observed	decrease	in	Treg	numbers	could	be	a	result	of	cell	death	rather	than	B-cell	modulation.		A	comparison	of	mean	Treg	frequencies	between	the	various	stimulatory	conditions,	for	both	the	QFN	positive	 and	 negative	 group,	 revealed	 that	 H37Rv	 stimulation	 resulted	 in	 slightly	 higher	 Treg	 levels	compared	 to	 CD40	 and	 IL5	 stimulation	 (QFN	 positive:	 0.37%	 vs	 0.29%;	 QFN	 negative:	 0.092%	 vs	0.079%),	 as	well	 as	H37Rv	 in	 combination	with	 CD40	 and	 IL5	 (QFN	 positive:	 0.37%	 vs	 0.3%;	QFN	negative:	0.092%	vs	0.037%).	Once	more,	the	implication	of	these	differences	could	not	be	determined,	due	to	pooling	of	samples	prior	to	flow	cytometry	analysis,	prohibiting	insight	into	individual	sample	variation.		Opposingly,	an	increase	in	Treg	frequencies	was	observed	for	both	QFN	positive	and	negative	individuals	within	the	BCG	pilot	study,	following	co-culture	of	T-cells	with	unstimulated	B-cells	(Figure	4.5b).	On	the	 contrary,	 a	 pattern	 of	 decreased	 Treg	 frequency,	 similar	 to	 that	 of	 the	 H37Rv	 pilot	 study,	 was	observed	for	both	QFN	positive	and	negative	individuals,	for	all	culture	conditions	where	pre-stimulated	B-cells	were	present	compared	to	T-cells	only	(Figure	4.5b).			Interestingly,	 elevated	 mean	 frequencies	 of	 Tregs	 were	 observed	 for	 the	 QFN	 positive	 group	 in	 all	instances	where	T-cells	were	cultured	in	combination	with	autologous	B-cells,	compared	to	the	QFN	negative	group.	Again,	in	the	case	of	the	BCG	pilot	study,	no	significant	differences	were	observed.			 		 	
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Figure	 4.5.	 Evaluation	 of	 regulatory	T-cell	 (Treg)	 frequencies	 following	 co-culture	with	
autologous	pre-stimulated	B-cells.		The	frequency	of	Tregs	was	expressed	as	a	percentage	of	CD3+	T-cells,	in	which	Tregs	were	defined	by	the	phenotype	CD3+CD4+CD25hi.	A	control	condition,	in	which	T-cells	were	cultured	in	the	absence	of	pre-stimulated	B-cells,	was	used	as	the	reference	for	basal	T-cell	phenotypic	frequencies.	Differences	in	mean	Treg	 frequencies	between	the	QFN	positive	and	negative	groups	were	investigated	for	the	relevant	stimulatory	conditions.	(a)	Treg	 frequencies	for	the	various	stimulatory	conditions	observed	for	H37Rv	Pilot	study.	Samples	were	pooled	according	to	QFN	status	and	stimulation	condition	prior	to	flow	cytometry	analysis,	prohibiting	the	performance	of	statistical	analysis	 (b)	 Treg	 frequencies	 for	 the	 various	 stimulatory	 conditions	 observed	 for	 BCG	 pilot	 study.	Whisker	denote	min	and	max.	Comparisons	between	groups	was	calculated	using	the	Mann	Whitney	U-test,	 and	 differences	 within	 groups	 was	 calculated	 using	 the	 Kruskal-Wallis	 with	 Dunns	 multiple	comparisons	post-hoc	test.	Statistical	significance	is	indicated	by	an	asterisk	(*),	where	the	p	<	0.05.				 	
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3.5	T-cell	cytokine	production	profiles	The	modulatory	effect	of	B-cells	on	T-cell	cytokine	production	was	evaluated,	to	determine	whether	or	not	B-cells	had	the	ability	to	manipulate	T-cell	function.	The	results	obtained	from	the	H37Rv	pilot	study	for	each	of	the	stimulation	conditions	with	respect	to	QFN	status	are	initially	described,	followed	by	the	results	observed	within	the	BCG	pilot	study	for	clear	comparison.			The	following	CD4+	T-cells	cytokine	profiles	were	observed	for	the	QFN	positive	group:	Unstimulated	B-cells	within	the	H37Rv	pilot	study	(Figure	4.6a)	induced	CD4+TNFa+	T-cells.	In	contrast,	unstimulated	B-cells	within	the	BCG	pilot	study	(Suppl	Figure	4.6a)	induced	CD4+IL2+T-cells,	as	well	as	CD4+IFNγ+IL2+	T-cells	(ns,	p>0.05).	B-cells	pre-stimulated	with	H37Rv	or	BCG	induced	a	similar	cytokine	milieu	to	that	of	unstimulated	B-cells	within	the	BCG	pilot	study,	with	the	addition	of	CD4+IFNγ+TNFa+	T-cells	(ns,	p>0.05).	B-cells	stimulated	with	CD40L	and	IL5	(i.e.	induction	of	FasL	expression),	within	the	H37Rv	pilot	 study,	 resulted	 in	 increased	 CD4+IFNγ+IL2+,	 CD4+IFNγ+	 and	 CD4+IL2+T-cells.	 Similarly,	 B-cells	stimulated	with	CD40L	and	IL5,	within	the	BCG	pilot	study,	induced	CD4+IFNγ+IL2+	T-cells	(ns,	p>0.05).	Lastly,	B-cells	stimulated	with	H37Rv	in	combination	with	CD40L	and	IL5	increased	CD4+IFNγ+TNFa+,	CD4+IL2+,	CD4+IFNγ+IL2+	and	CD4+TNFa+	T-cells,	whereas	B-cells	stimulated	with	BCG	in	combination	CD40L	and	IL5	induced	CD4+IFNγ+TNFa+	and	CD4+IFNγ+TNFa+	T-cells	(ns,	p>0.05).		The	CD4+	T-cells	cytokine	profiles	observed	for	the	QFN	negative	group	included:	Unstimulated	B-cells	within	 the	H37Rv	pilot	study	 induced	CD4+IL2+,	CD4+IFNγ+IL2+	and	CD4+IFNγ+TNFa+	T-cells	 (Figure	4.6b);	whereas,	unstimulated	B-cells	within	the	BCG	pilot	study	(Suppl	Figure	4.6b)	induced	an	increase	in	CD4+TNFa+,	CD4+TNFa+IL2+,	CD4+IFNγ+IL2+	and	CD4+IFNγ+TNFa+	T-cells	(ns,	p>0.05).	B-cells	pre-stimulated	with	H37Rv	induced	CD4+TNFa+IL2+	T-cells	(ns,	p>0.05),	while	B-cells	stimulated	with	BCG	induced	upregulation	of	CD4+TNFa+	T-cells.	B-cells	stimulated	with	CD40L	and	IL5	within	the	H37Rv	pilot	 study	 resulted	 in	 a	 distinct	 alteration	 in	 the	 cytokine	 milieu,	 in	 which	 CD4+IL2+,	 CD4+IFNγ+,	CD4+TNFa+,	 CD4+IFNγ+TNFa+	 and	 CD4+IFNγ+IL2+	 T-cells	 were	 induced.	 In	 comparison,	 B-cells	stimulated	 with	 CD40L	 and	 IL5	 within	 the	 BCG	 pilot	 study	 resulted	 in	 the	 induction	 of	 CD4+IL2+,	CD4+IFNγ+	and	CD4+TNFa+	T-cells.	Finally,	B-cells	stimulated	with	H37Rv	in	combination	with	CD40L	and	IL5	increased	CD4+IL2+,	CD4+IFNγ+TNFa+	and	CD4+TNFa+	T-cells.	Comparably,	B-cells	stimulated	with	BCG	in	combination	with	CD40L	and	IL5	increased	CD4+IL2+,	CD4+IFNγ+TNFa+	and	CD4+IFNγ+IL2+	T-cells	(ns,	p>0.05).				 	
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Figure	 4.6.	 Cytokine	 secretion	 profile	 of	 CD4+	 T-cells	 following	 co-culture	 with	 pre-
stimulated	B-cells	for	the	H37Rv	Pilot	study.	The	proportion	of	cells	expressing	various	combinations	of	cytokines	is	calculated	as	a	function	of	the	total	frequency	of	cytokine	producing	cells.	Alterations	in	cytokine	production	for	each	of	the	culture	conditions	was	compared	to	the	control	condition	consisting	of	T-cells	only.	The	control	condition	served	as	a	representation	of	basal	cytokine	production	 levels;	these	background	 levels	were	 subtracted	 from	 the	 various	 stimulatory	 conditions	 and	 the	 resulting	profiles	reported	(a)	Cytokine	profiles	of	CD4+	T-cells	for	each	of	the	stimulatory	conditions	observed	for	the	QFN	positive	group.	(b)	Cytokine	profiles	of	CD4+	T-cells	for	each	of	the	stimulatory	conditions	observed	for	the	QFN	negative	group.			 	
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The	CD8+	T-cells	cytokine	profiles	observed	for	the	QFN	positive	group	demonstrated:	Unstimulated	B-cells	within	 the	H37Rv	pilot	 study	 induced	CD8+TNFa+,	 CD8+IL2+	 and	CD8+IFNγ+IL2+	T-cells	 (Figure	4.7a),	whereas,	unstimulated	B-cells	within	the	BCG	pilot	study	(Suppl	Figure	4.7a)	did	not	induce	any	change	within	the	cytokine	milieu.	B-cells	stimulated	with	H37Rv	increased	the	number	of	CD8+IL2+,	CD8+IFNγ+	and	CD8+TNFa+IL2+	T-cells,	as	well	as	multifunctional	(CD8+IFNγ+TNFa+IL2+)	T-cells.	While	B-cells	pre-stimulated	with	BCG	induced	CD8+TNFa+,	CD8+IFNγ+TNFa+	and	CD8+TNFa+IL2+	T-cells	(ns,	p>0.05).	B-cells	stimulated	with	CD40L	and	IL5	within	the	H37Rv	pilot	study	induced	CD8+IFNγ+	and	CD8+IFNγ+TNFa+	 T-cells,	 and	 B-cells	 stimulated	 with	 H37Rv	 in	 combination	 with	 CD40L	 and	 IL5	increased	CD8+IL2+	and	CD8+IFNγ+	T-cell	frequencies.	In	contrast,	B-cells	stimulated	with	CD40L	and	IL5	within	the	BCG	pilot	study	resulted	 in	an	 increase	 in	CD8+IFNγ+,	CD8+IL2+,	CD8+	TNFa+	 IL2+	and	multifunctional	T-cells	(ns,	p>0.05).	B-cells	stimulated	with	BCG	in	combination	with	CD40L	and	IL5	induced	as	similar	cytokine	milieu,	with	the	addition	of	CD8+TNFa+	T-cells	(ns,	p>0.05).			Finally,	the	CD8+	T-cells	cytokine	profiles	observed	for	the	QFN	negative	group	showed:	Unstimulated	B-cells,	 within	 the	 H37Rv	 pilot	 study,	 induced	 CD8+IL2+,	 CD8+TNFa+	 and	 CD8+IFNγ+TNFa+	 T-cells	(Figure	4.7b).	In	contrast,	unstimulated	B-cells	within	the	BCG	pilot	study	(Suppl	Figure	4.7b)	induced	an	increase	in	CD8+IFNγ+,	CD8+IL2+	and	CD8+IFNγ+IL2+	T-cells.	B-cells	stimulated	with	H37Rv	resulting	in	increased	CD8+IFNγ+	T-cell	frequencies,	whilst	B-cells	pre-stimulated	with	BCG	induced	CD8+	TNFa+	and	CD8+	TNFa+IL2+	T-cells	(ns,	p>0.05).	B-cells	stimulated	with	CD40L	and	IL5,	within	the	H37Rv	pilot	study,	induced	CD8+IL2+	T-cells.	Similarly,	B-cells	stimulated	with	CD40L	and	IL5,	within	the	BCG	pilot	study,	resulted	in	an	increase	in	CD8+IL2+	T-cells,	as	well	as	CD8+IFNγ+	T-cells	(ns,	p>0.05).	Lastly,	B-cells	stimulated	with	H37Rv	in	combination	with	CD40L	and	IL5	induced	CD8+IFNγ+,	CD8+TNFa+	and	CD8+IFNγ+TNFa+	 T-cells,	 whereas	 B-cells	 stimulated	with	 BCG	 in	 combination	with	 CD40L	 and	 IL5	increased	CD8+IFNγ+	and	CD8+IL2+	and	CD8+TNFa+	T-cells	(ns,	p>0.05).		Importantly,	no	significant	differences	between	the	QFN	positive	and	negative	groups	were	observed	for	either	CD4+	or	CD8+	T-cell	cytokine	responses	within	the	BCG	pilot	study,	whilst	significance	within	the	H37Rv	pilot	study	could	not	be	evaluated	due	to	pooling	of	samples	according	to	QFN	status	and	stimulation	condition	prior	to	flow	cytometry	analysis.	
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Figure	 4.7.	 Cytokine	 secretion	 profile	 of	 CD8+	 T-cells	 following	 co-culture	 with	 pre-
stimulated	B-cells	for	the	H37Rv	Pilot	study.	The	proportion	of	cells	expressing	various	combinations	of	cytokines	is	calculated	as	a	function	of	the	total	frequency	of	cytokine	producing	cells.	Alterations	in	cytokine	production	for	each	of	the	culture	conditions	was	compared	to	the	control	condition	consisting	of	T-cells	only.	The	control	condition	served	as	a	representation	of	basal	cytokine	production	 levels;	these	background	 levels	were	 subtracted	 from	 the	 various	 stimulatory	 conditions	 and	 the	 resulting	profiles	reported	(a)	Cytokine	profiles	of	CD8+	T-cells	for	each	of	the	stimulatory	conditions	observed	for	the	QFN	positive	group.	(b)	Cytokine	profiles	of	CD8+	T-cells	for	each	of	the	stimulatory	conditions	observed	for	the	QFN	negative	group.		
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3.6	B-cell	cytokine	responses	The	 cytokine	 responses	 of	 B-cells	 following	 antigenic	 stimulation	 was	 investigated.	 Cell	 culture	supernatants	were	collected	at	different	time	points,	namely	3-hours	post	stimulation	(denoted	as	time	point	1)	and	19-hours	post	co-culture	with	autologous	T-cells	(denoted	as	time	point	2).			Differences	between	cell	 culture	supernatants	of	 stimulated	B-cells	 (in	 the	absence	of	autologous	T-cells),	collected	at	time	point	1	and	time	point	2,	were	investigated	to	determine	the	effects	of	culture	time	on	B-cell	cytokine	secretion.	A	general	pattern	of	decreased	cytokine	expression	was	observed	for	all	investigated	analytes	at	time	point	2	compared	to	time	point	1	(Figure	4.8).	Significant	differences	were	 observed	 for	 the	 majority	 of	 the	 measured	 cytokines,	 namely	 APRIL	 (p=0.0040),	 ICAM-1	(p=0.0044),	IFN-β	(p=0.0040),	IFN-γ	(p=0.0057),	IL-1β	(p=0.0040),	IL-2	(p=0.0089),	IL-4	(p=0.0040),	IL-6	(p=0.0090),	IL-10	(p=0.0040),	IL-12p70	(p=0.0041),	IL-21	(p=0.0040)	and	TNF-α	(p=0.0090);	with	the	exception	of	 soluble	FasL	 (sFasL)	 (p=0.0597),	BAFF	 (p=0.0230),	 IL17A	(p=0.2376)	and	all	 three	isotypes	 of	 TGFb	 (TGFb1,	 p=0.0827;	 TGFb2,	 p=0.2725;	 TGFb3,	 p=0.4004).	 Interestingly,	 QFN	 status	(Suppl	Figure	4.8)	and	stimulation	conditions	(Suppl	Figure	4.9)	had	no	significant	effect	on	the	overall	cytokine	production	by	B-cells.	However,	a	significant	increase	in	relative	cytokine	expression	of	APRIL	(p=0.0134),	IFN-b	(p=0.0105),	IL-1b	(p=0.0061),	IL-2	(p=0.0030),	IL-4	(p=0.0118),	IL-10	(p=0.0097),	IL-12	p70	(p=0.0238)	and	IL21(p=0.0360),	was	observed	following	infection	with	H37Rv	compared	to	unstimulated	controls.	Similarly,	a	 significant	 increase	 in	 the	expression	of	APRIL	(p=0.0413),	 IFN-b	(p=0.0233),	 IL-1b	 (p=0.0210),	 IL-2	 (p=0.0268),	 IL-4	 (p=0.0258),	 IL-10	 (p=0.0166),	 IL-12	 p70	(p=0.0386)	and	IL21(p=0.0123),	was	observed	following	infection	with	H37Rv	compared	to	CD40L	and	IL5	stimulate	samples.	Moreover,	a	considerable	increase	in	ICAM-1	(p=0.0093)	and	IFN-γ	(p=0.0346)	was	 observed	 following	 H37Rv	 infection	 compared	 to	 the	 unstimulated	 control,	 while	 negligible	differences	 were	 observed	 compared	 to	 CD40L	 and	 IL5	 stimulation,	 as	 well	 as	 CD40L	 and	 IL5	 in	combination	with	H37Rv.	A	considerable	increase	in	TNF-α	was	observed	for	all	stimulatory	conditions,	namely	H37Rv	(p=0.0414),	CD40L	and	IL5	(p=0.0208)	as	well	as	CD40	and	IL5	 in	combination	with	H37Rv	(p=0.0049),	compared	to	the	unstimulated	control.	Likewise,	a	considerable	increase	in	IL-6	was	observed	 for	 the	 stimulatory	 conditions	 CD40L	 and	 IL5	 (p=0.0145)	 as	 well	 as	 CD40	 and	 IL5	 in	combination	 with	 H37Rv	 (p=0.0019),	 compared	 to	 the	 unstimulated	 control.	 Lastly,	 the	 combined	effects	of	QFN	status	and	stimulation	condition	on	B-cell	cytokine	expression	was	investigated	(Suppl	Table	4.2).	For	all	cases,	no	significant	difference	between	QFN	positive	and	negative	 individuals	 for	each	of	the	stimulatory	conditions	was	observed	(Suppl	Figure	4.10),	but	rather	a	trend	of	heightened	cytokine	responses	in	response	to	H37Rv	infection	observed	for	all	individuals,	regardless	of	QFN	status.			
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Figure	 4.8.	 Effect	 of	 culture	 time	 on	 cytokine	 secretion	 by	 B-cells	 following	 antigenic	
stimulation	 for	 the	H37Rv	Pilot	 study.	 Cell	 culture	 supernatants	were	 collected	 at	 different	 time	points,	namely	3-hours	post	stimulation	and	19-hours	post	co-culture	with	autologous	T-cells.	Whisker	denote	10-90	percentile.	Statistical	differences	between	culture	conditions	was	calculated	using	a	four-way	mixed	model	ANOVA.	Comparisons	within	groups	was	calculated	using	the	Fishers	LSD	post-hoc	test.	A	two-way	step-up	Benjamini,	Krieger	and	Yekutieli	False	Discovery	rate	(FDR),	with	a	FDR	of	1%,	was	used	to	correct	for	multiple	testing.	Statistical	significance	is	indicated	by	an	asterisk,	in	which	p	<	0.05	 (*)	 and	 p<0.01(**).	 (a)	 Effect	 of	 culture	 time	 on	 B-cell	 secretion	 factors	 following	 antigenic	stimulation	 of	 B-cells.	 (b)	 Effect	 of	 culture	 time	 on	 interleukin	 (IL)	 production	 following	 antigenic	stimulation	 of	 B-cells.	 (c)	 Effect	 of	 culture	 time	 on	 TGFb	 isotype	 secretion	 following	 antigenic	stimulation	of	B-cells.		 	
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In	addition,	differences	between	cell	culture	supernatants	collected	19-hours	post	co-culture,	in	which	B-cells	 were	 culture	 with/without	 autologous	 T-cells,	 was	 investigated	 to	 determine	 whether	 the	presence	of	T-cells	had	any	effect/contribution	to	the	microenvironment.	Once	more,	the	effect	of	QFN	status	on	cytokine	expression	was	investigated,	in	which	no	significant	difference	between	QFN	positive	and	 negative	 individuals	 was	 observed	 (Suppl	 Figure	 4.11).	 Moreover,	 the	 effects	 of	 stimulation	condition	on	measured	cytokine	levels	was	investigated	(Suppl	Figure	4.12).	A	significant	decrease	in	BAFF	 was	 observed	 for	 the	 culture	 condition	 in	 which	 T-cells	 were	 cultured	 alone	 compared	 to	conditions	 in	 which	 B-cells	 were	 present,	 namely	 B-cells	 only	 (p=0.0000),	 B+H37Rv	 (p=0.0000),	B+CD40L+IL-5	 (p=0.0000),	 B+CD40L+IL-5+H37Rv	 (p=0.0000),	 T+B	 (p=0.0000),	 T+B+H37Rv	(p=0.0000),	 T+B+CD40L+IL-5	 (p=0.0000)	 and	 T+B+CD40L+IL-5+H37Rv	 (p=0.0000)	 (Suppl	 Figure	4.12e).	Similarly,	a	significant	decrease	in	TGF-b1	was	observed	for	the	culture	condition	in	which	T-cells	were	cultured	alone	compared	to	the	conditions	B-cells	only	(p=0.0024),	B+H37Rv	(p=0.0015),	B+CD40L+IL-5	 (p=0.0005),	 B+CD40L+IL-5+H37Rv	 (p=0.0012),	 T+B	 (p=0.0016),	 T+B+H37Rv	(p=0.0044),	 T+B+CD40L+IL-5	 (p=0.0016)	 and	 T+B+CD40L+IL-5+H37Rv	 (p=0.0134)	 (Suppl	 Figure	4.12p).	 Furthermore,	 a	 significant	 increase	 in	 sFasL	 expression	 was	 observed	 following	 culture	 of	unstimulated	 B-cells	 with	 autologous	 T-cells	 compared	 to	 B-cells	 alone	 (p=0.0375),	 B+H37Rv	(p=0.0439),	 B+CD40L+IL-5	 (p=0.0479),	 B+CD40L+IL-5+H37Rv	 (p=0.0113),	 T+B+H37Rv	 (p=0.0452)	and	T+B+CD40L+IL-5	(p=0.0310).			Once	 more,	 the	 combined	 effects	 of	 QFN	 status	 and	 stimulation	 condition	 on	 observed	 cytokine	expression	was	investigated.	For	majority	of	cases,	no	difference	was	observed	between	QFN	positive	and	negative	individuals	for	each	of	the	stimulatory	conditions	(Suppl	Table	4.3).	However,	a	significant	increase	 in	 sFasL	 expression	 (p=0.0006)	was	observed	 for	QFN	negative	 compared	 to	QFN	positive	individuals	 following	 culture	 of	 T-cells	 with	 unstimulated	 B-cells	 (Suppl	 Figure	 4.13b).	 Similarly,	 a	significant	increase	in	the	expression	of	IFN-b	(p=0.0349)	and	ICAM-1	(p=0.0168)	was	observed	for	QFN	negative	 individuals	 following	 co-culture	 of	 T-cells	 with	 H37Rv	 stimulated	 B-cells	 compare	 to	 QFN	positive	individuals	(Suppl	Figure	4.13c	and	f,	respectively).		Additionally,	a	significant	increase	in	the	expression	of	IL-2	(p=0.0475)	was	observed	for	QFN	negative	individuals	following	co-culture	of	T-cells	with	 H37Rv	 stimulated	 B-cells	 compare	 to	 QFN	 positive	 individuals	 (Suppl	 Figure	 4.13i).	 Finally,	 a	significant	increase	in	the	expression	of	IL-17A	(p=0.0007)	was	observed	for	QFN	negative	individuals	following	 co-culture	 of	 T-cells	 with	 CD40L	 and	 IL5	 stimulated	 B-cells	 compare	 to	 QFN	 positive	individuals	(Suppl	Figure	4.13n).		
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4.	Discussion	Immune	cells	capable	of	modulating	macrophage	and	T-cell	function	would	remarkably	impact	anti-TB	immunity	and	TB	disease	outcome.	Recent	advances	in	TB	research	have	highlighted	the	importance	of	additional	cells	types,	such	as	B-cells	and	NK	cells,	in	combating	M.tb	infection	(Achkar	et	al.,	2015;	Balu	et	al.,	2011;	Chan	et	al.,	2014;	Du	Plessis	et	al.,	2016b;	Kaufmann,	2002;	Li	et	al.,	2017;	Maglione	et	al.,	2007;	Rao	et	al.,	2015).	The	importance	of	B-cells	in	T-cell	activation	and	function	in	terms	of	traditional	immunological	roles	has	been	extensively	researched	(Abbas	et	al.,	2014;	Capra	et	al.,	1999;	Paul,	2013;	Pier	 et	 al.,	 2004).	 For	 instance,	 antigen	 presentation	 by	 B-cells	 greatly	 impacts	 T-cell	 behavior,	influencing	T-cell	differentiation	and	proliferation	(Crawford	et	al.,	2006;	Heesters	et	al.,	2016;	Kurt-Jones	 et	 al.,	 1988a;	 Lanzavecchia,	 1985).	 Furthermore,	 it	 has	 been	 revealed	 that	 T-cells	 acquire	additional	signaling	(apart	from	antigen	presentation)	in	order	for	complete	activation	to	occur.	This	includes	 direct	 engagement	 of	 co-receptors	 as	well	 as	 indirect	 signaling	 via	 soluble	 factors	 such	 as	cytokines,	illustrating	the	role	microenvironment	complexity	has	on	influencing	cell	function	(Abbas	et	al.,	2014;	Chambers	and	Allison,	1997;	Kurt-Jones	et	al.,	1988b;	Lanzavecchia,	1985).	These	complex	cellular	 interactions	 and	 the	 physiological	 relevance	 of	 each	 cell	 type	 during	 immune	 activation	translates	 to	 considerable	 changes	 in	 resulting	host	 immunity.	Emerging	evidence	 suggests	 that	 the	relationship	between	B-	and	T-cells	extends	far	beyond	this	simple	interaction,	and	that	B-cell	may	play	a	more	valuable	role	in	priming	T-cell	immune	responses	by	regulating	effector	and	regulatory	T-cell	frequencies	(Carter	et	al.,	2012,	2011;	Flores-Borja	et	al.,	2013;	Kessel	et	al.,	2012;	León	et	al.,	2014;	Linton	et	al.,	2003).		Thus,	 the	aim	of	 this	study	was	to	evaluate	 the	ability	of	B-cells	 to	modulate	T-cell	 function	–	 in	 the	context	 of	M.tb	 exposure	 -	 by	 investigating	 changes	 in	 T-cell	 phenotypic	 frequencies	 and	 cytokine	profiles	 following	 co-culture	 with	 autologous	 pre-stimulated	 B-cells.	 For	 the	 purpose	 of	 this	investigation,	 QFN	 positive	 and	 QFN	 negative	 individuals	 were	 recruited	 and	 analysed	 as	 separate	cohorts.	The	rationale	behind	comparing	the	observed	immune	responses	in	relation	to	QFN	status	is	the	fact	that	individuals	with	a	QFN	positive	status	represented	healthy	individuals	presumed	to	have	possible	latent	TB	infection	(LTBI);	while	the	latter	represented	healthy,	uninfected	individuals.	LTBI	may	 be	 defined	 as	 a	 state	 of	 persistence	 immune	 response	 to	 stimulation	 by	M.tb	 antigens,	 while	presenting	no	clinical	symptoms	of	active	disease	(WHO,	2018).	In	theory,	the	immune	response	of	QFN	positive	individuals	to	M.tb	infection	should	differ	in	magnitude	and	response	time	compared	to	QFN	negative	individuals	-	due	to	altered	basal	immune	function	and	acquisition	of	adaptive	memory.	It	is	assumed	 that	 QFN	 negative	 individuals	 will	 have	 heightened	 immune	 reaction	 in	 response	 to	immunogenic	stimulation	compared	to	QFN	positive	individuals,	whose	immune	cells	may	experience	cellular	 exhaustion	 due	 to	 constant	 antigenic	 stimulation.	 However,	 more	 investigation	 into	 this	occurrence	is	required	to	validate	this	perception.	Importantly,	QFN	positive	individuals	do	not	have	active	TB	disease,	indicating	that	their	immune	system	is	able	to	successfully	contain	or	eliminate	M.tb	
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infection	and	halt	progression	to	clinical	disease.	As	such,	understanding	the	complex	 functioning	of	immune	 cells	 within	 this	 cohort	 may	 reveal	 mechanisms	 that	 these	 individuals	 employ	 for	 the	successfully	combat	of	M.tb	 infection.	Evidently,	 the	absence	of	an	active	TB	cohort	within	the	study	design	 is	 a	 confounding	 limitation	 as	 all	 observations	 made	 within	 this	 study	 simply	 inferred	 the	proposed	significance	during	TB	disease,	rather	than	confirming	the	events.			Changes	in	B-cell	phenotypic	frequencies	in	response	to	M.tb	 infection	were	assessed	to	evaluate	the	potential	modulatory	effects	M.tb	stimulated	B-cells	may	have	on	anti-TB	immune	responses.	Currently,	no	distinct	phenotypic	signature	exists	 for	 the	classification	of	Bregs	or	killer	B-cells,	due	to	 the	 large	heterogenicity	 observed	 within	 these	 populations.	 Therefore,	 identification	 of	 the	 various	 B-cell	populations	 of	 interest	was	done	using	 a	 combination	of	markers	 listed	within	 literature	 and	 those	previously	 investigated	by	members	within	our	research	group	(Blair	et	al.,	2010;	Buffa	et	al.,	2013;	Flores-Borja	 et	 al.,	 2013;	 van	 Rensburg	 et	 al.,	 2017;	 van	 Rensburg	 and	 Loxton,	 2018b).	 Bregs	 were	identified	by	co-expression	of	the	cell	surface	markers	CD19	(the	B-cell	receptor),	CD38	(a	marker	of	activation)	 and	 CD24	 (a	 marker	 of	 cell	 maturation).	 Similarly,	 killer	 B-cells	 were	 identified	 by	 co-expression	of	CD19	and	CD38,	with	the	addition	of	CD178	(Fas	Ligand)	and	interleukin-5	receptor	alpha	(IL5Ra).	 It	 is	 important	to	note	that	due	to	 limited	cell	numbers,	samples	were	pooled	prior	to	 flow	cytometry	analysis,	prohibiting	assessment	of	individual	sample	distribution	and	statistically	significant	differences	 between	 cohorts	 or	 stimulation	 conditions.	 Consequently,	 observations	 made	 from	 the	resulting	data	depict	the	general	trends	for	each	of	the	experimental	conditions	under	comparison	and	is	not	based	on	statistical	analysis.	Markedly,	a	limitation	of	the	obtained	results	may	be	skewing	of	the	data	 by	 the	 inclusion	 of	 an	 outlier	 within	 the	 pooled	 sample	 fraction,	 resulting	 in	 artefactual	observations	that	are	not	 indicative	of	genuine	 immune	responses	within	the	general	population.	As	such,	any	assumptions	made	from	the	resulting	pilot	data	should	be	interpreted	with	caution.	Additional	experiments	 that	 address	 these	 restrictions	 are	 required	 before	 any	 convincing	 conclusions	 can	 be	made.		According	to	literature,	Bregs	function	within	the	immune	system	entails	suppression	of	effector		immune	responses,	such	as	those	elicited	by	CD4+	and	CD8+	T-cells	(Carter	et	al.,	2012,	2011;	Flores-Borja	et	al.,	2013;	Kessel	et	al.,	2012;	Liu	et	al.,	2016;	Lundy	and	Boros,	2002;	Nova-Lamperti	et	al.,	2016;	Siewe	et	al.,	2013).	In	many	cases,	Breg	frequencies	have	been	found	to	correlate	with	poor	disease	prognosis	-	due	to	suppression	of	protective	immune	responses	(Advani	et	al.,	2013;	Berntsson	et	al.,	2016;	Brown	et	al.,	2014;	Johansson	et	al.,	2001;	Lannutti	et	al.,	2011;	Liu	et	al.,	2016;	Lundgren	et	al.,	2016;	Ou	et	al.,	2015;	Siewe	et	al.,	2013;	Svensson	et	al.,	1998;	Tadmor	et	al.,	2011).	Whilst	in	other	cases	Breg	frequencies	have	 been	 associated	with	 improved	 health	 outcome	 -	 due	 to	 effective	 control	 of	 pro-inflammatory	immune	responses	 that	 if	unregulated	result	 in	pathological	 immune	conditions	 (Abbas	et	al.,	2014;	Carter	et	al.,	2012,	2011;	Chesneau	et	al.,	2013;	Daien	et	al.,	2014;	Evans	et	al.,	2007;	Matsumoto	et	al.,	
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2014;	Matsushita	et	al.,	2008;	Ray	and	Dittel,	2017;	Wang	et	al.,	2014).	Therefore,	the	frequency	of	these	cells	during	health	and	disease	contributes	significantly	to	the	well-being	of	the	host.	Elevated	Breg	levels	were	observed	for	the	QFN	negative	group	for	all	stimulatory	conditions,	compared	to	the	QFN	positive	group.	 These	 results	 are	 in	 agreement	 with	 the	 BCG	 pilot	 study	 conducted	 by	 van	 Rensburg	 and	colleagues	(van	Rensburg	and	Loxton,	2018),	in	which	elevated	levels	of	Bregs	were	observed	for	QFN	negative	 individuals	 compared	 to	 QFN	 positive	 individuals,	 regardless	 of	 simulation	 condition.	 As	previously	mentioned,	studies	have	demonstrated	dysregulation	and	decreased	frequencies	of	B-cells	during	TB	disease	(Du	Plessis	et	al.,	2016a;	Joosten	et	al.,	2016b;	Van	Rensburg	et	al.,	2017),	illustrating	that	M.tb	 infection	considerably	affects	B-cell	function.	This	evidence	supports	the	patterns	observed	within	 the	 study,	 in	 which	 B-cell	 activation	 and	 differentiation	 of	 the	 QFN	 positive	 group	was	 less	proficient	compared	to	the	QFN	negative	group,	 linking	to	the	aforementioned	assumption	that	QFN	negative	 individuals	 exhibit	 heightened	 immune	 responses	 compared	 to	 QFN	 positive	 individuals.	Intriguingly,	 a	marginal	 increase	 in	mean	Breg	 frequencies	was	observed	 for	 the	QFN	positive	group	following	antigenic	stimulation,	while	a	reduction	in	mean	Breg	frequencies	was	discovered	for	the	QFN	negative	group.	These	results	call	attention	to	possible	differences	in	immune	cell	function	between	QFN	positive	and	negative	individuals.			Studies	 investigating	 CD38	 expression	 by	 B-cells	 associated	 increased	 expression	 with	 protection	against	apoptosis	(Hamblin	et	al.,	2002),	and	suggested	possible	involvement	of	CD38	in	augmenting	B-cell	 receptor	 signaling	 (Deaglio	 et	 al.,	 2001).	 Thus,	 increased	 levels	 of	 CD19+CD38+	 B-cells	 may	 be	associated	with	heightened	immune	response	and	improved	host	immunity.	As	aforementioned,	QFN	positive	 individuals	are	presumed	to	be	 latently	 infected	and	are	thus	exposed	to	constant	antigenic	stimulation	 (Getahun	 et	 al.,	 2015;	 WHO,	 2018).	 This	 persistent	 stimulation	 could	 incite	 cellular	exhaustion,	resulting	in	compromised	immune	function	and	inapt	immune	responses	–	attributing	to	the	obtained	results	of	lower	mean	Breg	frequencies	within	the	QFN	positive	group	(Henao-Tamayo	et	al.,	 2011;	 Torrado	 et	 al.,	 2011;	 Wherry	 and	 Kurachi,	 2015).	 	 Conversely,	 the	 observed	 heightened	suppressive	immune	responses	of	the	QFN	positive	group	following	antigenic	stimulation	may	permit	effective	bacterial	containment	preventing	progression	to	active	disease.	Further	investigation	into	the	effects	 of	 QFN	 status	 on	 immune	 cells	 function	 is	 necessary	 before	 any	 presumptions	 can	 be	made	regarding	the	potential	significance	of	these	differences.		Moreover,	the	frequency	of	killer	B-cells	following	antigenic	stimulation	was	investigated.	An	increase	in	mean	killer-cell	frequencies	was	observed,	for	both	the	QFN	positive	and	negative	group,	following	antigenic	stimulation	with	H37Rv,	CD40L	and	IL5,	as	well	as	CD40	and	IL5	in	combination	with	H37Rv.	Similarly,	increased	frequencies	of	IL5Ra-expression	on	B-cell	were	observed	for	both	the	QFN	positive	and	negative	group	following	antigenic	stimulation	with	H37Rv,	CD40L	and	IL5,	as	well	as	CD40	and	IL5	in	combination	with	H37Rv.	Again,	these	results	are	in	agreement	with	the	BCG	pilot	study	conducted	
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by	van	Rensburg	and	colleagues	(van	Rensburg	and	Loxton,	2018),	in	which	elevated	levels	of	killer	B-cells	were	observed	for	QFN	positive	and	negative	individuals	following	antigenic	stimulation	with	BCG	and	CD40L	 in	 combination	with	 IL-5.	Decreased	killer	B-cell	 frequencies	have	been	 associated	with	active	TB	disease;	though,	upon	successful	TB	treatment	these	frequencies	were	observed	to	increase	to	levels	similar	to	that	of	healthy	controls	(Du	Plessis	et	al.,	2016a;	Joosten	et	al.,	2016b;	Van	Rensburg	et	al.,	2017;	van	Rensburg	et	al.,	2017).	This	implies	a	fundamental	role	of	killer	B-cells	in	the	successful	elimination	of	M.tb	infection.	Unexpectedly,	a	shared	pattern	of	enhanced	FasL	and	IL5Ra	expression	was	observed	for	the	QFN	positive	group	compared	to	the	QFN	negative	group,	suggesting	that	M.tb	exposure	did	not	have	an	effect	on	killer	B-cell	development.	A	possible	cause	for	the	minor	increase	in	mean	killer	B-cell	frequencies	observed	for	the	QFN	positive	group	may	be	a	result	of	persistent	M.tb	antigenic	stimulation	during	LTBI,	resulting	in	mounted	effector	immune	responses	that	if	unrestricted,	may	cause	severe	immunopathology.	Therefore,	the	observed	responses	may	be	a	mechanism	employed	by	 LTBI	 participants	 to	 prevent	 progression	 to	 active	 TB.	 However,	 further	 investigation	 into	 this	phenomenon	is	required	before	any	assumptions	can	be	made.		Fas	(CD95)	is	a	cell	surface	antigen	expressed	by	T-cells	following	cellular	activation	(Arase	et	al.,	1995;	Singer	and	Abbas,	1994;	Stalder	et	al.,	1994a;	Süss	and	Shortman,	1996).	Fas	plays	an	essential	role	in	immune	modulation	through	activation-induced	cell	death,	in	which	encounter	of	Fas	with	FasL,	triggers	signalling	 cascade	 initiating	 receptor-mediated	 apoptosis	 of	 Fas-expressing	 cells	 (Arase	 et	 al.,	 1995;	Lundy	et	al.,	2015;	Lundy	and	Boros,	2002;	Stalder	et	al.,	1994a;	Süss	and	Shortman,	1996;	van	Rensburg	et	al.,	2017;	Van	Rensburg	et	al.,	2017).	Studies	investigating	the	occurrence	of	activation-induced	cell	death	 in	 CD4+	 T-cells	 has	 identified	 B-cells	 and	 NK	 cell	 as	 key	 players	 in	mediating	 effector	 T-cell	frequencies	via	this	mechanism	(Alderson	and	Lynch,	1998;	Lundy	and	Boros,	2002;	Sedger	et	al.,	2002;	Stalder	 et	 al.,	 1994b;	 Süss	 and	 Shortman,	 1996;	 Tinhofer	 et	 al.,	 1998).	 Dysregulation	 of	 activation-induced	 elimination	 of	 effector	 T-cells	 has	 been	 associated	 with	 an	 imbalance	 of	 effector	 versus	suppressor	cell	frequencies,	impacting	the	ability	of	the	immune	system	to	adequately	combat	disease.		Hence,	the	degree	of	Fas	and	FasL	expression,	as	well	as	the	efficiency	of	this	regulatory	process,	greatly	influenced	disease	progression	and	observed	outcome.	Considering	the	hypothesized	role	of	killer	B-cells	during	M.tb	 infection,	 the	expression	of	Fas	 (CD95)	by	CD4+	and	CD8+	T-cells	was	 investigated	following	co-culture	with	autologous	pre-stimulated	B-cells.	A	marginal	increase	in	mean	Fas	expression	by	 CD4+	 and	 CD8+	 T-cells	 was	 observed	 for	 the	 QFN	 positive	 group	 following	 co-culture	 with	unstimulated	B-cells,	as	well	as	 for	 the	QFN	negative	group	 following	co-culture	of	T-cells	with	pre-stimulated	 B-cells.	 Opposingly,	 a	 decrease	 in	 mean	 Fas	 expression	 by	 CD4+	 and	 CD8+	 T-cells	 was	observed	for	the	QFN	negative	group	following	co-culture	of	T-cells	with	unstimulated	B-cells,	as	well	as	 for	 the	QFN	positive	 group	 following	 co-culture	 of	 T-cells	with	pre-stimulated	B-cells.	Notably,	 a	common	trend	of	enhanced	Fas	expression	by	CD4+	and	CD8+	T-cells	for	the	QFN	positive	group	was	observed	compared	to	the	QFN	negative	group.	These	results,	together	with	the	observed	killer	B-cell	
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frequencies,	 illuminate	 the	 relative	 importance	 and	 degree	 to	 which	 killer	 B-cells	 may	 influence	protective	 anti-TB	 immune	 response.	 These	 FasL-mediated	mechanisms	may	 be	 beneficial	 through	regulation	 of	 effector	 T-cell	 phenotypic	 frequencies	 and	 eradication	 of	 cellular	 reservoirs	 that	 aid	invading	bacilli	in	immune	evasion	during	M.tb	infection.		As	previously	alluded	to,	T-cells	have	been	regarded	as	key	players	in	anti-TB	immunity,	with	extensive	supporting	evidence	to	substantiate	this	statement	(Cliff	et	al.,	2015;	Kaufmann,	2002;	Lalvani	et	al.,	1998;	McKenzie	et	al.,	1993;	Orme	et	al.,	1993;	Ribeiro-Rodrigues	et	al.,	2006;	Schwander	and	Dheda,	2011;	Scriba	et	al.,	2016;	Sharma	et	al.,	2007;	Stevens	et	al.,	1988).	This	study	does	not	intend	to	refute	this	 claim,	 but	 rather	 emphasize	 an	 important	 fact	 that	 additional	 immune	 cells	with	 the	 ability	 to	modulate	T-cell	behaviour	play	as	crucial	a	role	in	anti-TB	immunity,	as	they	primarily	shape	protective	T-cell	immune	responses	against	M.tb	infection.	Decreased	mean	frequencies	of	TE	were	observed	for	the	QFN	positive	and	negative	group	following	co-culture	of	T-cells	with	pre-stimulated	B-cells.	This	is	in	accord	with	previous	studies	in	which	Breg	were	shown	to	suppress	Th1	and	Th17	responses	while	promoting	Treg	development	(Carter	et	al.,	2012,	2011;	Flores-Borja	et	al.,	2013;	Kessel	et	al.,	2012;	León	et	al.,	2014;	Linton	et	al.,	2003).	Similarly,	decreased	mean	Treg	frequencies	were	observed,	for	both	the	QFN	 positive	 and	 negative	 group,	 for	 all	 culture	 conditions	 in	 which	 T-cells	 were	 co-cultured	with	unstimulated	as	well	as	pre-stimulated	B-cells.	Collectively,	these	results	support	the	notion	that	B-cells	are	capable	of	regulating	T-cell	function	by	influencing	T-cell	population	frequencies.		Interestingly,	a	general	pattern	of	enhanced	TE	and	Treg	frequencies	was	observed	for	the	QFN	positive	group	compared	to	the	QFN	negative	group.	The	induction	of	suppressive	Tregs	during	TB	disease	could	result	in	impaired	ability	of	the	host	to	effectively	contest	infection,	resulting	in	immune	evasion	and	progression	to	active	disease.	This	notion	is	supported	by	literature,	in	which	studies	investigating	the	effect	 of	 Treg	 development	 during	 TB	 disease	 revealed	 that	 depletion	 of	 these	 cells	 correlated	with	effective	containment	and	improved	bacterial	clearance	(Chen	et	al.,	2007;	Mahnke	et	al.,	2007).	This	shared	 pattern	 of	 increased	 cellular	 frequencies	 of	 the	 QFN	 positive	 group	 for	 majority	 of	 the	investigated	 cell	 phenotypes	 (with	 the	 exception	 of	 Bregs)	 suggests	 dissimilarities	 in	 immune	 cell	activation	and	function	between	M.tb-infected	and	uninfected	individuals,	and	may	allude	to	possible	explanations	 as	 to	 why	 some	 individuals	 are	 able	 to	 successfully	 prevent	 M.tb	 infection,	 while	individuals	with	active	TB	disease	or	LTBI,	have	increased	susceptibility.			Recent	discoveries	have	suggested	an	essential	role	of	multifunctional	CD4+	T-cells,	that	is	T-cells	that	produce	 interferon-gamma	 (IFNg),	 tumor	 necrosis	 factor	 alpha	 (TNFa)	 and	 interleukin-2	 (IL-2)	simultaneously,	in	the	fight	against	M.tb	infection.	Several	studies	have	demonstrated	that	the	induction	of	multifunctional	CD4+	T-cells	is	associated	with	protection	and	better	disease	prognosis	(Derrick	et	al.,	2011;	Lindenstrøm	et	al.,	2009);	owing	to	enhanced	anti-TB	immune	responses	and	increased	killing	
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capacity.	 Conversely,	 several	 reports	 have	 identified	 a	 correlation	between	 elevated	multifunctional	CD4+	T-cells	frequencies	and	disease	incidence	(Caccamo	et	al.,	2010;	Forbes	et	al.,	2008);	likely	due	to	excessive	pro-inflammatory	immunity	resulting	in	immune	pathology	and	exacerbated	disease.	These	conflicting	findings	are	as	a	result	of	an	incomplete	understanding	of	the	complex	biological	processes	required	for	effective	elimination	of	M.tb	infection	and	the	spectrum	of	disease	states	within	TB	disease.	As	 such,	 the	 physiological	 relevance	 of	 these	 multifunctional	 CD4+	 T-cells	 during	M.tb	 infection,	 in	combination	with	additional	effector	and	regulatory	cells,	is	still	unclear.	In	some	instances,	in	which	equilibrium	 between	 pro-inflammatory	 and	 anti-inflammatory	 immune	 responses	 exists,	multifunctional	CD4+	T-cells	may	promote	bacterial	killing	and	successful	infection	control.	Dissimilar,	in	the	event	of	impaired	immune	cell	function	and	dysregulated	effector	cell	frequencies,	multifunctional	CD4+	T-cells	may	provoke	pathological	outcomes.	Thus,	the	exact	role	of	these	multifunctional	CD4+	T-cell	in	driving	the	immune	response	against	M.tb	infection	requires	further	investigation.		Current	 research	 investigating	 T-cell	 cytokine	 production	 during	 TB	 disease	 focuses	 of	 CD4+	 T-cell	rather	than	CD8+	T-cell	responses,	due	to	the	nature	 in	which	M.tb	 is	 internalized	and	processed	for	presentation	 by	 antigen	 presenting	 cells.	 Essentially,	 bacilli	 are	 phagocytosed	 and	 processed	 for	presentation	via	major	histocompatibility	complex	(MHC)	Class	II,	of	which	CD4+	T-cells	are	the	cellular	targets.	Whereas,	CD8+	T-cell	activation	occurs	through	presentation	via	MHC	Class	I,	in	which	foreign	proteins	 within	 the	 cytosol	 are	 tagged	 for	 processing	 and	 for	 presentation.	 A	 possible	 explanation	enabling	M.tb	antigen	presentation	to	CD8+	T-cell	by	MHC	Class	 I	 is	 translocation	of	 the	 internalized	bacilli	 for	the	phagosome	to	the	cytosol	via	several	resistance	mechanisms.	Henceforth,	we	aimed	to	investigate	 the	 cytokine	 profiles	 of	 both	 CD4+	 and	 CD8+	 T-cells	 to	 gain	 deeper	 insight	 into	 the	contribution	of	each	of	these	cell	type	in	anti-TB	immunity.	Observation	within	the	H37Rv	pilot	study	demonstrated	 the	 ability	 of	 pre-stimulated	 or	 naive	B-cells,	 for	 both	 the	QFN	positive	 and	 negative	group,	 to	 modulate	 CD4+	 and	 CD8+	 T-cell	 cytokine	 milieu,	 via	 the	 suppression	 or	 induction	 of	monofunctional,	bi-functional	and	multifunctional	T-cells.	Similar	observations	were	made	within	the	BCG	pilot	study,	 in	which	unstimulated	as	well	as	pre-stimulated	B-cells,	while	 insignificant,	had	the	capacity	to	alter	cytokine	secretion	profiles	of	both	CD4+	and	CD8+	T-cells.		Interestingly,	 CD8+	 T-cells	were	 observed	 to	 be	 the	main	 source	 of	 enhanced	multifunctional	 T-cell	activity,	drawing	attention	to	the	prominence	of	these	cells	in	manipulation	of	resulting	anti-TB	immune	responses.	 Slight	 discrepancies	were	 observed	when	 comparing	 the	 observed	CD4+	 and	CD8+	T-cell	cytokine	 profiles	 for	 the	 QFN	 positive	 and	 negative	 groups	within	 the	 H37Rv	 and	 BCG	 pilot	 study.	However,	the	physiological	relevance	of	these	differences	was	trivial,	in	which	small	alterations	within	cell	number	were	observed,	which	would	have	had	no	noticeable	effect	on	immune	function.	A	study	by		Soares	et	al.,	(2008)	showed	the	induction	of	complex	T-cell	cytokine	profiles,	including	the	generation	of	multifunctional	T-cells,	following	stimulation	of	whole	blood	with	BCG.	These	findings	support	the	
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observations	made	in	this	study,	in	which	M.tb	infection	resulted	in	the	development	of	intricate	effector	T-cell	 responses	 shown	by	 the	 induction	 of	multifaceted	 cytokine	 producing	T-cells.	 Therefore,	 this	study	revealed	the	importance	of	B-cells	in	driving	the	anti-TB	immune	responses	through	regulation	of	T-cell	population	development.	One	way	in	which	B-cells	may	elicit	this	control	is	via	the	secretion	of	immune	modulatory	cytokines	that	have	been	shown	to	influence	T-cell	function.	Alternatively,	cell-cell	contact,	enabling	cell	surface	receptor	engagement,	may	facilitate	manipulation	of	T-cell	behavior	by	B-cells.	 Studies	 investigating	 the	 relative	 physiological	 importance	 of	 each	 of	 the	 aforementioned	mechanisms	are	required	before	any	assumptions	regarding	this	complex	immune	interaction	can	be	made.		Research	 has	 demonstrated	 the	 ability	 of	 B-cell	 to	 interact	 with	 additional	 cell	 types	 by	 receptor-mediated	mechanisms	 and	via	 the	 secretion	of	 several	 soluble	molecules	 (Carter	 et	 al.,	 2012,	 2011;	DeFuria	et	al.,	2013;	Elgueta	et	al.,	2009;	Flores-Borja	et	al.,	2013;	Huard	et	al.,	2004;	Kessel	et	al.,	2012;	Kurt-Jones	et	al.,	1988a;	León	et	al.,	2014;	Linton	et	al.,	2003;	Liu	et	al.,	2016;	Lund	and	Randall,	2010;	Lundy	and	Boros,	2002;	Moulin	et	al.,	2000;	Ng	et	al.,	2010;	Nova-Lamperti	et	al.,	2016;	Opata	et	al.,	2015;	Siewe	et	al.,	2013;	Tadmor	et	al.,	2011;	Yoshizaki	et	al.,	2012).	As	with	most	immune	cells,	the	cytokine	profile	of	B-cells	 is	altered	in	response	to	stimulation.	Hence,	 the	cytokine	profile	of	B-cells	following	 stimulation	 and	 cellular	 activation	would	 impact	 the	 general	microenvironment	 in	which	these	 cells	 are	 situated,	 and	 ultimately	 influence	 the	 function	 of	 surrounding	 immunes	 cells.	Importantly,	each	of	these	molecules	have	varying	effects	on	T-cell	activation;	several	cytokines	may	induce	a	pro-inflammatory	immune	response	via	the	induction	of	Th1	and	Th17	responses	(Lund	and	Randall,	2010;	Mangan	et	al.,	2006),	while	others	stimulate	an	anti-inflammatory	Th2	response	or	the	development	of	a	regulatory	T-cell	phenotype	(Linton	et	al.,	2003).	As	one	may	recall,	a	function	of	B-cells	includes	antigen	presentation	(Crawford	et	al.,	2006;	Heesters	et	al.,	2016;	Kurt-Jones	et	al.,	1988a;	Lanzavecchia,	1985);	therefore	B-cells	are	among	the	first	immune	cell	types	within	adaptive	immunity	to	 respond	 to	antigenic	 challenge.	 In	 this	way,	B-cells	 activation	may	greatly	 impact	 resultant	T-cell	function,	 through	 co-stimulation	 via	 peptide	 presentation,	 co-receptor	 engagement	 and	 cytokine	expression.			A	significant	increase	in	the	expression	of	several	cytokines	(APRIL,	ICAM-1,	IFNg,	IFN-b,	,	IL-1b,	IL-2,	IL-4,	IL-10,	IL-12	p70	and	IL21)	was	observed	following	co-culture	of	B-cells	stimulation	with	H37Rv	compared	to	unstimulated	controls	and	B-cells	pulsed	with	CD40	and	IL5,	suggests	the	induction	of	a	heightened	 immune	response	 following	 infection	with	M.tb.	Within	 the	host,	 a	dynamic	 relationship	exists	between	cytokine	production	and	resultant	 immune	responses.	 In	the	event	of	a	physiological	stimulus,	transient	cytokine	production	and	consequential	immune	responses	arises	to	counteract	shifts	within	the	host	biological	system	and	return	the	cellular	environment	to	homeostasis	to	maintain	a	state	of	 health	 (Bocci,	 1988).	 As	 such,	 the	 secretion	 of	 these	 cytokines	 is	 dependent	 on	 the	 stimulus	
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encountered.	 IFN	 production	 is	 onset	 following	 viral	 or	 bacterial	 infection	 and	 is	 responsible	 for	containment	of	pathogens	for	effective	elimination.	IFNg	in	particular,	has	been	profoundly	associated	to	M.tb	 infection,	 in	which	 its	 relative	production	by	T-cells	 has	been	 linked	 to	 effective	TB	disease	control;	 whilst	 copious	 secretion	 	 has	 been	 linked	 to	 increased	 disease	 severity	 (Bocci,	 1988;	Dlugovitzky	 et	 al.,	 1999).	 IL-1b	 has	 been	 revealed	 as	 an	 important	 mediator	 of	 pro-inflammatory	immune	 responses	 and	 is	 involved	 in	 a	 variety	 of	 functions	 including	 cellular	 proliferation,	differentiation,	activation	and	cellular	communication	(Awomoyi	et	al.,	2005).	Similarly,	IL12	and	21	secretion	 are	observed	 to	promote	 the	production	of	 IFNg	 and	 tumor	necrosis	 factor	 alpha	 (TNFa),	thereby	induces	differentiation	of	T-cells	into	Th1	cells	(Cooper	et	al.,	1997;	Flynn	et	al.,	1995;	Korn	et	al.,	2007).			Together,	 secretion	 of	 the	 abovementioned	 cytokines	 by	 B-cells	 would	 induce	 pro-inflammatory	effector	 T-cells	 in	 response	 to	 the	 investigated	 stimulatory	 conditions.	 These	 responses	 have	 been	shown	to	be	essential	during	the	initial	stages	of	M.tb	infection,	stressing	the	prominent	role	B-cells	may	play	during	TB	disease.	On	the	other	hand,	IL-2,	4	and	10	have	been	associated	with	immune	tolerance	and	the	induction	suppressive	anti-inflammatory	responses	(Li	et	al.,	2001;	North,	1998;	Redford	et	al.,	2011).	Although,	IL-2	has	been	found	to	promote	effector	T-cell	differentiation	during	initial	stages	of	infection	-	aiding	 in	 fighting	off	 infection	contributing	to	the	 induction	of	Th1	cells	 (Millington	et	al.,	2007).	 Similarly,	 APRIL,	 IL-10,	 IL-21	 and	 IL-4	 have	 been	 shown	 to	 play	 a	 crucial	 role	 in	 B-cell	proliferation,	differentiation	and	isotype	switching	–	all	processes	that	are	crucial	for	protective	anti-TB	immunity	during	the	early	stages	of	 infection	(Aversa	et	al.,	1993;	Bryant	et	al.,	2007;	Rousset	et	al.,	1992;	Vincent	et	al.,	2013).			Differences	 between	 cytokine	 profiles	 of	 B-cells	 cultured	 with/without	 autologous	 T-cells	 was	investigated	to	determine	the	effect	of	co-culture	on	the	resulting	immune	environment.	An	insignificant	increase	in	the	expression	of	BAFF	and	TGF-b1	by	QFN	positive	individuals	was	observed	compared	to	QFN	negative	individuals,	wherein	BAFF	and	TGF-b1	production	was	observed	to	be	dependent	on	the	presence	of	B-cells	within	the	sample,	as	shown	by	the	significant	decrease	in	these	cytokine	levels	in	supernatants	where	T-cells	were	cultured	alone	compared	to	all	other	conditions	where	autologous	B-cells	were	present.	B-cell	activating	factor	(BAFF)	is	a	member	of	the	TNF	ligand	family	and	plays	an	important	role	in	B-cell	 function	by	promoting	of	B-cell	proliferation	and	differentiation	(Chen	et	al.,	2009;	Van	Rensburg	et	al.,	2017;	Vincent	et	al.,	2013).	Similarly,	TGF-b1	is	responsible	for	regulation	of	immune	responses	by	controlling	cellular	proliferation	and	differentiation	of	several	immune	cell	types	(Biancheri	 et	 al.,	 2014).	 Thus,	 the	 relative	 expression	 of	 these	 cytokines	 by	 B-cells	may	 contribute	substantially	to	the	proposed	beneficial	role	of	B-cells	during	TB	disease.	 	Furthermore,	a	significant	increase	in	sFasL,	ICAM-1,	IFN-b,	IL-2	and	IL-17	was	observed	for	QFN	negative	individuals	in	response	
Stellenbosch University  https://scholar.sun.ac.za
 109 
to	antigenic	stimulation	compared	to	QFN	positive	individuals,	in	which	sFasL	expression	was	enhanced	following	culture	of	B-cells	with	autologous	T-cells.				The	secretion	of	sFasL	by	B-cells	has	been	widely	investigated	by	Lundy	and	colleagues	(Lundy,	2009;	Lundy	et	al.,	2015),	in	which	they	describe	its	secretion	as	a	mechanism	of	immune	regulation	by	B-cells.	It	 is	 insinuated	that	FasL-expressing	B-cells	would	have	a	beneficial	 impact	on	TB	disease	prognosis	through	 the	 regulation	 of	 pro-inflammatory	 immune	 responses	 that	 if	 left	 unrestrained,	 result	 in	immune	pathology	and	exacerbated	disease	conditions	(Lundy,	2009;	van	Rensburg	et	al.,	2017;	Van	Rensburg	et	al.,	2017;	van	Rensburg	and	Loxton,	2018a).	A	likely	mechanisms	by	which	these	B-cells	may	mediate	this	protection	is	through	FasL-mediated	apoptosis	of	activated	CD4+	T-cells	(Alderson	and	Lynch,	1998;	Lundy	and	Boros,	2002;	Sedger	et	al.,	2002;	Stalder	et	al.,	1994b;	Süss	and	Shortman,	1996;	Tinhofer	et	al.,	1998)	that	develop	as	a	result	of	antigenic	stimulation.	This	theory	of	immune	regulation	by	 B-cells	 is	 in	 agreement	 with	 studies	 investigating	 the	 role	 of	 FasL-expressing	 B-cells	 during	autoimmunity	and	parasitic	infection	(Chervonsky	et	al.,	1997;	De	Maria	and	Testi,	1998;	Hu	et	al.,	1999;	Zhang	et	 al.,	 2008).	Additionally,	 ICAM-1	expression	has	been	 revealed	 to	play	an	 important	 role	 in	mycobacterial	 uptake	 and	 antigen	 processing.	 Studies	 have	 found	 increased	 expression	 of	 ICAM-1	following	infection	of	macrophages	with	M.tb	(Bohnet	et	al.,	1994;	Ghosh	and	Saxena,	2004).	It	has	been	suggested	 that	 this	 upregulation	 facilitates	 protective	 anti-TB	 immune	 responses	 by	 macrophages	during	M.tb	 infection.	Thus,	 this	significant	decline	 in	sFasL	and	 ICAM-1	expression	by	QFN	positive	individuals	 indicates	 possible	 dysregulation	 of	 crucial	 anti-TB	mechanisms	 attributing	 to	 increased	susceptibility	 to	 M.tb	 infection	 (Ghosh	 and	 Saxena,	 2004).	 Moreover,	 IFN-b	 production	 has	 been	associated	with	enhanced	IFN-g	secretion	during	M.tb	infection,	and	is	suspected	to	assist	in	effective	anti-TB	immunity	(Zhang	et	al.,	2018).	A	clinical	trial	investigating	the	use	of	IL-2	immunotherapy	in	TB	disease	indicated	enhanced	bacterial	clearance,	suggesting	potential	role	in	anti-TB	immunity	(Johnson	et	al.,	1997,	1995).	In	summary,	these	findings	illustrate	the	dysregulation	of	cytokine	expression	by	QFN	positive	 individuals	and	underlines	possible	protective	cellular	 functions	 irregulated	during	TB	disease	that	facilitate	the	establishment	of	infection	and	progression	to	active	disease.		It	 is	 important	 to	 note	 the	 presence	 of	 contaminating	 platelets	 (median	 proportion	 of	 total	 sample	content	58.15%;	range	29.1	-	87.5%)	within	isolated	B-cells	samples	prior	to	co-culture	with	autologous	T-cells	 (Suppl	 Figure	 4.13).	 Evidence	 has	 shown	 that	 platelets	 contribute	 to	 the	 in	 vitro	 cellular	microenvironment	and	have	the	capacity	to	modulate	the	function	of	B-	and	T-cells		(Sowa	et	al.,	2009).	One	way	in	which	platelets	achieve	this	is	via	the	expression	of	cytoplasmic	mRNA	encoding		(Denis	et	al.,	2005;	Power	et	al.,	1995;	Soslau	et	al.,	1997)	for	various	proteins,	such	as	cytokines,	known	to	effect	the	activation	and	function	of	surrounding	immune	cells	(Elzey	et	al.,	2005;	Kral	et	al.,	2016).	As	such,	these	 observed	 findings	may	 have	 been	 influenced	 by	 the	 incidence	 of	 contaminating	 platelets	 and	should	be	interpreted	with	this	in	mind.	Additionally,	the	effects	of	ex	vivo	manipulation	on	the	observed	
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results	must	be	 taken	 into	 consideration	as	 artefactual	observations	may	have	 incurred	 that	do	not	reflect	physiologically	relevant	events	within	whole	organism.			
5.	Concluding	Remarks	In	our	studies,	B-cells	had	the	ability	to	modulate	T-cell	 function,	and	thus	play	an	important	role	 in	directing	the	immune	response	against	M.tb	infection.	Collectively,	the	results	demonstrate	the	ability	of	B-cells	to	modulate	T-cell	activation	and	function	through	control	of	T-cell	population	dynamics	and	cytokine	profiles.	This	emphasizes	the	importance	of	investigating	the	role	of	additional	cell	types	within	TB	disease	incidence	and	progression,	previously	thought	to	have	minimal	contribution	to	the	general	disease	 outcome.	The	physiological	 implications	 of	 the	 results	 includes	 the	possibility	 for	 improved	vaccine	design	through	targeting	of	B-cell	function	to	induce	protective	CD4+	and	CD8+	T-cell	responses	that	facilitate	superior	protection	from	M.tb	infection	compared	to	the	current	commercially	available	BCG	vaccine.	Despite	 this,	 the	 results	 described	 in	 this	 paper	 serve	 as	preliminary	data	 and	 further	investigation	into	the	mechanisms	of	this	multifaceted	cellular	interaction	is	required,	in	which	a	larger	sample	size	and	the	addition	of	an	active	TB	cohort	are	included,	before	any	definitive	assumptions	can	be	made.		
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Supplementary	Information		
Condition	 B-cells	 BCG	or	H37Rv	 CD40L	&	IL5	 T-cells	
1	 X	 	 	 	
2	 X	 X	 	 	
3	 X	 	 X	 	
4	 X	 X	 X	 	
5	 	 	 	 X	
6	 X	 	 	 X	
7	 X	 X	 	 X	
8	 X	 	 X	 X	
9	 X	 X	 X	 X	
10	 	 X	 	 X	
	
	
Suppl	Table	4.1.	Description	of	stimulatory	and	co-culture	conditions.	B-cells	were	seeded	at	a	concentration	of	2.5x105/well,	while	T-cells	were	seeded	at	a	concentration	of	5x105/well	in	a	96-well	round	bottom	plate	in	a	total	volume	of	200uL.	The	BCG	pilot	study	utilized	BCG	(1.25x106	CFU/mL)	as	 their	M.tb	 antigen,	while	 the	H37Rv	pilot	study	stimulated	cells	with	 the	virulent	M.tb	 laboratory	strain	 H37Rv	 (MOI	 10:1).	Where	 applicable,	 IL-5	 (Sigma,	 USA)	was	 added	 at	 50	 ng/ml	 and	 CD40L	(Sigma,	USA)	at	2ug/ml.	Stimulatory	condition	10,	indicated	in	red,	was	incorporated	into	the	BCG	pilot	study	only.	As	such	comparison	between	the	studies	for	this	condition	cannot	be	made.	
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Suppl	Figure	4.1.	Gating	strategy	for	Regulatory	B-cells	for	the	H37Rv	pilot	study	
*Note:	Fluorescence-minus-one	(FMO)	control	samples	were	used	to	determine	appropriate	gating	cut-off	to	increase	accuracy	of	distinguishing	between	populations		
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Suppl	Figure	4.2.	Gating	strategy	for	Killer	B-cells	for	H37Rv	pilot	study	
*Note:	Fluorescence-minus-one	(FMO)	control	samples	were	used	to	determine	appropriate	gating	cut-off	to	increase	accuracy	of	distinguishing	between	populations		
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Suppl	Figure	4.3.	Gating	strategy	for	Effector	and	Regulatory	T-cells	for	the	H37Rv	and	BCG	pilot	study	
*Note:	Fluorescence-minus-one	(FMO)	control	samples	were	used	to	determine	appropriate	gating	cut-off	to	increase	accuracy	of	distinguishing	between	populations		
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Suppl	Figure	4.4.	Gating	Strategy	for	Fas-expressing	T-cells	for	the	H37Rv	pilot	study	
*Note:	Fluorescence-minus-one	(FMO)	control	samples	were	used	to	determine	appropriate	gating	cut-off	to	increase	accuracy	of	distinguishing	between	populations		
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Suppl	Figure	4.5.	Gating	strategy	for	cytokine	expression	evaluation	of	T-cells	for	the	H37Rv	and	BCG	pilot	study	
*Note:	Fluorescence-minus-one	(FMO)	control	samples	were	used	to	determine	appropriate	gating	cut-off	to	increase	accuracy	of	distinguishing	between	populations		
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Suppl	Figure	4.6.	Cytokine	secretion	profile	of	CD4+	T-cells	following	co-culture	with	pre-
stimulated	B-cells	for	the	BCG	pilot	study.	The	proportion	of	cells	expressing	various	combinations	of	cytokines	is	calculated	as	a	function	of	the	total	frequency	of	cytokine	producing	cells.	Alterations	in	cytokine	production	for	each	of	the	culture	conditions	was	compared	to	the	control	condition	consisting	of	T-cells	only.	The	control	condition	served	as	a	representation	of	basal	cytokine	production	 levels;	these	background	 levels	were	 subtracted	 from	 the	 various	 stimulatory	 conditions	 and	 the	 resulting	profiles	reported	(a)	Cytokine	profiles	of	CD4+	T-cells	for	each	of	the	stimulatory	conditions	observed	for	QFN	positive	individuals.	(b)	Cytokine	profiles	of	CD4+	T-cells	for	each	of	the	stimulatory	conditions	observed	for	QFN	negative	individuals.	 	
a) QFN + Individuals 
b) QFN - Individuals 
QFN+
IFN-TNF+IL2- IFN-TNF+IL2+ IFN+TNF+IL2+ IFN+TNF-IL2- IFN+TNF-IL2+ IFN-TNF-IL2+ IFN+TNF+IL2-
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Suppl	Figure	4.7.	Cytokine	secretion	profile	of	CD8+	T-cells	following	co-culture	with	pre-
stimulated	B-cells	for	the	BCG	pilot	study.	The	proportion	of	cells	expressing	various	combinations	of	cytokines	is	calculated	as	a	function	of	the	total	frequency	of	cytokine	producing	cells.	Alterations	in	cytokine	production	for	each	of	the	culture	conditions	was	compared	to	the	control	condition	consisting	of	T-cells	only.	The	control	condition	served	as	a	representation	of	basal	cytokine	production	 levels;	these	background	 levels	were	 subtracted	 from	 the	 various	 stimulatory	 conditions	 and	 the	 resulting	profiles	reported	(a)	Cytokine	profiles	of	CD8+	T-cells	for	each	of	the	stimulatory	conditions	observed	for	QFN	positive	individuals.	(b)	Cytokine	profiles	of	CD8+	T-cells	for	each	of	the	stimulatory	conditions	observed	for	QFN	negative	individuals.		 	
a) QFN + Individuals 
b) QFN - Individuals 
QFN+
IFN-TNF+IL2- IFN-TNF+IL2+ IFN+TNF+IL2+ IFN+TNF-IL2- IFN+TNF-IL2+ IFN-TNF-IL2+ IFN+TNF+IL2-
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Suppl	Figure	4.8.	Effect	of	QuantiFERON	status	on	cytokine	secretion	by	B-cells	following	
antigenic	stimulation	for	the	H37Rv	Pilot	study.	Cell	culture	supernatants	were	collected	at	different	time	 points,	 namely	 3-hours	 pre-co-culture	 (Time	 point	 1)	 and	 19-hours	 post-co-culture	 with	autologous	 T-cells	 (Time	 point	 2).	Whisker	 denote	 10-90	 percentile.	 Statistical	 differences	 between	culture	conditions	was	calculated	using	a	four-way	mixed	model	ANOVA.	Comparisons	within	groups	was	calculated	using	the	Fishers	LSD	post-hoc	test.	A	two-way	step-up	Benjamini,	Krieger	and	Yekutieli	False	 Discovery	 rate	 (FDR),	 with	 a	 FDR	 of	 1%,	 was	 used	 to	 correct	 for	multiple	 testing.	 Statistical	significance	is	indicated	by	an	asterisk,	in	which	p	<	0.05	(*)	and	p<0.01(**).	(a)	Effect	of	culture	time	on	B-cell	secretion	factors	following	antigenic	stimulation	of	B-cells.	(b)	Effect	of	culture	time	on	interleukin	(IL)	production	 following	antigenic	 stimulation	of	B-cells.	 (c)	Effect	of	 culture	 time	on	TGFb	 isotype	secretion	following	antigenic	stimulation	of	B-cells.	
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Suppl	Figure	4.9.	Effect	of	stimulation	condition	on	cytokine	secretion	by	B-cells	following	antigenic	stimulation	for	the	H37Rv	Pilot	study.	Cell	culture	supernatants	were	collected	at	different	time	points,	namely	3-hours	pre-co-culture	(Time	point	1)	and	19-hours	post	co-culture	with	autologous	T-cells	(Time	point2).	Whisker	denote	10-90	percentile.	Statistical	differences	between	culture	conditions	was	calculated	using	a	four-way	mixed	model	ANOVA.	Comparisons	within	groups	was	calculated	using	the	Fishers	LSD	post-hoc	test.	A	two-way	step-up	Benjamini,	Krieger	and	Yekutieli	False	Discovery	rate	(FDR),	with	a	FDR	of	1%,	was	used	to	correct	for	multiple	testing.	Statistical	differences	are	indicated	by	letters,	in	which	groups	denoted	with	different	letters	indicate	statistical	differences.	Effect	of	stimulation	condition	on	secretion	of		(a)	APRIL	(b)	soluble	FasL	(c)	IFN-b	(d)	TNF-a	(e)	BAFF	(f)	ICAM-1	(g)	IFN-g	(h)	IL-1b	(i)		IL-2	(j)	IL-4	(k)	IL-6	(l)	IL-10	(m)	IL-12	p70	(n)	IL-17A	(o)		IL-21	(p)	TGFb-1	(q)	TGFb-2	(r)	TGFb-3	
a)          b)                c)        d)              e)        f) 
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Analyte	 Time	Point	 Stimulation	 QFN	Status	 Stimulation*	
QFN	status	
	 P-value	 q-value	 P-value	 q-value	 P-value	 q-value	 P-value	 q-value	
APRIL	 0.00212	 0.00396	 0.6774	 0.76970	 0.55541	 0.99141	 0.12716	 0.19822	
sFasL	 0.08274	 0.05969	 0.86329	 0.87192	 0.97053	 0.99141	 0.13118	 0.19822	
IFN-b	 0.00143	 0.00396	 0.04686	 0.10635	 0.68867	 0.99141	 0.03755	 0.16292	
TNF-a	 0.01008	 0.00898	 0.02728	 0.10635	 0.84289	 0.99141	 0.87777	 0.89657	
BAFF	 0.02955	 0.02296	 0.18945	 0.24601	 0.51968	 0.99141	 0.78763	 0.89657	
ICAM-1	 0.00347	 0.00438	 0.05850	 0.10635	 0.92505	 0.99141	 0.02657	 0.16101	
IFN-g	 0.00506	 0.00568	 0.13859	 0.20188	 0.67763	 0.99141	 0.49327	 0.64055	
IL-1b	 0.00205	 0.00396	 0.03131	 0.10635	 0.49703	 0.99141	 0.08817	 0.19822	
IL-2	 0.00885	 0.00894	 0.00991	 0.10635	 0.65602	 0.99141	 0.00280	 0.05090	
IL-4	 0.00235	 0.00396	 0.05243	 0.10635	 0.71816	 0.99141	 0.05377	 0.16292	
IL-6	 0.01067	 0.00898	 0.01173	 0.10635	 0.57861	 0.99141	 0.82375	 0.89657	
IL10	 0.00202	 0.00396	 0.03882	 0.10635	 0.60442	 0.99141	 0.14055	 0.19822	
IL-12	p70	 0.00283	 0.00408	 0.09407	 0.15547	 0.82944	 0.99141	 0.10820	 0.19822	
IL-17A	 0.37638	 0.23759	 0.49002	 0.59390	 0.96870	 0.99141	 0.14174	 0.19822	
IL-21	 0.00073	 0.00396	 0.05489	 0.10635	 0.51599	 0.99141	 0.08296	 0.19822	
TGF-b1	 0.12276	 0.08266	 0.02339	 0.10635	 0.40323	 0.99141	 0.01036	 0.09417	
TGF-b2	 0.45872	 0.27253	 0.14436	 0.20188	 0.43993	 0.99141	 0.04925	 0.16292	
TGF-b3	 0.71364	 0.40043	 0.82922	 0.87192	 0.98159	 0.99141	 0.88769	 0.89657	
	
	
Suppl	 Table	 4.2.	 Evaluation	 of	 cytokine	 secretion	 by	 B-cells	 at	 different	 time	 points	
following	antigenic	stimulation	for	the	H37Rv	Pilot	study.	Cell	culture	supernatants	were	collected	at	different	 time	points,	namely	3-hours	pre-co-culture	(Time	point	1)	and	19-hours	post-co-culture	with	autologous	T-cells	(Time	point	2).	Statistical	differences	between	culture	conditions	was	calculated	using	a	four-way	mixed	model	ANOVA.	Comparisons	within	groups	was	calculated	using	the	Fishers	LSD	post-hoc	test.	A	two-way	step-up	Benjamini,	Krieger	and	Yekutieli	False	Discovery	rate	(FDR)	approach,	with	 a	 FDR	 of	 1%,	 was	 used	 to	 correct	 for	 multiple	 testing.	 Statistically	 significant	 p-values	 are	highlighted	in	red.	The	adjusted	p-value	is	denoted	‘q-value’.		
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Suppl	Figure	4.10.	Effect	of	stimulation	condition	and	QuantiFERON	status	in	combination	
on	cytokine	secretion	by	B-cells	following	antigenic	stimulation	for	the	H37Rv	Pilot	study.	Cell	culture	supernatants	were	collected	at	different	time	points,	namely	3-hours	pre-co-culture	(Time	point	1)	and	19-hours	post	co-culture	with	autologous	T-cells	(Time	point	2).	Median	with	interquartile	range	plotted.	Statistical	differences	between	culture	conditions	was	calculated	using	a	four-way	mixed	model	ANOVA.	Comparisons	within	groups	was	calculated	using	the	Fishers	LSD	post-hoc	test.	A	two-way	step-up	Benjamini,	Krieger	and	Yekutieli	False	Discovery	rate	(FDR)	approach,	with	a	FDR	of	1%,	was	used	to	correct	for	multiple	testing.	Statistical	differences	are	indicated	by	letters,	in	which	groups	denoted	with	different	letters	indicate	statistical	differences.	Effect	of	stimulation	condition	and	QFN	status	in	combination	on	secretion	of	(a)	APRIL	(b)	soluble	FasL	(c)	IFN-b	(d)	TNF-a	(e)	BAFF	(f)	ICAM-1	(g)	IFN-
g	(h)	IL-1b	(i)	IL-2		 	
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Suppl	 Figure	 4.10	 continued.	 Effect	 of	 stimulation	 condition	 and	 QFN	 status	 in	
combination	on	cytokine	secretion	by	B-cells	 following	antigenic	 stimulation	 for	H37Rv	Pilot	
study.	Cell	culture	supernatants	were	collected	at	different	time	points,	namely	3-hours	pre-co-culture	(Time	 point	 1)	 and	 19-hours	 post-co-culture	 with	 autologous	 T-cells	 (Time	 point	 2).	 Median	 with	interquartile	range	plotted.	Statistical	differences	between	culture	conditions	was	calculated	using	a	four-way	mixed	model	ANOVA.	Comparisons	within	groups	was	calculated	using	the	Fishers	LSD	post-hoc	test.	A	two-way	step-up	Benjamini,	Krieger	and	Yekutieli	False	Discovery	rate	(FDR)	approach,	with	a	FDR	of	1%,	was	used	to	correct	for	multiple	testing.	Statistical	differences	are	indicated	by	letters,	in	which	 groups	 denoted	 with	 different	 letters	 indicate	 statistical	 differences.	 Effect	 of	 stimulation	condition	and	QFN	status	in	combination	on	secretion	of	(j)	IL-4	(k)	IL-6	(l)	IL-10	(m)	IL-12	p70	(n)	IL-17A	(o)		IL-21	(p)	TGFb-1	(q)	TGFb-2	(r)	TGFb-3.	 	
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Suppl	Figure	4.11.	Effect	of	QuantiFERON	status	on	cytokine	secretion	profiles	of	B-	and	
T-cells	following	co-culture	for	the	H37Rv	Pilot	study.	Cell	culture	supernatants	were	collected	19-hours	 post-co-culture	 with/without	 autologous	 T-cells	 (Time	 point	 2).	 Whisker	 denote	 10-90	percentile.	Statistical	differences	between	culture	conditions	was	calculated	using	a	three-way	mixed	model	ANOVA.	Comparisons	within	groups	was	calculated	using	the	Fishers	LSD	post-hoc	test.	A	two-way	step-up	Benjamini,	Krieger	and	Yekutieli	False	Discovery	rate	(FDR)	approach,	with	a	FDR	of	1%,	was	used	to	correct	for	multiple	testing.	Statistical	significance	is	indicated	by	an	asterisk,	in	which	p	<	0.05	 (*)	 and	 p<0.01(**).	 (a)	 Effect	 of	 QFN	 status	 on	 B-cell	 secretion	 factors	 following	 antigenic	stimulation	 of	 B-cells.	 (b)	 Effect	 of	 QFN	 status	 on	 interleukin	 (IL)	 production	 following	 antigenic	stimulation	of	B-cells.	(c)	Effect	of	QFN	status	on	TGF-b	isotype	secretion	following	antigenic	stimulation	of	B-cells.
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Suppl	Figure	4.12.	Effect	of	stimulation	condition	on	cytokine	secretion	profiles	of	B-	and	T-cells	following	co-culture	for	the	H37Rv	Pilot	
study.	Cell	culture	supernatants	were	collected	19-hours	post-co-culture	with/without	autologous	T-cells	(Time	point	2).	Whisker	denote	10-90	percentile.	Statistical	differences	between	culture	conditions	was	calculated	using	a	three-way	mixed	model	ANOVA.	Comparisons	within	groups	was	calculated	using	the	Fishers	LSD	post-hoc	test.	A	two-way	step-up	Benjamini,	Krieger	and	Yekutieli	False	Discovery	rate	(FDR)	approach,	with	a	FDR	of	1%,	was	used	to	correct	for	multiple	testing.	Statistical	differences	are	indicated	by	letters,	in	which	groups	denoted	with	different	letters	indicate	statistical	differences.	Effect	of	stimulation	condition	on	secretion	of	(a)	APRIL	(b)	soluble	FasL	(c)	IFN-b	(d)	TNF-a	(e)	BAFF	(f)	ICAM-1	(g)	IFN-g	(h)	IL-1b	(i)		IL-2	(j)	IL-4	(k)	IL-6	(l)	IL-10	(m)	IL-12	p70	(n)	IL-17A	(o)		IL-21	(p)	TGFb-1	(q)	TGFb-2	(r)	TGFb-3
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Analyte	 Stimulation	 QFN	Status	 Stimulation*	
QFN	status	
	 P-value	 q-value	 P-value	 q-value	 P-value	 q-value	
APRIL	 0.24858	 0.75096	 0.48594	 0.92337	 0.71412	 0.86551	
sFasL	 0.38573	 0.81350	 0.35355	 0.92337	 0.00779	 0.07081	
IFN-b	 0.68833	 0.86298	 0.64539	 0.92337	 0.16233	 0.36449	
TNF-a	 0.48589	 0.83427	 0.81625	 0.92337	 0.94585	 0.95996	
BAFF	 0.00000	 0.00000	 0.86344	 0.92337	 0.95046	 0.95996	
ICAM-1	 0.03325	 0.19030	 0.27593	 0.92337	 0.18044	 0.36449	
IFN-g	 0.88702	 0.89977	 0.95727	 0.96684	 0.06191	 0.18627	
IL-1b	 0.14214	 0.61014	 0.80587	 0.92337	 0.41646	 0.58240	
IL-2	 0.94327	 0.89977	 0.81281	 0.92337	 0.07172	 0.18627	
IL-4	 0.59065	 0.86298	 0.56306	 0.92337	 0.27587	 0.44199	
IL-6	 0.70365	 0.86298	 0.80432	 0.92337	 0.92567	 0.95996	
IL10	 0.79769	 0.89977	 0.45388	 0.92337	 0.29174	 0.44199	
IL-12	p70	 0.26242	 0.75096	 0.67093	 0.92337	 0.05617	 0.18627	
IL-17A	 0.68532	 0.86298	 0.26530	 0.92337	 0.00282	 0.05127	
IL-21	 0.33997	 0.81350	 0.69598	 0.92337	 0.04040	 0.18362	
TGF-b1	 0.02174	 0.18664	 0.43682	 0.92337	 0.22916	 0.41661	
TGF-b2	 0.92098	 0.89977	 0.83167	 0.92337	 0.02552	 0.15465	
TGF-b3	 0.42641	 0.81350	 0.55124	 0.92337	 0.46140	 0.59916	
	
	
Suppl	Table	4.3.	Evaluation	of	cytokine	secretion	profiles	of	B-	and	T-cells	following	co-
culture	for	the	H37Rv	Pilot	study.	Cell	culture	supernatants	were	collected	19-hours	post-co-culture	with/without	autologous	T-cells	(Time	point	2).	Statistical	differences	between	culture	conditions	was	calculated	using	a	three-way	mixed	model	ANOVA.	Comparisons	within	groups	was	calculated	using	the	Fishers	LSD	post-hoc	 test.	A	 two-way	 step-up	Benjamini,	Krieger	 and	Yekutieli	 False	Discovery	 rate	(FDR)	approach,	with	a	FDR	of	1%,	was	used	to	correct	for	multiple	testing.	Statistically	significant	p-values	are	highlighted	in	red.	The	adjusted	p-value	is	denoted	‘q-value’.			
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Suppl	Figure	4.13.	Effect	of	stimulation	condition	and	QuantiFERON	status	in	combination	
on	cytokine	secretion	profiles	of	B-	and	T-cells	following	co-culture	for	the	H37Rv	Pilot	study.	Cell	 culture	 supernatants	 were	 collected	 19-hours	 post-co-culture	 with/without	 autologous	 T-cells	(Time	 point	 2).	 Median	 with	 interquartile	 range	 plotted.	 Statistical	 differences	 between	 culture	conditions	was	 calculated	 using	 a	 three-way	mixed	model	ANOVA.	 Comparisons	within	 groups	was	calculated	using	the	Fishers	LSD	post-hoc	test.	A	two-way	step-up	Benjamini,	Krieger	and	Yekutieli	False	Discovery	rate	(FDR)	approach,	with	a	FDR	of	1%,	was	used	to	correct	for	multiple	testing.	Statistical	differences	are	indicated	by	letters,	in	which	groups	denoted	with	different	letters	indicate	statistical	differences.	Effect	of	stimulation	condition	and	QFN	status	in	combination	on	secretion	of	(a)	APRIL	(b)	soluble	FasL	(c)	IFN-b	(d)	TNF-a	(e)	BAFF	(f)	ICAM-1	(g)	IFN-g	(h)	IL-1b	(i)	IL-2		
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Suppl	Figure	4.13	continued.	Effect	of	stimulation	condition	and	QuantiFERON	status	in	
combination	on	cytokine	secretion	profiles	of	B-	and	T-cells	following	co-culture	for	the	H37Rv	
Pilot	 study.	 Cell	 culture	 supernatants	 were	 collected	 19-hours	 post-co-culture	 with/without	autologous	 T-cells	 (Time	 point	 2).	 Median	 with	 interquartile	 range	 plotted.	 Statistical	 differences	between	culture	conditions	was	calculated	using	a	three-way	mixed	model	ANOVA.	Comparisons	within	groups	was	calculated	using	the	Fishers	LSD	post-hoc	test.	A	two-way	step-up	Benjamini,	Krieger	and	Yekutieli	 False	Discovery	 rate	 (FDR)	 approach,	with	 a	 FDR	of	 1%,	was	 used	 to	 correct	 for	multiple	testing.	Statistical	differences	are	indicated	by	letters,	 in	which	groups	denoted	with	different	letters	indicate	 statistical	 differences.	 Effect	 of	 stimulation	 condition	 and	 QFN	 status	 in	 combination	 on	secretion	of	(j)	IL-4	(k)	IL-6	(l)	IL-10	(m)	IL-12	p70	(n)	IL-17A	(o)	IL-21	(p)	TGFb-1	(q)	TGFb-2	(r)	TGFb-3	
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Suppl	Figure	4.14.	Degree	of	cell	debris/platelet	contamination	in	isolated	B-cell	samples	from	
QuantiFERON	positive	and	negative	individuals	used	in	B-	and	T-cells	co-culture	experiment	for	
the	H37Rv	Pilot	study.	B-cell	isolation	was	achieved	using	the	Miltenyi	B-cell	Isolation	kit	II,	from	a	starting	 volume	 of	 54mL	whole	 blood.	Median	with	 interquartile	 range	 plotted.	 Sample	 purity	was	assessed	by	flow	cytometry,	based	on	forward	and	side	scatter	properties,	using	a	CD19	monoclonal	antibody	 (mAb)	 to	 identify	 B-cells	 within	 the	 lymphocyte	 population	 and	 a	 CD36	 mAb	 to	 identify	platelets	within	the	cell	debris	population.	 	
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Chapter	5:				The	work	presented	in	this	chapter	has	been	formatted	in	the	style	of	a	manuscript	for	submission	to	an	immunology	journal.		 	
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Abstract	
Rationale:	 Studies	 on	 isolated	 cells,	 while	 important	 for	 investigating	 the	 function	 of	 a	 particular	immune	cell	type,	may	not	reflect	the	responses	that	occur	in	vivo	under	the	same	circumstances	–	due	to	the	presence	of	additional	cell	types.	This	study	aimed	to	investigate	the	effect	of	microenvironment	complexity	(i.e.	degree	of	cell	isolation)	on	cell	function,	with	an	emphasis	on	B-lymphocytes.		
Method:	B-cells	were	isolated	from	whole	blood,	during	which	a	sample	fraction	was	retained	following	each	 isolation	procedure	 (whole	blood,	PBMC’s,	 isolated	B-cells).	The	various	sample	 fractions	were	then	 stimulated	 with	 TLR9a	 or	 H37Rv	 and	 the	 resulting	 B-cell	 phenotypic	 frequencies	 and	immunoglobulin	profiles	of	each	stimulation	condition	for	all	sample	types	determined.		
Results:	 Alterations	 in	 the	 immunoglobulin	 profile	 and	 killer	 B-cell	 phenotypic	 frequencies	 were	observed	for	each	of	the	investigated	sample	types,	regardless	of	stimulation	condition.	Under	the	same	stimulation	conditions,	while	in	an	isolated	cellular	environment,	secretion	of	immunoglobulin	isotypes	IgA,	IgG2	and	IgG3	by	B-cells	was	hampered.	Additionally,	a	progressive	decrease	in	the	quantity	of	all	immunoglobulin	 isotypes	within	each	 sample	 type	was	observed	 following	 successive	 isolation.	The	observed	differences	in	the	immunoglobulin	profile	highlight	the	importance	of	cell-cell	communication	between	B-cells	and	additional	cell	types	for	B-cell	activation.	Furthermore,	a	decrease	in	marginal	zone	B-cell	 frequencies	 and	 an	 increase	 in	 T1	 B-cells	 was	 observed	 following	 cell	 isolation,	 indicating	impaired	B-cell	development	 in	response	 to	antigenic	stimulation	 in	 isolation.	 In	contrast,	 increased	frequencies	 of	 killer	 B-cells	 were	 observed	 following	 cellular	 isolation,	 suggesting	 a	 biased	 shift	 in	augmented	immune	response	in	vitro.	Further	discovery	showed	a	relationship	between	sample	type	and	 stimulation	 condition	 in	 which	 the	 elicited	 immune	 response	 to	 a	 particular	 stimulus	 differed	significantly	between	sample	types.	
Conclusion:	Microenvironment	 complexity	 plays	 a	 substantial	 role	 in	 immune	 cell	 polarisation	 and	function.	Humoral	B-cell	function,	as	well	as	development	of	mature	B-cell	populations,	was	impaired	following	 isolation,	 likely	 due	 to	 a	 lack	 of	 co-stimulatory	 signals	 from	 additional	 cell	 types,	 thereby	compromising	their	ability	to	elicit	an	efficient	immune	response.	Thus,	observations	inferring	B-cell	function	from	isolated	cell	studies,	while	useful	and	informative,	should	be	interpreted	carefully,	as	the	
in	vitro	microenvironment	may	have	considerably	influenced	the	observed	results.		
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1.	Introduction	Over	the	past	two	decades,	researchers	have	increased	the	use	of	cell	culture	and	isolated	tissue	samples	for	 biological	 research	 as	 an	 alternative	 to	 in	 vivo	 animal	 studies,	 due	 to	 the	 large	 cost	 and	 strict	regulatory	 conditions	 involved	 (Adams	 and	 Larson,	 2007;	 Brown	 Jr,	 1997;	Murphy,	 1991).	 For	 this	reason,	cell	culture	studies	have	formed	the	fundamental	basis	of	a	variety	of	research	topics	(Anderson	and	Wilbur,	1952;	Arase	et	al.,	1995;	Chess	et	al.,	1974;	Dounce,	1943;	Jonuleit	et	al.,	2001;	O’doherty	et	al.,	1993;	Tsuda	et	al.,	1974).	 	While	the	information	gained	from	these	isolated	cell	studies	provides	valuable	 insight	 into	 biological	mechanisms	 under	 investigation,	 they	 do	 not	 account	 for	 the	many	factors	that	control	these	physiological	responses	in	vivo.	Numerous	studies	have	illustrated	the	ability	of	various	cell	types	to	modulate	host	immune	response	under	different	conditions			(Bénard	et	al.,	2018;	Blair	et	al.,	2010;	Carter	et	al.,	2012;	Maglione	and	Chan,	2009;	Mauri	and	Bosma,	2012;	McKenzie	et	al.,	1993;	Shen	et	al.,	2014;	Sowa	et	al.,	2009;	Xu	et	al.,	2008).	The	presence	and	activation	of	these	cell	types	may	contribute	significantly	to	the	function	of	a	cell	type	of	interest,	through	directing	the	mounting	immune	response.	 	As	such,	absence	of	these	cells	during	isolated	cell	studies	may	result	 in	artificial	observation	 and	 inaccurate	 assumptions	 regarding	 the	 role	 of	 a	 cell	 population	 during	 health	 and	disease.		The	benefits	of	isolated	cell	culture	techniques	include,	the	ability	to	investigate	the	direct	effect	of	a	substance	 or	 compound	 on	 a	 cell	 type	 of	 interest,	 and	 the	 short	 time	 needed	 to	 conduct	 multiple		experiments	(Murphy,	1991).	However,	in	vivo,	endogenous	enzymes	and	various	biological	processes	may	 interact	with	said	drug	or	compound	under	 investigation	prior	 to	 it	 reaching	 its	cellular	 target,	thereby	contributing	to	any	physiological	responses	observed	(Igaz	et	al.,	2001;	Wrenshall	et	al.,	1999).	The	interaction	of	these	biological	processes	and	mechanisms	present	within	whole	organism	are	still	ill-defined.	Consequently,	there	is	no	way	to	simulate	all	of	the	possible	interactions	that	may	occur	to	account	 for	 this	 phenomenon	 in	 vitro.	 For	 this	 reason,	 variations	 in	 observations	 between	 in	 vitro	isolated	 cell	 studies	 and	 in	 vivo	 investigations	 exist.	 The	 effects	 of	 isolation	 on	 investigated	 cellular	responses	is	evident	in	many	studies	(Kondo	and	Magee,	1977;	Murphy,	1991;	Sanders	et	al.,	1983),	in	which	a	particular	 substance/condition	produced	a	measured	 immune	response	 in	whole	organism,	while	having	minimal/no	effect	on	isolated	target	cells	or	tissue;	or	vice	versa.	This	is	due	to	the	many	mechanisms	 that	 act	 simultaneously	within	 the	 immune	 system	 to	 regulate	 all	 biological	 processes,	some	 inhibitory	 while	 others	 stimulatory	 (Carter	 et	 al.,	 2012;	 Chen,	 2004;	 Kessel	 et	 al.,	 2012;	Schlessinger,	2000).	The	absence	of	these	processes	during	isolated	cell	culture	attributes	to	the	altered	responses	observed.			 	
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Importantly,	 each	 of	 the	 investigative	 techniques	 (whole	 organism,	 tissue	 culture	 or	 isolated	 cell	studies)	is	not	more	beneficial	than	the	next	–	individually	they	provided	vital	information	needed	to	fill	the	knowledge	gaps	currently	within	the	scientific	field.	Isolated	cell	studies	enable	investigation	into	cellular	functional	capacity	and	complex	immune	mechanisms	employed	by	cells	that	may	be	masked	by	the	presence	of	other	cell	types	through	direct	cell-cell	interactions	or	indirectly	by	the	secretion	of	several	soluble	molecules	(Igaz	et	al.,	2001;	McKenzie	et	al.,	1993;	Wrenshall	et	al.,	1999).	Moreover,	such	 studies	 allow	 for	 investigation	 into	 cellular	 cytotoxicity,	minimum	 effective	 dose	 and	 immune	modulatory	screening	prior	to	whole	animal	studies	(Combes	et	al.,	2003;	Kirkland	et	al.,	2007;	Knight	and	 Breheny,	 2002),	 saving	 both	 time	 and	money	 in	 the	 process.	 This	 information	must	 simply	 be	interpreted	 cautiously,	 keeping	 in	mind	 the	 effects	microenvironment	 complexity	may	 have	 on	 the	experimental	outcome.	Ultimately,	all	research	needs	to	be	translated	into	clinically	relevant	events	in	whole,	 living	 organism;	 intrinsically	 there	 will	 always	 be	 a	 need	 for	 live	 animal	 testing	 following	isolation	studies	for	proof	of	concept	and	to	ensure	compound	safety	(Hajar,	2011;	Murphy,	1991;	Wall	and	Shani,	2008).		Emerging	 evidence	 has	 acknowledged	B-cells	 as	 fundamental	 in	 the	 defense	 against	Mycobacterium	
tuberculosis	 (M.tb).	Prior	 to	 the	participation	of	B-cells	 in	host	 immune	responses,	development	and	migration	 of	 precurosr	 cells	 known	 as	 transitional	 B-cells	 from	 the	 bone	 marrow	 to	 the	 spleen	 is	required;	where	they	give	rise	to	mature	B-cells	in	response	to	antigenic	stimulation	(Abbas	et	al.,	2014;	Paul,	2013).	Immature	transitional	1	(T1)	B-cells	(CD19+CD21-CD23-)	form	the	foundation	from	which	transitional	 2	 (T2)	 B-cells	 (CD19+CD21+CD23+)	 and	mature	 B-cells	 sequentially	 derive	 (Petro	 et	 al.,	2002).	Notably,	studies	have	demonstrated	the	expansion	of	mature	B-cells	from	both	T1	and	T2	B-cells	(Loder	et	al.,	1999).	However,	T2	B-cells	have	been	found	to	be	more	receptive	to	cellular	activation	and	proliferation,	in	comparison	to	T1	B-cells	(Chung	et	al.,	2003;	Mackay	and	Browning,	2002).	Importantly,	T2	 B-cells	 are	 the	 principal	 source	 from	which	mature	 B-cells	 such	 as	 marginal	 zone	 (MZ)	 B-cells	(CD19+CD21+CD23-)	 and	 follicular	 (FO)	 B-cells	 (CD19+CD21-CD23+)	 develop	 (Cariappa	 et	 al.,	 2001;	Kuroda	et	al.,	2003;	Martin	and	Kearney,	2002).	As	such,	the	presence	and	regulation	of	these	T2	B-cells	dramatically	affects	the	course	of	mounted	immune	responses.	This	complex	developmental	process	of	B-cells	has	been	shown	to	be	partially	affected	during	TB	disease,	in	which	dysregulation	expression	of	genes	involved	in	B-cell	development	have	been	found.			 	
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Recent	studies	investigating	the	role	of	B-cells	during	tuberculosis	(TB)	disease	revealed	impaired	B-cell	function	and	decreased	B-cell	frequencies	during	active	disease	(Joosten	et	al.,	2016a;	Van	Rensburg	et	 al.,	 2017).	A	 regulatory	B-cell	 (Breg)	 subtype,	 killer	B-cells,	was	 recently	discovered	 and	has	been	implicated	in	a	variety	of	immune	conditions,	including		M.tb	infection	(Lundy,	2009;	Lundy	et	al.,	2015;	van	 Rensburg	 and	 Loxton,	 2018a).	 Functional	 analysis	 of	 these	 cells	 in	 numerous	 health	 settings	identified	the	role	of	these	cells	as	potential	immune	modulators	responsible	for	controlling	the	immune	response	during	disease	and	infection.	(Chesneau	et	al.,	2013;	Lundy,	2009;	Lundy	and	Boros,	2002;	Lundy	et	al.,	2015;	Matsushita	et	al.,	2008).	A	study	by	van	Rensburg	and	colleagues	(van	Rensburg	et	al.,	2017)	investigated	the	frequency	of	these	killer	Bregs	during	active	TB	disease;	in	which	a	decrease	in	the	 frequency	of	 killer	B-cells	was	observed	 for	TB	diseased	 individuals	when	 compared	 to	healthy	individuals.	Upon	successful	TB	treatment,	these	killer	B-cell	frequencies	returned	to	levels	comparable	to	 that	 of	 healthy	 controls,	 suggesting	 a	 pivotal	 role	 of	 these	 Bregs	 in	 protective	 anti-TB	 immunity		(Joosten	et	al.,	2016a;	van	Rensburg	et	al.,	2017;	Van	Rensburg	et	al.,	2017).	The	objective	of	this	study	was	to	elucidate	the	influence	of	microenvironment	complexity	on	B-cell	polarisation	and	function	-	in	the	context	of	TB	disease.	Current	research	findings	inferring	the	role	of	B-cells	during	M.tb	infection	utilized	isolated	cell	culture	techniques	to	investigate	their	functional	capacity.	As	such,	the	observed	physiological	response	may	simply	be	a	result	of	the	controlled	laboratory	environment	in	which	the	cells	were	 studied	and	may	not	 reflect	 events	 that	occur	within	whole	organism,	 in	 the	presence	of	additional	 immune	 cells	 and	 endogenous	 factors.	 In	 turn,	 biased	 conclusions	 as	 to	 the	 relative	importance	 of	 this	 cell	 type	 during	 TB	 disease	 may	 have	 occurred	 -	 resulting	 in	 exaggerated	 or	understated	findings	concerning	their	physiological	relevance.		
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2.	Methods	
2.1	Ethics	Statement	Ethical	approval	was	obtained	 from	the	health	research	ethics	committee	of	Stellenbosch	University	(N16/05/070)	 and	 the	 City	 of	 Cape	 Town	 City	Health.	 The	 study	 was	 conducted	 according	 to	 the	Helsinki	 Declaration	 and	 International	 Conference	 of	 Harmonisation	 guidelines.	 Written	 informed	consent	was	obtained	from	all	study	participants.	
	
2.2	Study	Participants	For	this	pilot	study,	we	recruited	23	healthy	individuals	(15	individuals	with	a	negative	QuantiFERON	(QFN)	status)	in	the	year	2018.	The	QFN	status	was	suggestive	of	exposure	to	M.tb,	and	participants	with	a	positive	status	were	considered	latently	infected.	Recruited	participants	did	not	present	with	any	clinical	symptoms	of	TB	and	had	no	previous	record	of	active	disease.	All	participants	for	this	study	were	HIV	 negative.	 QFN	 positive	 and	 negative	 participants	 were	 matched	 according	 to	 socio-economic	background.	The	study	was	performed	in	Cape	Town,	South	Africa.	
	
2.3	B-cell	Isolation	Heparinized	peripheral	blood	(18ml)	was	collected,	of	which	3mL	was	set	aside	for	stimulation.	From	the	remaining	whole	blood,	peripheral	blood	mononuclear	cells	(PBMCs)	were	isolated	using	the	ficoll-histopaque	(GE	Healthcare	Life	Sciences,	USA)	density	gradient	method.	A	fraction	of	the	PBMC’s	(3x106	cells)	was	set	aside	for	stimulation.	Subsequently,	B-cells	were	negatively	isolated	from	the	remaining	PBMCs	 using	 MACS	 bead	 technology,	 according	 to	 the	 manufacturer's	 instructions,	 with	 the	 B-cell	isolation	kit	II	(Miltenyi	Biotec,	South	Africa).	Once	all	the	sample	fractions	had	been	collected,	the	cells	were	 stimulated	 as	 described	 below.	 Purity	 of	 the	 enriched	 B-cell	 samples	 was	 confirmed	 by	 flow	cytometry	using	anti-human	CD19	mAb.	All	 samples	with	resulting	gated	purity	of	above	90%	were	included	in	analysis.		
2.4	Stimulation	assays	Whole	 blood	 (1mL	blood/well),	 PBMC’s	 (1x106	 cells/well)	 and	 isolated	B-cells	 (100	000	 cells/well)	were	stimulated	under	3	conditions:	unstimulated,	H37Rv	(1x106	CFU)	or	TLR9a	(Sigma,	USA)	at	50	ng/ml.	PBMCs	and	isolated	B-cells	were	cultured	 in	96-well	round-bottom	plates	 in	a	total	of	200uL	complete	media	(RPMI	plus	L/Glutamine	(Sigma,	USA))	supplemented	with	10%	Fetal	Calf	Serum	(FCS,	Lonza,	South	Africa).	Whole	blood	samples	were	incubated	in	a	24-well	flat	bottom	plate	in	a	total	of	1.1mL	 (in	 which	 stimulants	 were	 diluted	 in	 complete	media	 and	 added	 to	 1mL	 blood).	 All	 sample	fractions	were	incubated	at	37oC	and	5%	CO2	for	24	hours.	Following	incubation,	the	plasma	(in	case	of	whole	 blood)	 and	 culture	 supernatants	 (in	 the	 case	 of	 PBMCs	 and	 isolated	B-cells)	were	harvested,	passed	through	a	filter	of	0.22µm	(to	remove	any	bacilli	that	may	be	contained	within	the	sample)	and	stored	 at	 -80oC	 for	measurement	 of	 immunoglobulin	 secretion.	 The	 cells	 were	 then	 fixed	 with	 4%	
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paraformaldehyde	(eBioscience,	USA)	for	30min	at	37oC,	washed	with	phosphate	buffered	saline	(PBS	(Lonza,	South	Africa)	and	cryopreserved	(90%	FCS	and	10%	Dimethyl	sulfoxide	(DMSO),	Sigma-Aldrich,	St,	Louis,	MO)	in	liquid	nitrogen	for	future	analysis	by	flow	cytometry.	
	
2.5	Immunoglobulin	isotype	analysis	by	Luminex	technology	Quantification	of	immunoglobulins	within	the	plasma	and	culture	supernatant,	following	the	24-hour	stimulation,	was	determined	using	the	MAGPix	and	Bioplex	platforms	(Bio-rad	Laboratories,	California,	USA).	The	immunoglobulins	included	IgA,	IgE,	IgG1,	IgG2,	IgG3,	IgG4	and	IgM.	The	experiments	were	performed	according	to	the	kit	manufacturer’s	recommendations.		
2.6	Phenotype	Analysis	by	Flow	Cytometry	The	antibody	panel	for	cell	surface	receptor	analysis	consisted	of:	CD19-BV605,	CD21-PE/Dazzle,	CD23-BV421,	 CD5-PerCP/Vio770,	 CD125	 (IL5RA)-PE	 (All	 from	 Biolegend,	 California),	 CD3-FITC	 (BD,	Germany)	and	CD178	(FASL)-APC	(Miltenyi	Biotec,	South	Africa).	Cells	were	stained	for	1	hour	at	room	temperature	in	the	dark,	washed	and	acquired	on	a	BD	LSR	II	(BD	Biosciences).	The	resulting	data	was	analyzed	using	FlowJo	v10	software	(Treestar,	USA).	The	gating	strategies	used	can	be	found	in	Suppl	Figures	5.8	to	5.10.	
	
2.7	Statistical	Analysis		Quantification	of	the	immunoglobulin	isotypes	by	Luminex	was	expressed	as	a	percentage	of	the	total	immunoglobulin	and	statistical	analysis	performed	on	the	relative	percentage	contribution	of	each	of	the	isotypes	within	a	sample.	The	rationale	of	standardizing	the	data	was	that	whole	blood,	comprising	of	plasma,	contained	circulating	antibody	that	were	present	prior	to	stimulation,	while	PBMCs	and	B-cells	were	cultured	 in	 fresh	media.	This	would	 result	 in	 large	 significant	differences	between	whole	blood	and	other	sample	types	being	observed	based	on	the	quantity	of	immunoglobulin	present	rather	than	the	immunoglobulin	isotype	expression	patterns,	and	in	turn	functional	capacity	of	the	B-cells.	Data	analysis	for	all	Luminex	results	was	performed	using	Statistica	12	software	(Statsoft,	Ohio,	USA)	and	Prism	7	Software	(San	Diego,	CA).	Raw	data	was	checked	for	normality	using	normality	plots.	Statistical	differences	between	sample	fractions	(Whole	Blood,	PBMC,	B-cells),	QFN	status	and	culture	conditions	(unstimulated,	TLR9a,	H37v)	was	calculated	using	a	four-way	mixed	model	ANOVA.	Comparisons	within	groups	was	calculated	using	the	Fishers	LSD	post-hoc	test.	A	two-way	step-up	Benjamini,	Krieger	and	Yekutieli	 False	Discovery	 rate	 (FDR)	 approach,	with	 a	 FDR	of	 1%,	was	 used	 to	 correct	 for	multiple	testing.		Data	analysis	of	the	flow	cytometric	plots	was	done	using	FlowJo	V10	(Treestar,	USA)	and	the	resulting	cell	 frequencies	 analyzed	 using	 Statistica	 and	 Prism	 7	 Software.	 Note:	 isolated	 B-cell	 samples	were	pooled	 prior	 to	 flow	 cytometry	 analysis,	 due	 to	 inadequate	 cell	 numbers	 compromising	 acquisition	event	rate,	thereby	prohibiting	the	performance	of	statistical	analysis.	Statistical	differences	between	
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sample	fractions	(Whole	Blood	and	PBMC),	QFN	status	and	culture	conditions	(unstimulated,	TLR9a,	H37v)	was	calculated	as	described	 for	 the	Luminex	data.	Raw	data	was	checked	for	normality	using	normality	plots	and	winsorised	using	the	Huber	mean	and	MAD	as	necessary	to	reduce	the	residual	distribution	into	close	agreement	with	a	normal	distribution.	Statistical	significance	is	indicated	by	an	asterisk,	in	which	the	p	<	0.05	(*),	p<.	0.01	(**)	and	p<0.001(***)	or	by	letters,	in	which	groups	denoted	with	different	letters	indicate	statistical	differences.		
	
3.	Results		3.1	First	order	effects	on	Immunoglobulin	expression	profile		The	 mechanisms	 employed	 by	 B-cells	 toward	 facilitating	 enhanced	 anti-TB	 immunity	 remains	unresolved.	 Subsequently,	 the	 effects	 of	 microenvironment	 complexity	 i.e.	 the	 degree	 of	 cellular	isolation	 on	 B-cell	 function	was	 investigated.	 This	was	 achieved	 by	 examining	 the	 immunoglobulin	expression	 patterns	 within	 culture	 supernatants	 following	 stimulation	 of	 B-cells	 in	 various	 sample	fractions	(whole	blood,	PBMCs	and	isolated	B-cells).		Sample	 type	 was	 observed	 to	 considerably	 influence	 B-cell	 performance	 (Figure	 5.1).	 Altered	immunoglobulin	profiles	were	observed	across	the	various	sample	fractions,	regardless	of	stimulation	condition.	A	significant	difference	(p<0.05)	in	the	immunoglobulin	profile	was	observed	for	all	isotypes,	except	IgG4,	following	isolation	of	B-cells	from	whole	blood	(Figure	5.2a).	In	some	instances,	the	relative	abundance	of	an	isotype	within	a	given	sample	set,	such	as	IgE	(p=0.0001),	IgG3	(p=0.0000)	and	IgA	(ns,	p>0.05),	was	observed	to	increase	following	PBMC	isolation.	However,	in	majority	of	cases	a	decrease	in	the	relative	abundance	of	an	immunoglobulin	isotype,	specifically	IgG1	(p	=	0.0000),	IgG2	(ns,	p>0.05)	IgG4	 (ns,	 p>0.05)	 and	 IgM	 (ns,	 p>0.05),	 within	 a	 given	 sample	 set	 was	 observed	 following	 PBMC	isolation.	A	significant	decrease	in	the	relative	abundance	of	most	 isotype,	 including	IgA	(p=0.0000),	IgG1	(p=0.0000)	and	IgG2	(p=0.0000),	was	observed	following	isolation	of	B-cells	compared	to	whole	blood,	whilst	an	increase	in	the	relative	abundance	of	IgE	(p=0.0004)	and	IgM	(p=0.0000)	was	found.	Likewise,	 a	 substantial	 decrease	 in	 the	 relative	 abundance	 of	 most	 isotypes,	 IgA	 (p=0.0000),	IgG1(p=0.0001),	 IgG2	 (p=0.0000)	 and	 IgG3	 (p=0.0000),	 was	 observed	 following	 isolation	 of	 B-cells	compared	 to	 the	 PBMC	 sample	 fraction,	 whereas	 an	 increase	 in	 the	 relative	 abundance	 of	 IgM	(p=0.0000)	 was	 found.	 Incidentally,	 the	 effect	 of	 sample	 type	 on	 the	 abundance	 of	 the	 various	immunoglobulin	isotypes	was	investigated	to	discern	the	effect	of	cellular	isolation	on	the	magnitude	of	subsequent	B-cell	responses.	A	significant	difference	in	quantified	immunoglobulin	levels	was	observed	for	all	isotypes	following	each	successive	isolation	procedure	(Figure	5.3).	To	account	for	the	obviously	limitations	 involved	 in	 comparing	 plasma	 supernatants	 to	 culture	 supernatants,	 only	 differences	between	 PBMCs	 and	 isolated	 B-cells	 were	 considered.	 A	 significant	 decrease	 in	 the	 observed	concentration	 of	 all	 immunoglobulin	 isotypes,	 IgA	 (p=0.00),	 IgE	 (p=0.0000),	 IgG1	 (p=0.0000),	 IgG2	(p=0.00),	IgG3	(p=0.0000),	IgG4	(p=0.00)	and	IgM	(p=0.0000),	was	observed	for	isolated	B-cell	culture	supernatants	when	comparing	to	those	of	PBMC	samples.
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Figure	5.1.	 Immunoglobulin	profile	of	 supernatants	obtained	 from	each	of	 the	 stimulatory	 conditions	of	 the	various	 cellular	 fractions	
(n=23).	Following	a	24-hour	stimulatory	period,	plasma/culture	supernatants	of	each	of	the	stimulatory	conditions	for	all	sample	types	was	collected	and	the	immunoglobulin	secretion	profile	determined	using	Luminex.	(a)	Representation	of	the	average	secretion	of	each	isotype	within	whole	blood	for	each	stimulatory	condition	(b)	Representation	of	the	average	secretion	of	each	isotype	within	the	PBMC	fraction	for	each	stimulatory	condition	(c)	Representation	of	the	average	secretion	of	each	isotype	within	the	isolated	B-cell	fraction	for	each	stimulatory	condition.		
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Figure	 5.2.	 Evaluation	 of	 the	 effect	 of	 various	 experimental	 factors	 on	 B-cell	
immunoglobulin	 profile	 (n=23).	 Following	 a	 24-hour	 stimulatory	 period,	 plasma/culture	supernatants	 of	 each	 of	 the	 stimulatory	 conditions	 for	 all	 sample	 types	 was	 collected	 and	 the	immunoglobulin	profile	determined	using	Luminex.	The	Immunoglobulin	 isotype	 levels	depicted	are	reported	as	a	percentage	of	the	total	immunoglobulin	within	a	given	sample.	Median	with	interquartile	range	plotted.	Statistical	differences	between	culture	conditions	was	calculated	using	a	four-way	mixed	model	ANOVA.	Comparisons	within	groups	was	calculated	using	the	Fishers	LSD	post-hoc	test.	A	two-way	step-up	Benjamini,	Krieger	and	Yekutieli	False	Discovery	rate	(FDR)	approach,	with	a	FDR	of	1%,	was	used	to	correct	for	multiple	testing.	Statistical	significance	is	indicated	by	an	asterisk,	in	which	the	p	<	0.05	(*),	p<.	0.01	(**)	and	p<0.001(***).	(a)	Effects	of	sample	type	i.e.	microenvironment	complexity	on	 immunoglobulin	 isotype	 abundance	 following	 antigenic	 stimulation	 (b)	 Effects	 of	 QuantiFERON	(QFN)	 status	 on	 immunoglobulin	 isotype	 abundance	 following	 antigenic	 stimulation	 (c)	 Effects	 of	stimulatory	conditions	on	immunoglobulin	isotype	abundance	following	antigenic	stimulation.	 	
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Figure	5.3.	Evaluation	of	the	effect	of	sample	type	on	observed	immunoglobulin	isotype	
concentration	(n=23).	Following	a	24-hour	stimulatory	period,	plasma/culture	supernatants	of	each	of	 the	 stimulatory	 conditions	 for	 all	 sample	 types	was	 collected	 and	 the	 immunoglobulin	 secretion	profile	 determined	 using	 Luminex.	 The	 observed	 concentration	 for	 each	 immunoglobulin	 isotypes	within	 a	 given	 sample	 is	 reported.	 Median	 with	 interquartile	 range	 plotted.	 Statistical	 differences	between	culture	conditions	was	calculated	using	a	four-way	mixed	model	ANOVA.	Comparisons	within	groups	was	calculated	using	the	Fishers	LSD	post-hoc	test.	A	two-way	step-up	Benjamini,	Krieger	and	Yekutieli	 False	Discovery	 rate	 (FDR)	 approach,	with	 a	 FDR	of	 1%,	was	 used	 to	 correct	 for	multiple	testing.	Statistical	significance	is	indicated	by	an	asterisk,	in	which	the	p	<	0.05	(*),	p<.	0.01	(**)	and	p<0.001(***).	 	The	scale	on	the	 left	represent	 the	measured	 immunoglobulin	concentration	(ng/mL)	within	 the	PBMC	 and	B-cell	 sample	 supernatants,	while	 the	 right	 scale	 left	 represent	 the	measured	immunoglobulin	 concentration	 (ng/mL)	 within	 whole	 blood	 sample	 supernatants.	 Two	 scales,	indicating	the	same	variable,	were	utilized	for	ease	of	display	due	to	the	large	difference	in	[Ig]	between	sample	types.		 	
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Additionally,	 the	 effects	 of	 QFN	 status	 and	 stimulation	 condition	 on	 immunoglobulin	 profiles	 were	investigated.	We	 investigated	whether	or	not	M.tb-exposed	 (QFN	positive)	 individuals	with	 immune	memory	 would	 respond	 differently	 to	M.tb	 challenge	 compared	 to	 QFN	 negative	 individuals.	 In	 all	instances,	 QFN	 status	 was	 found	 to	 have	 no	 effect	 on	 the	 relative	 abundance	 of	 the	 various	immunoglobulin	 isotypes	 (Figure	 5.2b).	 To	 conclude,	 the	 impact	 of	 stimulation	 condition	 on	immunoglobulin	 profiles	 were	 investigated	 to	 determine	 the	 effect	 of	 M.tb	 infection	 on	 	 B-cell	performance.	For	majority	of	 immunoglobulin	 isotypes,	 stimulation	 condition	was	 found	 to	have	no	effect	on	the	measured	immunoglobulin	abundance	(Figure	5.2c).	However,	a	significant	decrease	in	IgA	levels	 were	 observed	 following	 TLR9	 stimulation	 for	 all	 sample	 types	 compared	 to	 unstimulated	controls	(p=0.0038)	and	H37Rv	stimulated	(p=0.0292)	samples.	Conversely,	an	increase	in	IgG3	levels	were	 observed	 following	 TLR9	 stimulation	 for	 all	 sample	 types	 compared	 to	 unstimulated	 controls	(p=0.0482).	
	3.2		B-cell	Development	In	addition	to	investigating	alterations	within	the	immunoglobulin	profile	of	B-cells,	variations	in	the	phenotypic	 frequencies	 of	 various	 B-cell	 subsets	 was	 investigated	 to	 evaluate	 the	 effect	 of	microenvironment	complexity	on	cell	function.	The	expression	of	the	cell	surface	receptors	CD21	and	CD23	by	B-cells	was	examined	 to	determine	 the	proportion	of	B-cells	within	various	developmental	stages	following	antigenic	stimulation.	Taking	into	account	the	magnitude	B-cell	development	has	on	elicited	host	immunity,	the	effects	of	microenvironment	complexity	on	B-cell	maturity	and	expansion	was	investigated.	Following	a	24-hour	stimulatory	period,	cells	from	all	stimulatory	conditions	for	each	of	 the	 cellular	 fractions	 was	 collected	 and	 phenotypic	 frequencies	 of	 the	 various	 B-cell	 population	determined	using	flow	cytometry.	It	is	important	to	note	that	due	to	limited	cell	numbers,	isolated	B-cell	samples	(B-cells	only)	were	pooled	according	to	QFN	status	and	stimulatory	conditions	prior	to	flow	cytometry	 analysis,	 prohibiting	 the	 assessment	 of	 individual	 sample	 distribution	 and	 statistically	significant	 differences	 between	 B-cells	 only	 and	 other	microenvironment	 conditions.	 Consequently,	observations	made	from	the	resulting	data	 focus	principally	on	difference	between	whole	blood	and	PBMC,	while	inferring	the	physiological	implications	of	the	trends	observed	for	isolated	B-cells.		The	effect	of	sample	type	on	B-cell	development	was	investigated,	in	which	no	significant	difference	in	T1,	T2,	MZ	and	FO	B-cell	frequencies	was	observed	between	whole	blood	and	PBMCs.	However,	a	shared	pattern	of	decreased	CD19+CD21+CD23-	(MZ)	B-cells,	whilst	an	increase	in	CD19+CD21+CD23+	(T2)	B-cells,	CD19+CD21-CD23+	(FO)	B-cells	and	CD19+CD21-CD23-	(T1)	B-cells	was	observed	for	all	sample	types	 following	 each	 successive	 isolation	 procedure	 (Figure	 5.4a).	 Regrettably,	 the	 significance	 of	alterations	in	these	B-cell	frequencies	for	isolated	B-cell	samples	cannot	be	analyzed,	however	a	sizeable	difference	in	the	investigated	frequencies	is	apparent.	These	results	indicate	the	potential	impact	cell	isolation	has	on	B-cell	development	in	response	to	stimulation	in	vitro.	
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Figure	5.4.	Analysis	of	developmental	B-cell	phenotypic	frequencies.	Following	a	24-hour	stimulatory	period,	cells	from	each	of	the	stimulatory	conditions,	for	all	sample	types,	was	collected	and	the	B-cell	phenotypic	frequencies	determined	using	flow	cytometry.	Notable,	statistical	significance	was	only	investigated	for	whole	blood	and	PBMC	sample	type	as	isolated	B-cell	samples	for	the	respective	QFN	groups	were	pooled	(according	to	stimulation	condition)	prior	to	flow	analysis,	due	to	inadequate	cell	numbers.	Whiskers	denote	10-90	percentile.	Statistical	differences	between	culture	conditions	was	calculated	 using	 a	 four-way	mixed	model	 ANOVA.	 Comparisons	within	 groups	was	 calculated	 using	 the	 Fishers	 LSD	 post-hoc	 test.	 A	 two-way	 step-up	Benjamini,	Krieger	and	Yekutieli	False	Discovery	rate	(FDR)	approach,	with	a	FDR	of	1%,	was	used	to	correct	for	multiple	testing.	Statistical	significance	is	indicated	by	an	asterisk,	in	which	the	p	<	0.05	(*),	p<.	0.01	(**)	and	p<0.001(***).	(a)	Effects	of	sample	type	on	the	developmental	state	of	B-cells	(b)	Effects	of	QuantiFERON	(QFN)	status	on	the	developmental	state	of	B-cells	(c)	Effects	of	stimulation	condition	on	the	developmental	state	of	B-cells.
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Additionally,	 the	 effects	 of	 QFN	 status	 and	 stimulation	 conditions	 on	 B-cell	 development	 was	investigated.	For	majority	of	the	investigated	populations,	QFN	status	was	found	to	have	no	significant	effect	on	the	observed	B-cell	frequencies	(Figure	5.4b).	A	general	trend	of	decreased	frequencies	for	all	populations	 was	 observed	 for	 QFN	 negative	 individuals	 compared	 to	 QFN	 positive	 individuals.	 In	accordance,	 a	 significant	 decrease	 in	 the	 observed	 frequency	 of	 CD19+CD21+CD23+	 (T2)	 B-cells	(p=0.0012)	 was	 observed	 for	 QFN	 negative	 individuals.	 Furthermore,	 the	 effects	 of	 stimulation	condition	were	examined	(Figure	5.4c).	A	common	shift	of	increased	B-cell	frequencies	was	observed	for	most	of	the	population	subsets	investigated	following	TLR9a	stimulation	compare	to	unstimulated	controls.	 A	 significant	 increase	 in	 the	 frequency	 of	 CD19+CD21+CD23-	 (MZ)	 B-cells,	 was	 observed	following	TLR9a	stimulation	(p=0.0000)	and	M.tb	infection	(p=0.0000),	compared	to	unstimulated	cells.	Similarly,	a	significant	increase	in		CD19+CD21+CD23+	(T2)	B-cells	and	CD19+CD21-CD23+	(FO)	B-cells	was	observed	 in	 response	 to	TLR9a	stimulated	compare	 to	unstimulated	 (p=0.0000;	p=0.0061)	and	H37Rv	stimulated	(p=0.0000;	p=0.0198)	samples,	respectively.	Contrariwise,	a	significant	decreases	in	CD19+CD21-CD23-	(T1)	B-cells	was	observed	for	samples	stimulated	with	either	TLR9a	(p=0.0000)	or	H37Rv	(p=0.0000)	compared	to	unstimulated	controls.		3.3	Killer/FasL-expressing	B-cell	frequencies	As	previously	stated,	recent	finding	within	the	TB	research	field	have	revealed	a	particular	B-cell	subset,	killer	B-cells,	and	instrumental	players	in	the	fight	against	TB	disease	(Lundy,	2009;	van	Rensburg	and	Loxton,	2018b;	van	Rensburg	et	al.,	2017;	Van	Rensburg	et	al.,	2017).	The	proposed	function	of	these	cells	 in	 health	 and	 disease	 is	 regulation	 of	 effector	 and	 suppressive	 immune	 responses	 through	activated-cell	death	mechanisms	involving	the	FasL-Fas	interaction	and	the	induction	of	regulatory	T-cells	(Tregs)	and	myeloid-derived	suppressor	cell	(MDSCs),	respectively	(Kessel	et	al.,	2012;	Liu	et	al.,	2016;	Lundy	et	al.,	2015).	Taking	into	consideration	the	relative	importance	of	killer	B-cells	in	health	and	disease,	the	effects	of	microenvironment	complexity	of	the	development	of	this	cell	population	was	investigated.			Currently,	no	defined	phenotype	exists	for	the	identification	of	killer	B-cells	within	biological	samples,	due	to	the	large	heterogenicity	observed	within	these	cell	populations.	Thus,	the	phenotypic	signatures	used	within	 this	 study	was	based	on	a	 combination	of	 cell	 surface	markers	previously	 identified	by	members	within	our	 research	 group	 and	 those	 listed	 in	 literature	 (Lundy,	 2009;	Mauri	 and	Menon,	2015;	van	Rensburg	and	Loxton,	2018b;	van	Rensburg	et	al.,	2017).	Killer	B-cells	were	defined	by	the	co-expression	 of	 CD19	 and	 FasL	 (CD178),	 with	 the	 addition	 of	 various	 supplementary	 cell	 surface	markers	to	distinguish	diverse	killer	B-cell	subsets	within	the	population.	The	separation	of	killer	B-cell	subclasses	was	achieved	by	evaluating	the	co-expression	of	CD5	with	FasL,	as	well	as	CD21	and	CD23	individually	 and	 in	 combination.	 The	 expression	 of	 CD178	 was	 evaluated	 in	 association	 with	CD125/interleukin-5	receptor	alpha	(IL5Ra)	as	expression	and	engagement	of	this	receptor	is	involved	
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in	 immune	 signalling	 responsible	 for	 killer	 B-cell	 development.	 As	 previously	 noted,	 isolated	 B-cell	samples	 for	 each	 of	 the	 stimulatory	 conditions	 were	 pooled	 prior	 to	 flow	 cytometry	 analysis.	Consequently,	observations	made	from	the	resulting	data	focus	primarily	on	difference	between	whole	blood	and	PBMC,	while	inferring	the	physiological	implications	of	these	trends	for	isolated	B-cells.		The	effect	of	sample	type	of	killer	B-cell	phenotypic	frequencies	is	apparent	upon	initial	inspection,	in	which	alterations	in	the	frequency	of	FasL	-expressing	CD19+	cells	is	observed	for	all	population	subsets.	A	 general	 pattern	 of	 increase	 killer	 B-cell	 levels	 was	 observed	 for	 all	 population	 subsets	 following	cellular	 isolation	 (Figure	 5.5a-d).	 In	 accordance,	 a	 significant	 increase	 in	 CD19+IL5Ra+FasL+	 B-cells	(p=0.0017),	 CD19+CD21+CD23+IL5Ra+FasL+	 B-cells	 (p=0.0029)	 and	 CD19+CD21+CD23-IL5Ra+FasL-	 B-cells	 (p=0.0002)	 was	 observed	 following	 PBMC	 isolation.	 Conversely,	 a	 significant	 decrease	 in	CD19+CD21+CD23-IL5Ra-FasL+	 B-ells	 (p=0.0000)	 and	 was	 observed	 following	 PBMC	 isolation.	Regrettably,	the	significance	of	alterations	in	killer	B-cell	frequencies	for	isolated	B-cell	samples	cannot	be	analyzed,	however	an	indication	of	the	vast	differences	in	killer	B-cell	frequencies	is	evident.	It	can	be	assumed	that	large	physiological	implications	may	result	from	this	difference,	thereby	influencing	the	observed	immunological	responses	under	investigation.	Additionally,	the	effects	of	QFN	status	and	stimulation	conditions	on	killer	B-cell	 frequencies	was	 investigated.	 In	all	 instances,	QFN	status	was	found	to	have	no	significant	effect	on	killer	B-cell	frequencies	(Figure	5.6a-d).	However	a	general	trend	of	decreased	killer	B-cell	frequencies	was	observed	for	QFN	negative	individuals	was	observed.			The	effects	of	 stimulation	 condition	on	killer	B-cell	 frequencies	was	well-defined	 (Figure	5.7a-d).	 In	which	a	general	pattern	of	increased	killer	B-cell	frequencies	was	observed	for	all	population	subsets	following	 TLR9a	 stimulation	 compare	 to	 unstimulated	 or	 H37Rv	 stimulated	 samples.	 Significant	increases	 for	 the	 population	 subsets,	 CD19+IL5Ra-FasL+	 B-cells	 (p=0.0058),	 CD19+CD21-CD23-IL5Ra-FasL+	 B-cells	 (p=0.0044),	 CD19+CD21+CD23+IL5Ra+FasL+	 B-cells	 (p=0.0075),	CD19+CD21+CD23+IL5Ra+FasL-	 B-cells	 (p=0.0081)	 and	 CD19+CD21-CD23+IL5Ra+FasL-	 B-cells	(p=0.0153),	was	 observed	 following	TLR9a	 stimulation	 compared	 to	 unstimulated	 cells.	 Similarly,	 a	significant	 increase	 in	 	 CD19+IL5Ra-FasL+	 B-cells	 (p=0.0003),	 CD19+CD21+CD23-IL5Ra-FasL+	 B-cells	(p=0.0025),	 CD19+CD21-CD23-IL5Ra-FasL+	 B-cells	 (p=0.0013)	 was	 observed	 for	 TLR9a	 stimulated	samples	compare	to	H37Rv	stimulated	samples.	Likewise,	a	pattern	of	marginally	increased	levels	of	IL5Ra+FasL+	 and	 IL5Ra+FasL-	 B-cells	 was	 observed	 for	 all	 population	 subtypes	 following	 H37Rv	stimulation	compared	to	unstimulated	controls	(Figure	5.7b-d).	A	significant	increase	for	the	population	subsets	CD19+CD21+CD23+IL5Ra+FasL+	B-cells	 (p=0.0276)	and	CD19+CD21+CD23+IL5Ra+FasL-	B-cells	(p=0.0103)	 was	 observed	 when	 comparing	 unstimulated	 verses	 M.tb	 stimulated	 samples.	 On	 the	contrary,	a	tendency	of	minor	decreases	in	IL5Ra-FasL+	B-cells	was	observed	for	all	population	subtypes	following	 H37Rv	 infection	 compared	 to	 unstimulated	 controls,	 although	 insignificant	 in	 all	 cases	(p>0.05)	(Figure	5.7a	and	d).	
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Figure	5.5.	Evaluation	of	the	effect	of	sample	type	on	killer	B-cell	phenotypic	frequencies.	Following	a	24-hour	stimulatory	period,	cells	from	each	of	 the	stimulatory	conditions,	 for	all	sample	 types,	was	collected	and	the	B-cell	phenotypic	 frequencies	determined	using	 flow	cytometry.	Notable,	statistical	significance	was	only	investigated	for	whole	blood	and	PBMC	sample	type	as	isolated	B-cell	samples	for	the	respective	QFN	groups	were	pooled	(according	to	stimulation	condition)	prior	to	flow	analysis,	due	to	inadequate	cell	numbers.	Whiskers	denote	10-90	percentile.	Statistical	differences	between	culture	conditions	was	calculated	using	a	four-way	mixed	model	ANOVA.	Comparisons	within	groups	was	calculated	using	the	Fishers	LSD	post-hoc	test.	A	two-way	step-up	Benjamini,	Krieger	and	Yekutieli	False	Discovery	rate	(FDR)	approach,	with	a	FDR	of	1%,	was	used	to	correct	for	multiple	testing.	Statistical	significance	 is	 indicated	by	 an	 asterisk,	 in	which	 the	p	<	 0.05	 (*),	 p<.	 0.01	 (**)	 and	p<0.001(***).	 Effects	 of	 sample	 type	 on	 (a)	 IL5Ra-FasL+	B-cells	 (b)	IL5Ra+FasL+	B-cells	(c)	IL5Ra+FasL-	B-cells	(d)	CD19+CD5+	FasL-expressing	B-cells		
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Figure	5.6.	Evaluation	of	the	effect	of	QuantiFERON	status	on	killer	B-cell	phenotypic	frequencies.	Following	a	24-hour	stimulatory	period,	cells	from	each	of	the	stimulatory	conditions,	for	all	sample	types,	was	collected	and	the	B-cell	phenotypic	frequencies	determined	using	flow	cytometry.	Notable,	statistical	significance	was	only	investigated	for	whole	blood	and	PBMC	sample	type	as	isolated	B-cell	samples	for	the	respective	QFN	groups	were	pooled	(according	to	stimulation	condition)	prior	to	flow	analysis,	due	to	inadequate	cell	numbers.	Whiskers	denote	10-90	percentile.	Statistical	differences	between	culture	conditions	was	calculated	using	a	four-way	mixed	model	ANOVA.	Comparisons	within	groups	was	calculated	using	the	Fishers	LSD	post-hoc	test.	A	two-way	step-up	Benjamini,	Krieger	and	Yekutieli	False	Discovery	rate	(FDR)	approach,	with	a	FDR	of	1%,	was	used	to	correct	for	multiple	testing.	Statistical	significance	is	indicated	by	an	asterisk,	in	which	the	p	<	0.05	(*)	and	p<.	0.01	(**).	Effects	of	QFN	status	on	(a)	IL5Ra-FasL+	B-cells	(b)	IL5Ra+FasL+	B-cells	(c)	IL5Ra+FasL-	B-cells	(d)	CD19+CD5+	FasL-expressing	B-cells.	
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Figure	5.7.	Evaluation	of	the	effect	of	stimulation	condition	on	killer	B-cell	phenotypic	frequencies.	Following	a	24-hour	stimulatory	period,	cells	from	each	of	the	stimulatory	conditions,	for	all	sample	types,	was	collected	and	the	B-cell	phenotypic	frequencies	determined	using	flow	cytometry.	Notable,	statistical	significance	was	only	investigated	for	whole	blood	and	PBMC	sample	type	as	isolated	B-cell	samples	for	the	respective	QFN	groups	were	pooled	(according	to	stimulation	condition)	prior	to	flow	analysis,	due	to	inadequate	cell	numbers.	Whiskers	denote	10-90	percentile.	Statistical	differences	between	culture	conditions	was	calculated	using	a	four-way	mixed	model	ANOVA.	Comparisons	within	groups	was	calculated	using	the	Fishers	LSD	post-hoc	test.	A	two-way	step-up	Benjamini,	Krieger	and	Yekutieli	False	Discovery	rate	(FDR)	approach,	with	a	FDR	of	1%,	was	used	to	correct	for	multiple	testing.	Statistical	significance	is	indicated	by	an	asterisk,	in	which	the	p	<	0.05	(*),	p<.	0.01	(**),	p<0.001(***)	and	p<0.0001(****).	Effects	of	stimulation	condition	on	(a)	IL5Ra-FasL+	B-cells	(b)	IL5Ra+FasL+	B-cells	(c)	IL5Ra+FasL-	B-cells	(d)	CD19+CD5+	FasL-expressing	B-cells.		
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Discussion	Over	 the	 past	 century,	 the	 standard	 quality	 of	 scientific	 research	 conducted	 has	 progressed	tremendously	 in	 terms	 of	 the	 development	 of	 state	 of	 the	 art	 technologies,	 improved	 scientific	techniques,	advanced	data	analysis	and	the	implementation	of	rigorous	validation	processes.	Examples	of	the	aforementioned	superior	scientific	advances	includes	the	ability	to	analyse	biological	samples	at	a	single	cell	level	(Wang	and	Bodovitz,	2010;	Wheeler	et	al.,	2003),	multiplexing	of	gene	expression	and	phenotypic	 analysis	 using	 the	 10x	 genomics	 platform	 (Coombe	 et	 al.,	 2016;	 Jiao	 and	 Schneeberger,	2017)	and	the	evolution	of	powerful	imaging	tools	enabling	in-depth	investigation	into	cell	structure,	composition	 and	 intercellular	 communication	 (Neu	 et	 al.,	 2010;	 Tezera	 et	 al.,	 2017).	 All	 of	 these	progressions	 have	 fundamentally	 changed	 the	 way	 we	 conduct	 immunological	 research	 and	 have	facilitated	the	discovery	of	many	phenomena,	providing	crucial	knowledge	needed	to	improve	health	management,	 disease	 control,	 drug	 development	 and	 more.	 Alongside	 these	 advances	 come	 new	challenges	for	research,	such	as	those	encountered	following	the	standard	application	of	isolated	cell	studies	for	the	investigation	of	cell	function.	This	technique	enables	investigation	into	the	development	and	mechanisms	employed	by	a	specific	cell	population	 in	response	to	a	drug	or	stimulus,	devoid	of	external	influences	that	may	otherwise	mask	the	resulting	immune	response.	However,	these	studies	do	not	account	for	the	multidimensional	immune	intervention	by	additional	cells	types	that	occurs	in	
vivo.	As	previously	mentioned,	an	abundance	of	ill-defined	intricate	cellular	interactions	occurs	amongst	immune	cells	within	the	host.	This	cellular	communication	results	in	physiological	events	that	shape	the	immune	response	to	a	particular	stimulus.	During	cell	isolation	studies	these	events	are	amiss,	and	may	result	in	altered	immune	cell	function.	In	such	cases,	erroneous	discernment	as	to	the	physiological	role	of	 the	 investigated	 cell	 population	 during	 health	 and	 disease	 may	 result;	 markedly	 impeding	 the	discovery	of	physiological	phenomenon	vital	for	effective	disease	management	and	enhanced	immune	protection.			In	 accordance,	 the	 purpose	 of	 this	 pilot	 study	 was	 to	 determine	 the	 effect	 of	 microenvironment	complexity	on	B-cell	function.	Additionally,	the	effect	of	cell	isolation	on	the	functional	capacity	of	B-cells	during	M.tb	 infection	was	 investigated,	 to	determine	 the	 significance	of	 the	use	of	 isolated	 cell	culture	 techniques	 in	 studies	 inferring	 the	 role	of	 this	 cell	 type	during	TB	disease.	Current	 research	findings	have	signified	the	importance	of	B-cells	during	M.tb	 infection,	in	which	absence	or	impaired	function	of	this	immune	cell	type	has	been	associated	with	poor	disease	prognosis	(Achkar	et	al.,	2015;	Bénard	et	al.,	2018;	Du	Plessis	et	al.,	2016a,	2016b;	Joosten	et	al.,	2016b;	Rao	et	al.,	2015).	For	decades,	the	primary	function	of	B-cells	was	considered	to	be	antibody	secretion,	forming	part	of	the	adaptive	humoral	 response	 (Abbas	 et	 al.,	 2014;	 Capra	 et	 al.,	 1999;	 Zabriskie,	 2009).	 These	 humoral	 immune	response	were	considered	to	be	effective	in	controlling	the	growth	and	survival	of	extracellular	invading	pathogens	exclusively.	However,	 recent	 investigations	analysing	 the	efficiency	of	 antibody-mediated	immunity	 against	 several	 intracellular	 pathogens,	 including	M.tb,	 have	 since	 disproven	 this	 notion	
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(Achkar	and	Casadevall,	2013;	Balu	et	al.,	2011;	Buccheri	et	al.,	2009;	Chan	et	al.,	2014;	Hamasur	et	al.,	2004;	Teitelbaum	et	al.,	1998).	In	addition,	studies	have	indicated	non-humoral	B-cell	function,	such	as	immune	modulation	 through	 receptor	 engagement	 and	 cytokine	 expression,	 as	 key	mechanisms	 by	which	these	cells	contribute	to	the	successful	control	of	M.tb	infection	(Bénard	et	al.,	2018;	Chen	et	al.,	2007;	Cooper	et	al.,	1997;	Du	Plessis	et	al.,	2016b;	van	Rensburg	and	Loxton,	2018b;	Van	Rensburg	et	al.,	 2017).	 As	 such,	 the	 influence	 of	 in	 vitro	 isolated	 cell	 culture	 studies	 on	 B-cell	 development	 and	function	is	of	great	importance,	as	currently	observational	findings	inferring	the	physiological	role	of	these	cells	during	TB	disease	utilize	this	techniques	(Du	Plessis	et	al.,	2016b;	van	Rensburg	and	Loxton,	2018b).	Intrinsically,	the	results	from	such	studies	form	the	foundation	upon	which	new	TB	drugs,	host-directed	therapies	and	TB	vaccines	are	based.			In	light	of	the	above,	the	impact	of	microenvironment	complexity	(i.e.	the	degree	of	cellular	isolation)	on	 immunoglobulin	expression	patterns	and	B-cell	development	was	 investigated.	Antibody	profiles	were	 assumed	 to	 be	 a	 direct	 indication	 of	 the	 relative	 functional	 capacity	 of	 B-cells	 within	 the	investigated	 samples.	 Notable,	 the	 presence	 of	 circulating	 antibody	 within	 the	 plasma	 samples	compromises	the	inference	of	B-cell	activity	within	whole	blood	samples	and	is	a	limitation	of	the	study.	Considerable	changes	in	the	immunoglobulin	profile	were	observed	across	the	different	sample	types,	in	which	the	relative	percentage	contribution	of	each	of	the	measured	isotypes,	with	the	exception	of	IgG4,	differed	significantly.	Sample	type,	rather	than	stimulation	condition,	had	a	significant	effect	on	the	observed	immunoglobulin	profile.	More	specifically,	a	significant	decrease	in	the	relative	abundant	of	IgG1	was	observed	following	PBMC	isolation	compared	to	whole	blood	samples,	while	a	significant	increase	in	the	relative	abundance	of	IgG3	was	found.	Similarly,	a	significant	decrease	IgG1,	as	well	as	IgA	 and	 IgG2,	was	 observed	 following	B-cell	 isolation	 compare	 to	whole	 blood,	whilst	 a	 substantial	increase	 in	 the	 relative	 abundance	 of	 IgE	 and	 IgM	 was	 observed.	 The	 same	 pattern	 in	 the	immunoglobulin	 expression	was	 observed	when	 comparing	 isolated	 B-cell	 samples	with	 PBMCs,	 in	which	a	decrease	in	the	abundance	of	IgA,	IgG1	and	IgG2,	as	well	as	IgG3	was	observed;	whereas	an	increase	in	IgM	levels	was	found.	Importantly,	the	observed	‘increase/decrease’	in	antibody	levels	is	not	equivalent	to	the	concentration	of	these	isotypes	within	a	given	sample	but	rather	indicates	the	relative	immunoglobulin	 diversity	within	 the	 cellular	microenvironment.	 Bearing	 this	 in	mind,	 the	 effect	 of	sample	type	on	the	observed	concentration	for	each	of	the	immunoglobulin	isotypes	was	investigated;	to	discern	the	effect	of	cellular	isolation	on	the	magnitude	of	elicited	B-cell	responses.	The	physiological	implications	of	altered	immunoglobulin	production	have	been	extensively	reviewed	in	several	disease	states,	where	deficiency	has	been	associated	with	increased	susceptibility	to		bacterial	infection	(Franz	et	al.,	1997;	Hermans	et	al.,	1976;	Twomey	et	al.,	1969).			The	quantity	of	immunoglobulin	[Ig]	secreted	for	each	isotype	was	greatly	impacted	by	sample	type,	in	which	a	systematic	decrease	in	antibody	levels	was	observed	following	successive	cellular	isolation.	It	
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is	 important	 to	 note	 that	 immunoglobulins	 been	 shown	 to	 have	 a	 half-life	 of	 between	 5-21	 days	(Anderson	 et	 al.,	 2006;	 Kim	 et	 al.,	 2007;	Waldmann	 and	 Strober,	 1969).	 Thus,	 circulating	 levels	 of	antibodies	were	present	within	the	plasma	of	whole	blood	samples	prior	to	stimulation,	whereas	cells	within	the	PBMC	and	isolated	B-cell	fraction	were	incubated	in	fresh	media.	This	may	have	resulted	in	possible	artefactual	observations	regarding	the	relative	reduction	in	immunoglobulin	levels	for	whole	blood	samples	compare	to	PBMC	and	isolated	B-cell	samples.	As	such,	significance	of	the	observed	[Ig]	decrease	 was	 only	 considered	 between	 PBMCs	 and	 isolated	 B-cells.	 For	 all	 isotypes,	 an	 immense	decrease	 in	 antibody	 quantification	 was	 observed	 following	 isolation.	 Collectively,	 these	 results	illustrated	 that	 isolation	 procedures	 profoundly	 hindered	 the	 ability	 of	 B-cells	 to	 secrete	 several	immunoglobulin	isotypes;	underscoring	the	fact	that	the	presence	of	additional	cell	types	is	required	for	augmented	B-cell	activation	and	function.				Research	has	implicated	IgA	and	IgG	as	leaders	in	protective	anti-TB	humoral	immunity	(Abebe	et	al.,	2018;	Achkar	et	al.,	2015;	Balu	et	al.,	2011).	A	murine	study	investigating	the	role	of	humoral	immunity	in	TB	disease	associated	 IgA	deficiency	with	 increased	susceptibility	 to	M.tb	 infection	(Achkar	et	al.,	2015).	Additionally,	IgA	has	been	found	to	be	differentially	expressed	during	M.tb	infection;	in	which	differences	 in	the	relative	expression	of	 IgA	can	be	used	to	discriminate	between	clinically	diseased,	
M.tb-infected	and	uninfected	 individuals	 (Abebe	et	al.,	2018).	The	exact	mechanisms	by	which	these	immunoglobulins	 achieve	 this	protective	 effect	 is	 still	 unknown,	 and	 further	 investigation	 into	 their	cellular	targets	is	needed	to	better	understand	the	role	they	play	during	TB	disease	(Li	et	al.,	2017).	As	cited	afore,	an	isolated	cellular	environment	was	observed	to	significantly	impair	the	ability	of	B-cells	to	 produce	 various	 antibody	 isotypes,	 including	 IgA,	 IgG1	 and	 IgG2.	 Hence,	 studies	 evaluating	 the	effectiveness	of	B-cells	to	control	M.tb	infection,	within	an	isolated	environment,	may	incur	imprecise	conclusions	due	to	diminished	competence	of	B-cells	to	suitably	response	to	antigenic	stimulation.	It	has	been	well	documented	that	B-cells	require	co-stimulation	from	T-cell	and	dendritic	cells	in	order	to	undergo	isotype/class	switching	(Coffman	et	al.,	1993;	Fayette	et	al.,	1997;	Le	Bon	et	al.,	2001a;	McAdam	et	al.,	2001;	Stevens	et	al.,	1988).	Notable,	IgA	secretion	is	associated	with	mucosal	immunity,	and	is	a	key	defence	mechanism	employed	at	the	site	of	disease	(Williams,	et	al.	2004;	Woof	&	Kerr,	2006)	.	As	such,	investigation	as	to	the	effect	of	isolated	cell	studies	on	B-cells	at	the	site	of	infection	may	provide	valuable	 insight	 into	 anti-TB	 immunity.	Mechanisms	 by	which	 T-cells	 and	 dendritic	 cell	 induce	 this	process	 are,	 directly	 through	 cell-cell	 interactions	 with	 adjacent	 B-cells	 and	 indirectly	 through	 the	secretion	of	various	soluble	molecules	(Coffman	et	al.,	1993;	Fayette	et	al.,	1997;	Le	Bon	et	al.,	2001b;	Stevens	et	al.,	1988).	Therefore,	experiments	investigating	the	humoral	response	of	B-cells	during	TB	disease	in	isolation	could	lead	investigators	to	believe	that	B-cells	are	ineffective	in	protecting	the	host	against	M.tb	infection	and	that	the	observed	humoral	responses	are	insufficient	in	neutralizing	invading	bacilli.	Whereas,	studies	utilising	animal	models	to	study	anti-TB	humoral	immunity	in	vivo	and	ex	vivo	analysis	of	human	samples	from	healthy	and	active	TB	participants	has	proved	that	humoral	responses	
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do	in	fact	aid	in	the	defence	against	M.tb	infection	(Achkar	and	Casadevall,	2013;	Achkar	et	al.,	2015;	Balu	et	al.,	2011;	Casadevall	and	Pirofski,	2006;	Chan	et	al.,	2014;	Li	et	al.,	2017;	Maglione	and	Chan,	2009;	 Teitelbaum	 et	 al.,	 1998).	 This	 emphasizes	 the	 need	 to	 validate	 experimental	 observations	 in	several	 independent	 experiments,	 utilizing	 difference	 techniques,	 before	 making	 any	 definitive	conclusions	regarding	the	relative	importance	of	a	cell	type	in	health	and	disease.		Furthermore,	the	effect	of	sample	type	on	B-cell	phenotypic	frequencies	was	investigated.	As	previously	stated,	due	to	limited	cell	numbers,	isolated	B-cell	were	pooled	according	to	QFN	status	and	stimulation	condition	 prior	 to	 flow	 cytometry	 analysis.	 Consequently,	 observations	 made	 from	 the	 resulting	phenotypic	data	 focus	primarily	on	difference	between	whole	blood	and	PBMCs,	while	 inferring	 the	physiological	implications	of	the	mean	B-cell	frequencies	observed	for	isolated	B-cell	samples.	The	effect	of	sample	type	of	B-cell	development	was	investigated	via	evaluation	of	the	relative	frequencies	on	T1,	T2,	 MZ	 and	 FO	 B-cells	 within	 each	 sample	 type	 following	 antigenic	 stimulation.	 Interestingly,	 no	significant	 difference	 in	 the	 frequency	 of	 all	 B-cell	 subsets	was	 observed	 between	whole	 blood	 and	PBMCs.	However,	a	shared	pattern	of	decreased	MZ	B-cells	was	observed	for	all	sample	types	following	each	successive	isolation	procedure.	In	contrast	an	increase	in	T1,	T2	and	FO	B-cells	was	observed	for	all	sample	types	following	cellular	isolation.	Regrettably,	the	significance	of	alterations	within	isolated	B-cell	 samples	 could	 not	 be	 determined,	 however	 a	 parallel	 trend	 with	 sizeable	 difference	 in	 the	investigated	frequencies	was	evident.			The	involvement	of	MZ	B-cells	in	T-independent	early	adaptive	immune	responses	is	well	established,	in	which	amplified	inclination	for	plasma	cell	differentiation	and	superior	induction	of	Th1	expansion	has	been	shown	by	MZ	B-cells	in	comparison	to	FO	B-cells	(Attanavanich	and	Kearney,	2004;	Crawford	et	al.,	2006;	Lopes-Carvalho	et	al.,	2005).	As	such,	MZ	B-cells	are	regarded	as	primarily	responsible	for	protective	humoral	and	effector	T-cell	immune	response.	In	contrast,	activation	of	FO	B-cells	occurs	via	T-cell	dependant	mechanisms,	and	is	thus	involved	in	late	immune	responses	(Balázs	et	al.,	2002;	Martin	et	al.,	2001).	FO	B-cells	have	been	shown	to	primarily	be	involved	in	memory	B-cell	development;	while	some	FO	B-cells	may	differentiate	into	plasma	cells	 for	the	expansion	of	 long-lived	humoral	 immune	cells	 (Calame,	 2001;	 Kerfoot	 et	 al.,	 2011).	 Hence,	 the	 regulation	 of	 MZ	 B-cell	 development	 during	immunogenic	 challenge	 substantially	 influences	 host	 immune	 responses.	 These	 results	 indicate	 the	potential	impact	of	cell	isolation	on	B-cell	derived	immune	responses;	in	which	decreased	frequencies	of	MZ	B-cells	was	found.	Thus,	impaired	B-cell	development,	as	a	result	of	diminished	microenvironment	complex	due	to	cellular	isolation,	may	result	in	the	manifestation	of	inappropriate	cellular	responses	to	antigenic	stimulation	in	vitro.	The	subsequent	implication	of	this	for	immunology	research	inferring	cell	function	utilizing	isolated	cell	culture	techniques	is	paramount.		
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Lastly,	the	effect	of	sample	type	on	killer	B-cell	phenotypic	frequencies	was	investigated.	A	significant	increase	in	B-cell	frequencies	for	all	population	subsets,	with	the	exception	of	IL5Ra-FasL+	MZ	B-cells,	was	observed	following	PBMC	isolation.	Inversely,	a	significant	decrease	in	the	aforementioned	FasL-expressing	 MZ	 B-cell	 subset	 was	 observed	 following	 PBMC	 isolation.	 Again,	 the	 significance	 of	alterations	 observed	 for	 isolated	 B-cell	 samples	 could	 not	 be	 determined,	 however	 similar	 trends	illustrating	vast	differences	in	B-cell	frequencies	was	observed	for	isolated	B-cell	samples.	It	is	well	to	remember	that	the	induction	and	maintenance	of	killer	B-cells	during	immunogenic	challenge	greatly	impacts	the	resulting	immune	response	through	suppression	of	effector	T-cell	 function	via	receptor-mediated	apoptosis	(Alderson	and	Lynch,	1998;	Arase	et	al.,	1995;	Lundy,	2009;	Lundy	and	Boros,	2002;	Lundy	 et	 al.,	 2015;	 van	 Rensburg	 et	 al.,	 2017;	 Stalder	 et	 al.,	 1994;	 Süss	 and	 Shortman,	 1996).	 The	expression	of	Fas,	the	cellular	target	of	FasL,	by	activated	T-cells	has	been	widely	reviewed,	in	which	an	increase	in	Fas	expression	by	effector	CD4+	T-cells	following	immunogenic	stimulation	has	been	shown	(Arase	 et	 al.,	 1995;	 Singer	 and	Abbas,	 1994;	 Stalder	 et	 al.,	 1994a;	 Süss	 and	 Shortman,	 1996).	 Upon	engagement	 of	 Fas	 with	 FasL,	 activation	 of	 an	 intracellular	 signalling	 cascade	 follow,	 resulting	 in	commencement	of	receptor-mediated	apoptosis	(Alderson	and	Lynch,	1998;	Arase	et	al.,	1995;	Lundy,	2009;	Lundy	and	Boros,	2002;	Lundy	et	al.,	2015;	van	Rensburg	et	al.,	2017;	Stalder	et	al.,	1994;	Süss	and	Shortman,	1996).	This	delicate	balance	between	pro-inflammatory,	anti-inflammatory	and	immune	suppressive	 function	 ultimately	 determines	 the	 incident	 of	 successful	 disease	 management	 or	immunopathological	effects.	As	such,	it	is	suspected	that	physiological	alterations	in	the	frequencies	of	killer	B-cells,	such	as	the	considerable	increase	observed	within	the	pilot	study	following	successive	B-cell	isolation,	could	deleteriously	influencing	immunological	responses	under	investigation	and	result	in	improper	diagnosis	as	to	the	relative	position	of	a	cell	type	for	a	particular	immune	condition.	For	instance,	adequate	 levels	of	killer	B-cells	during	acute	 inflammation	may	assistance	be	beneficial,	by	preventing	exacerbated	immunopathology	while	having	modest	effect	effector	function	(van	Rensburg	and	 Loxton,	 2018a;	 van	 Rensburg	 et	 al.,	 2017;	 Van	 Rensburg	 et	 al.,	 2017).	 Whereas,	infrequent/abundant	 killer	B-cell	 frequencies	may	have	detrimental	 effects	 on	 the	 observed	 clinical	outcome.	Examples	of	such	instances	include	autoimmune	disease	(De	Maria	and	Testi,	1998;	Sharpe	et	al.,	2007)	and	cancer,	respectively	(Lee-Chang	et	al.,	2013;	Schwartz	et	al.,	2016;	Tadmor	et	al.,	2011).		In	addition	to	the	effects	of	sample	type	on	B-cell	 function,	 the	effects	of	stimulation	condition	were	investigated.	 Currently,	 a	 large	 gap	 in	 TB	 research	 with	 respect	 to	 the	 role	 of	 previously	underappreciated	cell	types	in	TB	disease	exists.	Majority	of	studies	investigating	and	implying	the	role	of	 these	neglected	cell	 types	utilize	 isolated	cell	culture	techniques.	As	such,	determination	as	to	the	relative	impact	of	M.tb	infection	on	B-cell	function	was	investigated.	The	effect	of	stimulation	condition	on	 immunoglobulin	 isotype	 abundance	 was	 investigated,	 in	 which	 upon	 first	 glance	 no	 obvious	alterations	in	the	immunoglobulin	profile	were	observed.	However	upon	further	analysis,	statistically	significant	 differences	 between	 TLR9a	 stimulation	 and	 unstimulated	 samples,	 as	 well	 as	 TLR9a	
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stimulation	and	M.tb	 infection	samples,	 for	the	secretion	of	IgA	were	observed.	In	both	cases,	TLR9a	stimulation	 significantly	 decreased	 the	 relative	 abundance	 of	 IgA	 within	 the	 microenvironment.	Moreover,	a	statistically	significant	difference	in	the	relative	abundance	of	IgG3	was	observed	between	TLR9a	stimulation	and	unstimulated	samples.	In	which	an	increase	in	the	relative	abundance	of	IgG3	was	observed	in	response	to	TLR9a	stimulation.	No	significant	difference	between	H37Rv	stimulated	and	unstimulated	samples	was	observed	indicating	that	M.tb	exposure	did	not	have	an	immediate	effect	of	humoral	immunity.		Furthermore,	 the	effects	of	 stimulation	condition	on	B-cell	phenotypic	 frequencies	was	examined.	A	general	pattern	of	enhanced	B-cell	development	was	observed	following	TLR9a	stimulation	compare	to	unstimulated	 controls.	 Wherein,	 a	 significant	 increase	 in	 T2	 B-cell	 and	 FO	 B-cell	 frequencies	 was	observed	following	TLR9a	stimulated.	Similarly,	a	significant	increase	in	the	frequency	of	MZ	B-cells,	was	observed	 in	 response	 to	TLR9a	stimulation	as	well	 as	M.tb	 infection	compared	 to	unstimulated	control.	In	constant,	a	significant	decreases	in	T1	B-cells	was	observed	in	response	to	TLR9a	stimulation	as	well	as	M.tb	infection	compared	to	unstimulated	control.	The	observed	results	are	in	agreement	with	findings	in	literature,	in	which	TLR9a	stimulation	has	been	shown	to	induced	MZ	B-cell	development	(Lenert	 et	 al.,	 2005).	 The	 induction	 of	 MZ	 B-cells	 following	 H37Rv	 stimulation	 indicates	 that	M.tb	challenge	 evokes	 early	 non-humoral	 B-cell	 responses	 that	may	 play	 an	 importance	 role	 in	 the	 host	defence	against	M.tb	 infection.	These	responsibilities	may	include	the	stimulation	of	T-cell	activation	and	proliferation	to	facilitate	augmentation	of	protective	effector	CD4+	T-cell	responses	(Attanavanich	and	Kearney,	2004;	Crawford	et	al.,	2006;	Lopes-Carvalho	et	al.,	2005),	shown	to	be	highly	correlated	with	enhanced	bacterial	containment	and	clearance	(Forbes	et	al.,	2008;	Maglione	et	al.,	2007).		Moreover,	the	effects	of	stimulation	condition	on	killer	B-cell	frequencies	was	investigated,	in	which	a	general	pattern	of	increased	killer	B-cell	frequencies	was	observed	for	all	population	subsets	following	TLR9a	stimulation.	In	accordance,	a	significant	increases	in	CD19+IL5Ra-FasL+	B-cells,	IL5Ra-FasL+	T1	B-cells,	 IL5Ra+FasL+	 T2	 B-cells,	 	 IL5Ra+FasL-	 T2	 B-cells	 and	 IL5Ra+	 FasL-	 MZ	 B-cells	 was	 observed	following	TLR9a	stimulation,	compared	to	unstimulated	samples.	Likewise,	a	significant	increase	in	the	cellular	frequencies	of	CD19+IL5Ra-FasL+	B-cells,	IL5Ra-FasL+	T1	B-cells	and	IL5Ra-FasL+	MZ	B-cells	was	observed	following	TLR9a	stimulation,		compare	to	H37Rv	stimulated	samples.	Additionally,	a	pattern	of	increased	levels	of	IL5Ra-expressing	B-cells,	although	not	significant	in	all	cases,	was	observed	for	all	population	subtypes	following	H37Rv	infection.	Specifically,	a	significant	increase	in	IL5Ra+FasL+	T2	B-cells	and	IL5Ra+FasL-	T2	B-cells	was	observed	following	H37Rv	infection,	compared	to	unstimulated	samples.	Opposingly,	following	H37Rv	infection,	a	minor	decreases,	although	not	statistically	relevant,	in	IL5Ra-FasL+	B-cells	was	observed	for	all	stimulation	conditions	compared	to	unstimulated	controls.	These	results	underscore	the	ability	of	B-cell	to	actively	response	to	M.tb	challenge	and	insinuate	the	
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possibility	 that	 B-cells	 may	 be	 involved	 in	 directing	 and	 shaping	 the	 immune	 response	 during	 TB	disease.		According	to	the	World	Health	Organization	(WHO),	one	third	of	world’s	population	is	estimated	to	be	latently	infected	with	M.tb	(Corbett	et	al.,	2003;	Dodd	et	al.,	2014;	Houben	and	Dodd,	2016;	World	Health	Organization,	2017).	Latent	tuberculosis	infection	(LTBI)	can	be	defined	as	a	state	of	constant	immune	response	to	stimulation	by	M.tb	antigens,	while	exhibiting	no	clinical	manifestation	of	active	disease	(Getahun	et	al.,	2015;	World	Health	Organization,	2017).	The	occurrence	of	LTBI	can	be	determined	by	a	simple	blood	test,	known	as	the	IFNg	release	assay;	wherein	heightened	levels	of		IFNg	production	in	response	 to	 stimulation	 with	M.tb	 specific	 antigens,	 such	 as	 ESAT-6	 and	 CFP-10,	 are	 indicative	 of	immunogenic	 memory	 and	 thus	 pre-exposure	 to	M.tb.	 Individuals	 observed	 to	 have	 this	 amplified	response	are	regarded	as	latently	infected	and	are	denoted	QFN	positive.	It	is	assumed	that	the	immune	response	 elicited	 in	 QFN	 positive	 individuals	 in	 response	 to	 a	 particular	 stimulus	 may	 differs	significantly	from	QFN	negative	individuals	in	their	course,	magnitude	and	response	time.			Consequently,	 the	 effect	 of	QFN	 status	 on	 immunoglobulin	 expression	 patterns	was	 investigated,	 in	which	no	significant	difference	in	the	relative	abundance	of	each	of	the	immunoglobulin	isotypes	was	observed	between	QFN	positive	and	negative	individuals.	Likewise,	the	effects	of	QFN	status	on	B-cell	development	was	investigated.	A	general	pattern	of	decreased	B-cell	frequencies	was	observed	for	all	investigated	populations	 for	QFN	negative	 individuals	compared	 to	QFN	positive	 individuals	 (Figure	4b).	For	majority	of	 the	 investigated	populations,	namely	T1	B-cells,	MZ	B-cells	and	FO	B-cells,	QFN	status	was	found	to	have	no	significant	effect	on	the	observed	B-cell	frequencies,	whilst,	a	significant	decrease	 in	 the	observed	 frequency	of	T2	B-cells	was	observed	 for	QFN	negative	 individuals.	These	results	are	intriguing	as	T2	B-cells	are	regarded	as	the	principal	precursors	for	both	MZ	and	FO	B-cells	and	 have	 been	 shown	 to	 be	 heavily	 involved	 in	 effector	 T-cell	 development	 (Cariappa	 et	 al.,	 2001;	Kuroda	 et	 al.,	 2003;	Martin	 and	Kearney,	 2002).	 Therefore,	 alterations	 in	 the	 frequency	 of	 this	 cell	population	could	largely	impact	successive	immunological	responses.	Last	but	not	least,	the	effects	of	QFN	status	on	killer	B-cell	frequencies	was	investigated,	in	which	a	general	pattern	of	decreased	killer	B-cell	frequencies	was	observed	for	QFN	negative	individuals	was	observed.	In	all	instances,	QFN	status	was	found	to	have	no	significant	effect	on	all	investigated	killer	B-cell	populations.	Notably,	a	limitation	of	 this	 study	 included	 the	 relatively	 	 small	 sample	 size,	 which	 may	 account	 for	 the	 insignificant	differences	between	QFN	positive	and	negative	individuals	observe.		Apart	from	investigating	the	effects	of	each	of	the	experimental	conditions	on	the	relative	expression	of	the	various	immunoglobulin	isotypes	and	B-cell	development,	the	effect	of	these	factor	in	combination	was	investigated.	In	doing	so,	the	effects	of	a	single	variable	on	another	experimental	condition	could	be	examined	to	identify	whether	or	not	a	relationship	between	the	two	existed.	Firstly,	the	effect	of	QFN	
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status	in	combination	with	sample	type	was	investigated.	In	all	cases,	factors	in	combination	with	QFN	status	were	observed	to	have	modest	effects,	while	in	some	instances	statistical	significance	was	found.	With	regards	to	the	effect	on	QFN	status	and	sample	type	in	combination	on	the	relative	abundance	of	each	 immunoglobulin	 isotype,	 no	 significance	 was	 observed.	 Though,	 a	 discrepancy	 in	 the	responsiveness	 of	 B-cells	 between	 QFN	 positive	 and	 negative	 individuals	 was	 observed,	 in	 which	immunoglobulin	responses	of	QFN	positive	individuals	were	found	to	be	less	intense	compared	to	QFN	negative	individuals.	Likewise,	an	inconsequential	effect	of	QFN	status	in	relation	to	sample	type	was	observed	for	the	induction	of	killer	B-cells.	In	contrast,	a	substantial	difference	in	the	frequency	of	T2	B-cells	 was	 observed	 in	 the	 PBMC	 fraction	 of	 QFN	 positive	 individuals	 compared	 to	 QFN	 negative	individuals,	while	no	difference	was	observed	in	whole	blood.	Additionally,	no	significance	difference	in	the	frequency	of	T1	B-cells,	MZ	B-cells	or	FO	B-cells	between	QFN	positive	and	negative	individuals	was	observed	 for	 whole	 blood	 or	 PBMC	 samples.	 Collectively,	 these	 results	 indicated	 that	 although	 not	significant	 in	 all	 instances,	 QFN	 status	 had	 a	 moderate	 on	 the	 immune	 response	 elicited	 following	antigenic	challenge.	Wherein,	alterations	within	the	humoral	response	of	QFN	positive	individuals	was	observed	to	be	less	receptive	to	stimulation.	Opposingly,	QFN	positive	individuals	were	found	to	have	heightened	 immune	responses	 to	antigenic	challenge	with	regards	 to	 the	 induction	of	various	B-cell	populations,	particularly	FasL-expressing	B-cells.	The	physiological	 implications	of	 this	phenomenon	include	predisposition	of	QFN	positive	individuals	to	develop	suppressive	immune	responses	following	immune	 challenge.	 As	 previously	 disclosed	 abundance	 of	 these	 killer	 B-cells	 during	 a	 particular	physiological	condition	may	impose	effector	function	and	exacerbate	disease	conditions.		In	conclusion,	the	effect	of	stimulation	condition	and	sample	type	in	combination	was	investigated	(refer	to	 supplementary).	 For	 all	 investigated	 immune	 responses,	 a	 general	 theme	was	observed	 in	which	PBMCs	were	found	to	be	more	susceptible	to	antigenic	stimulation	compared	to	whole	blood	or	isolated	B-cells.	A	significant	decrease	in	the	relative	abundance	of	IgA	was	observed	for	PBMCs	following	TLR9a	stimulation	compared	to	unstimulated	controls,	while	no	difference	in	the	immunoglobulin	profile	of	all	other	 isotypes	 was	 observed	 for	 whole	 blood,	 PBMCs	 or	 isolated	 B-cells	 in	 response	 to	 antigenic	stimulation.	Correspondingly,	a	significant	increase	in	T2	B-cell	frequencies	was	observed	for	PBMCs	following	TLR9a	stimulation	compared	to	unstimulated	controls,	while	no	difference	was	observed	for	whole	blood.	Equally,	a	significant	increase	in	T1	B-cell	frequencies	was	observed	for	PBMC	following	H37Rv	infection	compared	to	unstimulated	controls,	while	no	difference	was	observed	for	whole	blood.	Dissimilar,	a	significant	increase	in	MZ	B-cell	frequencies	was	observed	for	all	stimulatory	conditions	in	whole	blood	compare	to	PBMCs.	Further	investigation	revealed	QFN	positive	individuals	to	be	the	cause	of	this	observed	response.	Finally,	the	effect	of	stimulation	condition	in	combination	with	sample	types	on	killer	B-cell	frequencies	was	examined.	A	significant	increase	of	all	IL5Ra+FasL+	B-cell	subpopulations	was	observed	for	PBMCs	following	TLR9a	stimulation	or	H37Rv	infection	compared	to	the	unstimulated	control,	while	a	decrease	was	observed	in	whole	blood	samples	under	the	same	conditions.		
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	These	 results	demonstrating	 the	 impact	microenvironment	 composition	has	 in	 guiding	 immune	 cell	activation	and	function,	give	prominence	to	the	fact	that	cellular	isolation	profoundly	affect	cell	function.	Additionally,	the	stupefaction	of	these	complex	interaction	underscores	the	basis	for	the	use	isolated	cell	 studies	 to	 investigate	 cellular	 function,	 in	 an	 attempt	 to	 limit	 the	 degree	 of	 external	 factors	influencing	 the	 observed	 results.	 This	 allows	 for	 the	 assumption,	 with	 complete	 certainty,	 that	 the	measured	output	 for	a	cell	population	 is	 in	response	to	a	particular	drug	or	stimulus.	However,	 it	 is	important	to	remember	that	this	isolated	interaction	is	not	indicative	of	real-life	scenarios.	Composite	cellular	interactions	exist	in	vivo	that	may	drastically	influence	the	function	of	the	cell	type	of	interest	resulting	in	a	different	reaction	of	these	cells	to	the	same	drug	or	stimulus	in	whole	organism.		
Concluding	Remarks	Our	study	illustrates	that	microenvironment	complexity	i.e.	sample	type	had	a	profound	impact	of	the	activation	and	 function	of	B-cells.	Wherein,	a	burdened	ability	of	B-cells	 to	secrete	various	antibody	classes,	 as	well	 as	dysregulated	 induction	of	B-cell	 subtypes	 such	as	killer	B-cells	 and	altered	B-cell	development,	 was	 observed	 following	 cell	 isolation.	 This	 emphasizes	 the	 impact	 that	 isolated	 cell	studies	may	have	on	the	measured	immune	responses,	and	that	while	isolated	cell	culture	techniques	allow	for	in-depth	functional	analysis,	the	resulting	findings	may	be	artefactual	observations	and	if	not	interoperated	cautiously	can	lead	to	inappropriate	conclusions	regarding	authentic	cellular	function.	As	a	final	confirmation	of	scientific	discovery	all	in	vitro	results	should	be	verified	in	several	independent	experiments,	utilizing	various	experimental	techniques	(including	in	vivo	animal	model)	to	ensure	the	integrity	of	the	obtained	results.	
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Supplementary	Information		
1. Second	and	third	order	effects	on	Immunoglobulin	expression	profile	In	addition	to	investigating	the	effects	of	each	of	the	experimental	conditions	on	the	relative	abundance	of	the	various	immunoglobulin	isotypes,	the	effect	of	these	factor	in	combination	was	investigated.		The	reason	for	this	was	to	observe	if	a	relationship	between	either	(denoted	second-order	interactions)	or	all	 (denoted	 the	 third-order	 interaction)	 of	 the	 experimental	 conditions	 existed.	 Consequently,	 the	effects	 of	 QFN	 status	 and	 sample	 type	 in	 combination	 on	 immunoglobulin	 expression	 patterns	was	investigated	(Suppl	Figure	5.1).	No	significant	difference	(p>0.05)	was	 found	when	 investigating	 the	general	correlation	between	QFN	status	and	sample	type.	These	results	illustrate	that	the	consequential	effect	of	QFN	status	and	sample	type	on	immunoglobulin	expression	patterns	are	independent	of	one	another.	Likewise,	the	effects	of	QFN	status	and	stimulation	condition	in	combination	was	investigated	(Suppl	Figure	2).	 In	 all	 cases,	 no	 significant	difference	 (p>0.05)	between	QFN	positive	 and	negative	individuals	was	observed	for	each	of	the	stimulation	conditions;	whilst	significant	differences	between	stimulation	conditions	within	a	particular	QFN	group	were	detected.	A	significant	decrease	in	IgA	was	observed	following	TLR9a	stimulation	for	QFN	negative	individual	(p=0.0177).	A	similar	trend	was	seen	for	 QFN	 positive	 individuals	 however	 these	 differences	 were	 not	 significant	 (Suppl	 Figure	 5.2a).	Similarly,	 a	 significant	 decrease	 in	 IgE	was	 observed	 for	 QFN	 negative	 individuals	 following	 TLR9a	stimulation	(p=0.019)	or	H37Rv	infection	(p=0.0287)	compared	to	the	unstimulated	control;	whilst	a	trivial	decrease	was	observed	for	QFN	positive	individuals	(Suppl	Figure	5.2b).	A	marginal	decrease	in	IgG1	 was	 observed	 for	 QFN	 positive	 individuals	 in	 response	 to	 TLR9a	 stimulation	 (ns,	 p>0.05)	Comparably,	a	decrease	in	IgG1	was	observed	in	response	to	TLR9a	stimulation	(ns,	p>0.05),	as	well	as	H37Rv	infection	(p>0.05),	compared	to	the	unstimulated	control	for	QFN	negative	individuals	(Suppl	Figure	5.2c).	A	general	trend	of	decreased	IgG2	was	observed	for	QFN	negative	individuals	following	antigenic	stimulation	(ns,	p>0.05),	whereas	a	decrease	in	IgG2	for	QFN	positive	individuals	was	only	observed	in	response	to	TLR9a	stimulation	(ns,	p>0.05)	(Suppl	Figure	5.2d).	The	same	immunogenic	response	was	observed	for	both	QFN	positive	and	negative	individuals	with	regards	to	IgG3	abundance,	in	which	a	minor	decrease	was	observed	following	antigenic	stimulation	(ns,	p>0.05)	(Suppl	Figure	2e).	No	 difference	 in	 IgG4	 abundance	 was	 observed	 for	 QFN	 negative	 individuals	 following	 antigenic	stimulation,	 whilst	 a	 minor	 decrease	 was	 observed	 for	 QFN	 positive	 individuals	 following	 TLR9a	stimulation	(ns,	p>0.05)	(Suppl	Figure	5.2f).	To	finish,	no	difference	in	IgM	abundance	was	observed	for	both	QFN	positive	and	negative	individuals	following	antigenic	stimulation	(ns,	p>0.05)	(Suppl	Figure	5.2g).	These	results	indicate	a	slight	discrepancy	in	the	activation	state	of	B-cells	between	QFN	positive	and	negative	individuals,	in	which	immunoglobulin	responses	of	QFN	positive	individuals	were	found	to	be	less	responsive	to	antigenic	stimulation	compared	to	QFN	negative	individuals.	However,	these	differences	were	not	significant.		
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Suppl	 Figure	 5.1.	 Effect	 of	 QuantiFERON	 status	 and	 sample	 type	 in	 combination	 on	
immunoglobulin	expression	pattern	of	B-cells	 following	antigenic	stimulation.	Following	a	24-hour	 stimulatory	 period,	 plasma/culture	 supernatants	 of	 each	 of	 the	 stimulatory	 conditions	 for	 all	sample	types	was	collected	and	the	immunoglobulin	isotype	profile	determined	using	Luminex.	Median	with	interquartile	range	plotted.	Statistical	differences	between	culture	conditions	was	calculated	using	a	four-way	mixed	model	ANOVA.	Comparisons	within	groups	was	calculated	using	the	Fishers	LSD	post-hoc	test.	A	two-way	step-up	Benjamini,	Krieger	and	Yekutieli	False	Discovery	rate	(FDR)	approach,	with	a	FDR	of	1%,	was	used	to	correct	for	multiple	testing.	Statistical	differences	are	indicated	by	letters,	in	which	 groups	 denoted	 with	 different	 letters	 indicate	 statistical	 differences.	 Effect	 of	 QuantiFERON	(QFN)	status	and	sample	type	in	combination	on	secretion	of	(a)	IgA	(b)	IgE	(c)	IgG1	(d)	IgG2	(e)	IgG3	(f)	IgG4	(g)	IgM	
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Suppl	Figure	5.2.	Effect	of	QuantiFERON	status	and	stimulation	condition	in	combination	
on	immunoglobulin	expression	pattern	of	B-cells	following	antigenic	stimulation.	Following	a	24-hour	 stimulatory	 period,	 plasma/culture	 supernatants	 of	 each	 of	 the	 stimulatory	 conditions	 for	 all	sample	types	was	collected	and	the	immunoglobulin	isotype	profile	determined	using	Luminex.	Median	with	interquartile	range	plotted.	Statistical	differences	between	culture	conditions	was	calculated	using	a	four-way	mixed	model	ANOVA.	Comparisons	within	groups	was	calculated	using	the	Fishers	LSD	post-hoc	test.	A	two-way	step-up	Benjamini,	Krieger	and	Yekutieli	False	Discovery	rate	(FDR)	approach,	with	a	FDR	of	1%,	was	used	to	correct	for	multiple	testing.	Statistical	differences	are	indicated	by	letters,	in	which	 groups	 denoted	 with	 different	 letters	 indicate	 statistical	 differences.	 Effect	 of	 QuantiFERON	(QFN)	status	and	stimulation	condition	in	combination	on	secretion	of	(a)	IgA	(b)	IgE	(c)	IgG1	(d)	IgG2	(e)	IgG3	(f)	IgG4	(g)	IgM	
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	Furthermore,	the	effect	of	stimulation	condition	and	sample	type	in	combination	on	immunoglobulin	expression	 patterns	 was	 investigated	 (Suppl	 Figure	 5.3).	 Upon	 inspection,	 a	 general	 theme	 was	observed	 in	which	PBMCs	were	 found	 to	be	more	 susceptible	 to	 antigenic	 stimulation	 compared	 to	whole	blood	or	isolated	B-cells.	For	example,	a	significant	decrease	in	IgA	levels	was	detected	for	PBMCs	following	TLR9a	stimulation	compared	to	unstimulated	(p=0.0000)	or	H37Rv	stimulated	(p=0.0000)	samples;	while	no	significant	difference	for	was	observed	for	whole	blood	or	 isolated	B-cell	samples	(Suppl	 Figure	 5.3a).	 Additionally,	 a	 significant	 difference	 in	 IgA	 between	 whole	 blood	 and	 PBMC	(p=0.0124),	 whole	 blood	 and	 B-cells	 (p=0.0000)	 and	 PBMC	 and	 B-cells	 (0.0000)	 for	 unstimulated	samples	was	observed;	as	well	as	between	whole	blood	and	B-cells	(p=0.0000)	and	PBMCs	and	B-cells	(p=0.0000)	 for	 TLR9a	 stimulation	 and	 H37Rv	 infection,	 respectively.	 A	 comparable	 pattern	 was	observed	for	all	immunoglobulin	isotypes	with	regards	to	the	variable	immunoglobulin	profile	of	PBMCs	in	comparison	to	whole	blood	or	isolated	B-cells.	Wherein,	significant	variations	were	observed	for	IgG1	(Suppl	Figure	5.3c),	 IgG2	(Suppl	Figure	5.3d),	 IgG3	(Suppl	Figure	5.3e)	and	 IgM	(Suppl	Figure	5.3g),	while	similar	but	non-significant	differences	were	observed	for	IgE	(Suppl	Figure	5.3b)	and	IgG4	(Suppl	Figure	5.3f).	Lastly,	the	effect	of	QFN	status,	stimulation	condition	and	sample	type	in	combination	on	immunoglobulin	expression	patterns	was	investigated.	In	all	instances,	the	overall	effect	of	these	factors	in	combination	resulted	in	insignificant	alterations	to	the	observed	immunoglobulin	isotype	levels.	In	spite	of	this,	a	slight	discrepancy	was	observed	when	comparing	the	immunoglobulin	profile	of	PBMCs	following	 TLR9a	 stimulation	 (Figure	 5.3b).	Wherein	 an	 increase	 in	 the	 relative	 abundance	 of	 IgG3	(p=0.0262)	was	observed	for	QFN	positive	compared	to	QFN	negative	individuals	(Suppl	Figure	5.4).	However,	this	was	not	the	case	for	all	other	stimulatory	conditions	for	whole	blood	(Suppl	Figure	5.5),	PBMCs	 or	 isolated	 B-cells	 (Suppl	 Figure	 5.6).	 Depicted	 in	 Suppl	 Figure	 5.7	 is	 an	 example	 of	 the	multifaceted	relationship	between	all	investigated	experimental	conditions	for	a	single	immunoglobulin	isotype.	The	 resulting	perplexity	 of	 this	 complex	 interaction	highlights	 the	 rationale	behind	 the	use	isolated	 cell	 studies	 to	 investigate	 cellular	 function,	 in	 order	 to	 limit	 the	 degree	 of	 external	 factors	influencing	the	observed	results.	A	summary	of	the	significance	of	each	of	the	various	first,	second	and	third	order	interactions	investigated	is	described	in	Suppl	Table	5.1.			 	
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Suppl	 Figure	 5.3.	 Effect	 of	 stimulation	 condition	 and	 sample	 type	 in	 combination	 on	
immunoglobulin	expression	patterns	of	B-cells	following	antigenic	stimulation.	Following	a	24-hour	 stimulatory	 period,	 plasma/culture	 supernatants	 of	 each	 of	 the	 stimulatory	 conditions	 for	 all	sample	types	was	collected	and	the	immunoglobulin	isotype	profile	determined	using	Luminex.	Median	with	interquartile	range	plotted.	Statistical	differences	between	culture	conditions	was	calculated	using	a	four-way	mixed	model	ANOVA.	Comparisons	within	groups	was	calculated	using	the	Fishers	LSD	post-hoc	test.	A	two-way	step-up	Benjamini,	Krieger	and	Yekutieli	False	Discovery	rate	(FDR)	approach,	with	a	FDR	of	1%,	was	used	to	correct	for	multiple	testing.	Statistical	differences	are	indicated	by	letters,	in	which	 groups	 denoted	 with	 different	 letters	 indicate	 statistical	 differences.	 Effect	 of	 stimulation	condition	and	sample	type	in	combination	on	secretion	of	(a)	IgA	(b)	IgE	(c)	IgG1	(d)	IgG2	(e)	IgG3	(f)	IgG4	(g)	IgM	
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Suppl	Figure	5.4.	Comparison	of	Immunoglobulin	expression	patterns	of	QuantiFERON	positive	and	negative	participants	for	each	of	the	
stimulatory	conditions	in	PBMCs.	Following	a	24-hour	stimulatory	period,	plasma/culture	supernatants	of	each	of	the	stimulatory	conditions	for	all	sample	types	was	collected	and	the	 immunoglobulin	 isotype	profile	determined	using	Luminex.	 	 (a)	Representation	of	 the	average	secretion	of	each	 isotype	by	QuantiFERON	 (QFN)	positive	 and	negative	 individuals	within	unstimulated	PBMCs	 (b)	Representation	of	 the	average	 secretion	of	 each	 isotype	by	QFN	positive	and	negative	individuals	within	TLR9a	stimulated	PBMCs	(c)	Representation	of	the	average	secretion	of	each	isotype	by	QFN	positive	and	negative	individuals	within	M.tb-stimulated	PBMCs.		 	
QFN+ Unstim
IgA IgE IgG1 IgG2 IgG3 IgG4 IgM
QFN- Unstim
IgA IgE IgG1 IgG2 IgG3 IgG4 IgM
QFN+ TLR9a
IgA IgE IgG1 IgG2 IgG3 IgG4 IgM
QFN+ H37Rv
IgA IgE IgG1 IgG2 IgG3 IgG4 IgM
QFN- H37Rv
IgA IgE IgG1 IgG2 IgG3 IgG4 IgM
a)	 b)	 c)	
QFN- TLR9a
IgA IgE IgG1 IgG2 IgG3 IgG4 IgM
Stellenbosch University  https://scholar.sun.ac.za
Stellenbosch University  https://scholar.sun.ac.za
 186 
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Suppl	Figure	5.5.	Comparison	of	Immunoglobulin	expression	patterns	of	QuantiFERON	positive	and	negative	participants	for	each	of	the	
stimulatory	conditions	in	whole	blood.	Following	a	24-hour	stimulatory	period,	plasma/culture	supernatants	of	each	of	the	stimulatory	conditions	for	all	sample	types	was	collected	and	the	immunoglobulin	isotype	profile	determined	using	Luminex.	(a)	Representation	of	the	average	secretion	of	each	isotype	by	QuantiFERON	(QFN)	positive	and	negative	individuals	within	unstimulated	whole	blood	(b)	Representation	of	the	average	secretion	of	each	isotype	by	QFN	positive	and	negative	individuals	within	TLR9a	stimulated	whole	blood	(c)	Representation	of	the	average	secretion	of	each	isotype	by	QFN	positive	and	negative	individuals	within	M.tb-stimulated	whole	blood.		 	
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Suppl	Figure	5.6.	Comparison	of	Immunoglobulin	expression	patterns	of	QuantiFERON	positive	and	negative	participants	for	each	of	the	
stimulatory	conditions	in	Isolated	B-cells.	Following	a	24-hour	stimulatory	period,	plasma/culture	supernatants	of	each	of	the	stimulatory	conditions	for	all	sample	types	was	collected	and	the	immunoglobulin	isotype	profile	determined	using	Luminex.		(a)	Representation	of	the	average	secretion	of	each	isotype	by	QuantiFERON	(QFN)	positive	and	negative	individuals	within	unstimulated	B-cells	(b)	Representation	of	the	average	secretion	of	each	isotype	by	QFN	positive	and	negative	individuals	within	TLR9a	stimulated	B-cells	(c)	Representation	of	the	average	secretion	of	each	isotype	by	QFN	positive	and	negative	individuals	within	M.tb-stimulated	B-cells.
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Suppl	Figure	5.7.	Evaluation	of	the	effects	of	third	order	interactions	with	respect	to	the	
investigated	 factors	 on	 immunoglobulin	 expression	 patterns.	 Following	 a	 24-hour	 stimulatory	period,	 plasma/culture	 supernatants	 of	 each	 of	 the	 stimulatory	 conditions	 for	 all	 sample	 types	was	collected	and	the	immunoglobulin	isotype	profile	determined	using	Luminex.	An	example	of	the	various	second	and	third	order	interactions	within	the	data	set	is	depicted.	The	Immunoglobulin	levels	depicted	are	reported	as	a	percentage	of	the	total	immunoglobulin	within	a	given	sample.	Whiskers	denote	10-90	percentile.		Statistical	differences	between	culture	conditions	was	calculated	using	a	four-way	mixed	model	ANOVA.	Comparisons	within	groups	was	calculated	using	the	Fishers	LSD	post-hoc	test.	A	two-way	step-up	Benjamini,	Krieger	and	Yekutieli	False	Discovery	rate	(FDR)	approach,	with	a	FDR	of	1%,	was	used	to	correct	for	multiple	testing.	Statistical	differences	are	indicated	by	letters,	in	which	groups	denoted	with	 different	 letters	 indicate	 statistical	 differences.	 (a)	 Collective	 effect	 of	 negative	 status,	stimulation	condition	and	sample	type	on	immunoglobulin	G2	secretion	(b)	Collective	effect	of	positive	status,	stimulation	condition	and	sample	type	on	immunoglobulin	G2	secretion
Un
sti
mu
lat
ed
TL
R9
a
H3
7R
v
-5
0
5
10
15
Effect of Stimulation, Sample type and 
QFN status on Immunoglobulin G2 levels
Stimulation in QFN negative participants
%
 Ig
G
2
Whole Blood
PBMC
B-cells
abc
a a
a
abcd bcdeg
fh efgh efgh
Un
sti
mu
lat
ed
TL
R9
a
H3
7R
v
-5
0
5
10
15
20
Effect of Stimulation, Sample type and 
QFN status on Immunoglobulin G2 levels
Stimulation in QFN positive participants
%
 Ig
G
2
Whole Blood
PBMC
B-cells
abcdef
abcde
defgh
abcdef abcdef
gh gh
abcdef
cdefgh
a)	 b)	
Stellenbosch University  https://scholar.sun.ac.za
189 
Ig	Isotype	 IgA	 IgE	 IgG1	 IgG2	 IgG3	 IgG4	 IgE	
Effect	 P-value	 q-value	 P-value	 q-value	 P-value	 q-value	 P-value	 q-value	 P-value	 q-value	 P-value	 q-value	 P-value	 q-value	
QFN_status	 0.73	 0.91	 0.90	 0.91	 0.65	 0.91	 0.50	 0.91	 0.48	 0.91	 0.78	 0.91	 0.22	 0.91	
Stimulation	 0.01	 0.07	 0.15	 0.34	 0.20	 0.34	 0.33	 0.39	 0.14	 0.34	 0.53	 0.54	 0.24	 0.34	
Sample	type	 0.00	 0.00	 0.00	 0.00	 0.00	 0.00	 0.00	 0.00	 0.00	 0.00	 0.59	 0.09	 0.00	 0.00	
QFN_status*	
Stimulation	
0.72	 0.79	 0.33	 0.69	 0.62	 0.79	 0.14	 0.69	 0.39	 0.69	 0.78	 0.79	 0.29	 0.69	
QFN_status*	
Sample	type	
0.77	 0.91	 0.91	 0.92	 0.18	 0.82	 0.53	 0.82	 0.40	 0.82	 0.28	 0.82	 0.58	 0.82	
Stimulation*	
Sample	type	
0.00	 0.00	 0.02	 0.06	 0.35	 0.33	 0.35	 0.33	 0.05	 0.10	 0.20	 0.30	 0.38	 0.33	
QFN_status*	
Stimulation*	
Sample	type	
0.20	 0.35	 0.61	 0.85	 0.99	 1.00	 0.04	 0.28	 0.15	 0.35	 0.72	 0.85	 0.11	 0.35	
Suppl	Table	5.1.	Fixed	effects	observed	for	immunoglobulin	expression	patterns	of	B-cells.	Statistical	differences	between	culture	conditions	was	calculated	using	a	four-way	mixed	model	ANOVA.	Comparisons	within	groups	was	calculated	using	the	Fishers	LSD	post-hoc	test.	A	two-way	step-up	Benjamini,	Krieger	and	Yekutieli	False	Discovery	rate	(FDR)	approach,	with	a	FDR	of	1%,	was	used	to	correct	for	multiple	testing.	Statistically	significant	p-values	are	highlighted	in	red.	The	adjusted	p-value	is	denoted	‘q-value’.	
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2. Second	and	third	order	effects	on	B-cell	Development		The	effect	of	each	experimental	conditions	in	combination	on	the	B-cell	development	was	investigated	(Suppl	Table	5.2).	The	effects	of	QFN	status	and	sample	type	in	combination	on	T1,	T2,	MZ	and	FO	B-cell	frequencies	was	examined,	 in	which	no	significance	difference	(p>0.05)	was	observed	between	QFN	positive	and	negative	individuals	for	all	but	one	population.	A	substantial	difference	was	observed	for	CD19+CD21+CD23+	(T2)	B-cells	(p=0.0033),	in	which	increased	frequencies	were	observed	in	the	PBMC	fraction	 for	QFN	positive	 individuals	compared	 to	QFN	negative	 individuals	while	no	difference	was	observed	in	whole	blood.	Moreover,	the	effects	of	QFN	status	and	stimulation	condition	in	combination	was	 investigated.	Generally,	 no	effect	on	 the	 investigated	B-cell	 frequencies	was	observed	 (p<0.05);	however,	a	sizeable	impact	was	observed	for	a	single	population,	namely	CD19+CD21+CD23+	(T2)	B-cells	(p=0.0002).	 In	which	QFN	positive	 individuals	were	observed	to	have	 increased	cellular	 frequencies	following	TLR9a	stimulation,	compared	to	all	other	stimulatory	conditions	 in	both	QFN	positive	and	negative	individuals.	Lastly,	the	effect	of	stimulation	condition	and	sample	types	in	combination	was	investigated.	Remarkably,	a	significant	relationship	was	observed	for	all	but	one	of	the	investigated	cell	phenotypes,	specifically	CD19+CD21-CD23+	(FO)	B-cells	(p=0.1443),	demonstrating	the	prominent	role	microenvironment	 composition	 plays	 in	 manipulating	 immune	 cell	 activation	 and	 function.	 A	substantial	 increase	 in	 CD19+CD21+CD23-	 (MZ)	 B-cells	 (p=0.0000)	was	 observed	 for	 all	 stimulatory	conditions	in	whole	blood	compared	to	PBMC.	Conversely,	a	considerable	increase	in	CD19+CD21+CD23+	(T2)	 B-cells	 (p=0.0003),	 with	 enhanced	 immune	 response	 to	 TLR9a	 stimulation,	 was	 observed	 for	PBMCs	 compared	 to	 whole	 blood.	 Upon	 further	 investigation,	 it	 was	 discovered	 that	 QFN	 positive	individuals	were	solely	responsible	for	the	former	observed	response	(p=0.0034).	Equally,	increased	levels	of	CD19+CD21-CD23-	(T1)	B-cells	(p=0.0000),	with	enhanced	immune	response	to	M.tb	infection	and	higher	basal	levels	within	unstimulated	samples,	was	observed	for	PBMCs	compared	to	whole	blood	samples.
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Suppl	Table	5.2.	Fixed	effects	observed	for	of	B-cell	population	distribution.	Statistical	differences	between	culture	conditions	was	calculated	using	a	four-way	mixed	model	ANOVA.	Comparisons	within	groups	was	calculated	using	the	Fishers	LSD	post-hoc	test.	A	two-way	step-up	Benjamini	,	Krieger	and	Yekutieli	False	Discovery	rate	(FDR)	approach,	with	a	FDR	of	1%,	was	used	to	correct	for	multiple	testing.	Statistically	significant	p-values	are	highlighted	in	red.	The	adjusted	p-value	is	denoted	‘q-value’.	
Effect	 QFN	Status	
(QFN)	 Stimulation	(Stim)	 Sample	type	(Type)	 QFN*Stim	 QFN*Type	 Stim*Type	 QFN*Stim*Type	
CD19+	Cell	Population	 P-value	 q-value	 P-value	 q-value	 P-value	 q-value	 P-value	 q-value	 P-value	 q-value	 P-value	 q-value	 P-value	 q-value	CD21+CD23-	 0.24	 0.37	 0.00	 0.00	 0.03	 0.05	 0.13	 0.19	 0.20	 0.34	 0.00	 0.00	 0.12	 0.52	CD21+CD23+	 0.00	 0.00	 0.00	 0.00	 0.28	 0.26	 0.00	 0.00	 0.00	 0.00	 0.00	 0.00	 0.00	 0.00	CD21-CD23+	 0.15	 0.37	 0.01	 0.02	 0.05	 0.06	 0.10	 0.19	 0.10	 0.34	 0.14	 0.13	 0.57	 0.65	CD21-CD23-	 0.32	 0.42	 0.00	 0.00	 0.04	 0.06	 0.31	 0.34	 0.25	 0.34	 0.00	 0.00	 0.25	 0.54	CD125+FasL-	 0.31	 0.42	 0.25	 0.23	 0.07	 0.08	 0.05	 0.13	 0.23	 0.34	 0.70	 0.46	 0.21	 0.54	CD125+FasL+	 0.72	 0.74	 0.35	 0.29	 0.00	 0.00	 0.43	 0.41	 0.26	 0.34	 0.00	 0.00	 0.46	 0.62	CD125-FasL+	 0.11	 0.37	 0.00	 0.00	 0.25	 0.25	 0.00	 0.00	 0.04	 0.29	 0.18	 0.14	 0.90	 0.88	CD21+CD23-CD125+FasL-	 0.24	 0.37	 0.63	 0.46	 0.00	 0.00	 0.28	 0.33	 0.68	 0.73	 0.38	 0.28	 0.61	 0.65	CD21+CD23-CD125+FasL+	 0.21	 0.37	 0.14	 0.14	 0.02	 0.04	 0.14	 0.19	 0.14	 0.34	 0.00	 0.00	 0.11	 0.52	CD21+CD23-CD125-FasL+	 0.73	 0.74	 0.01	 0.02	 0.00	 0.00	 0.12	 0.19	 0.14	 0.34	 0.05	 0.06	 0.29	 0.55	CD21+CD23+CD125+FasL-	 0.10	 0.37	 0.01	 0.02	 0.53	 0.44	 0.05	 0.13	 0.05	 0.29	 0.04	 0.05	 0.60	 0.65	CD21+CD23+CD125+FasL+	 0.18	 0.37	 0.02	 0.03	 0.00	 0.00	 0.04	 0.13	 0.09	 0.34	 0.00	 0.00	 0.06	 0.52	CD21+CD23+CD125-FasL+	 0.22	 0.37	 0.11	 0.13	 0.03	 0.05	 0.14	 0.19	 0.35	 0.43	 0.49	 0.34	 0.22	 0.54	CD21-CD23+CD125+FasL-	 0.50	 0.61	 0.04	 0.05	 0.01	 0.03	 0.39	 0.39	 0.53	 0.61	 0.02	 0.03	 0.37	 0.62	CD21-CD23-CD125-FasL+	 0.04	 0.23	 0.00	 0.00	 0.02	 0.04	 0.00	 0.00	 0.21	 0.34	 0.12	 0.12	 0.47	 0.62	CD5+CD125+FasL-	 0.72	 0.74	 0.39	 0.30	 0.34	 0.30	 0.28	 0.33	 0.75	 0.76	 0.18	 0.14	 0.92	 0.88	CD5+CD125+FasL+	 0.84	 0.80	 0.35	 0.29	 0.09	 0.10	 0.53	 0.45	 0.25	 0.34	 0.00	 0.00	 0.42	 0.62	CD5+CD125-FasL+	 0.02	 0.17	 0.14	 0.14	 0.99	 0.78	 0.54	 0.45	 0.80	 0.76	 0.96	 0.59	 0.23	 0.54	
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3. Second	and	third	order	effects	on	Killer/FasL-expressing	B-cell	frequencies	The	effect	of	each	experimental	conditions	in	combination	on	the	killer	B-cell	levels	was	investigated	(Suppl	Table	5.2).	The	effects	of	QFN	status	and	sample	type	in	combination	on	killer	B-cell	frequencies	was	explored,	 in	which	no	significance	difference	(p>0.05)	was	observed	between	QFN	positive	and	negative	individuals	for	each	sample	type	(Suppl	Table	5.2).	These	results	illustrate	the	inconsequential	effect	 of	 QFN	 status	 and	 sample	 type	 in	 relation	 to	 one	 another	 on	 the	 induction	 of	 killer	 B-cells.	Likewise,	 the	 effects	 of	 QFN	 status	 and	 stimulation	 condition	 in	 combination	 was	 investigated.	Interestingly,	for	majority	of	the	killer	B-cell	subsets	no	effect	was	observed,	while	a	considerable	effect	was	observed	for	two	IL5Ra-FasL+	populations,	namely	CD19+IL5Ra-FasL+	(p=0.0041)	and	CD19+CD21-CD23-IL5Ra-FasL+	B-cells	(p=0.0047).	For	each	of	these	cases,	QFN	positive	individuals	were	observed	to	have	increased	cellular	frequencies	following	TLR9a	stimulation	compared	to	all	other	stimulatory	conditions	in	both	QFN	positive	and	negative	individuals.	Finally,	the	effect	of	stimulation	condition	and	sample	 types	 in	 combination	on	killer	B-cell	 frequencies	was	 examined,	 to	which	 rather	 imperative	findings	 arose.	 For	 all	 killer	 B-cell	 subsets,	 the	 frequencies	 of	 cells	 co-expressing	 IL5Ra+FasL+	were	observed	to	be	significantly	affected.	In	all	cases,	following	TLR9a	stimulation	or	H37Rv	infection,	an	increase	 in	 killer	 B-cell	 frequencies,	 specifically	 CD19+IL5Ra+FasL+	 B-cells	 (p=0.0005),	CD19+CD21+CD23-IL5Ra+FasL+	B-cells	 (p=0.0003),	 CD19+CD21+CD23+IL5Ra+FasL+	B-cells	 (p=0.0040)	and	CD19+CD5+IL5Ra+FasL+	(p=0.0009),	was	observed	compared	to	the	unstimulated	control	of	PBMC	samples,	while	a	decrease	was	observed	in	whole	blood	samples.	This	discovery	accentuates	the	point	that	 isolation	 can	 dramatically	 affect	 cell	 function,	 resulting	 in	 incongruent	 observations	 between	studies	utilizing	different	sample	types.		
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Suppl	Figure	5.8.	Gating	strategy	for	FasL-expressing	CD19+	B-cells	
*Note:	Fluorescence-minus-one	(FMO)	control	samples	were	used	to	determine	appropriate	gating	cut-off	to	increase	accuracy	of	distinguishing	between	populations
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Suppl	Figure	5.9.	Gating	strategy	for	T1,	T2,	MZ	and	FO	B-cells	
*Note:	Fluorescence-minus-one	(FMO)	control	samples	were	used	to	determine	appropriate	gating	cut-off	to	increase	accuracy	of	distinguishing	between	populations	
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Suppl	Figure	5.10.	Gating	strategy	for	CD5+CD19+	B-cells	
*Note:	Fluorescence-minus-one	(FMO)	control	samples	were	used	to	determine	appropriate	gating	cut-off	to	increase	accuracy	of	distinguishing	between	populations		
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Chapter	6:	Summary	and	Concluding	Remarks		To	gain	insight	into	the	multitude	of	processes	required	for	effective	control	and	eradication	of	M.tb,	a	comprehensive	overview	of	the	complex	immune	interactions	that	occur	within	the	host	is	necessary.	This	 includes	understanding	 the	 relative	 significance	of	 each	cell	 type	 in	determining	 the	 fate	of	TB	incidence	and	progression.	Thus	far,	an	incomplete	understanding	of	the	role	of	each	cell	type	within	TB	disease	 exists,	 attributing	 to	 the	 slow	 progress	 made	 towards	 improved	 TB	 prevention	 strategies	(Andersen,	2001).	Initial	studies	investigating	anti-TB	humoral	responses	of	B-cells	during	TB	disease	showed	enhanced	protection	to	M.tb	infection;	however,	these	responses	were	shown	to	inessential	for	successful	M.tb	 eradication	 (De	 Valliere	 et	 al.,	 2005;	 Manivannan	 et	 al.,	 2012).	 Conversely,	 recent	findings	have	 suggested	 a	 clinically	 relevant	 role	 of	B-cells	 during	 the	 early	 stages	 of	M.tb	 infection	(Achkar	et	al.,	2015;	Bénard	et	al.,	2018;	Du	Plessis	et	al.,	2016;	Joosten	et	al.,	2016;	Rao	et	al.,	2015).	Researchers	 have	 since	 discovered	 several	 non-humoral	 functions	 of	 B-cells	 whose	 incidence	 and	influence	during	TB	disease	remain	ill	defined.	Characterization	of	various	B-cell	subtypes,	such	as	Bregs	or	killer	B-cells,	presumed	to	be	responsible	for	these	non-humoral	responses	have	been	well	examined	within	autoimmunity	(Bao	and	Cao,	2014;	De	Maria	and	Testi,	1998;	Sharpe	et	al.,	2007;	Vincent	et	al.,	2013),	cancer	(Lee-Chang	et	al.,	2013;	Mor	et	al.,	2000;	Schwartz	et	al.,	2016;	Shao	et	al.,	2014)	and	transplantation	 (Adams	 and	 Newell,	 2012;	 Chesneau	 et	 al.,	 2013;	 Firl	 et	 al.,	 2017).	 However,	 no	conclusive	discoveries	as	to	the	physiological	relevance	of	these	B-cell	subtypes	during	TB	disease	have	been	made.	This	emerging	evidence	led	us	to	think	that	these	B-cell	subsets,	particularly	killer	B-cells,	may	have	a	vital	role	during	M.tb	infection.	Hence,	the	purpose	of	this	research	project	was	to	investigate	the	potential	role	of	B-cells	in	the	defense	against	M.tb.	As	previously	alluded	to,	cell	types	capable	of	modulating	 the	 function	 of	 T-cells	 and	 macrophages	 may	 contribute	 substantially	 to	 the	 disease	incidence	and	progression.			We	hypothesize	that	B-cells	possess	the	ability	to	regulate	T-cell	function	either	through	direct	cell-cell	interaction	or	indirectly	through	the	secretion	of	various	soluble	molecules.	In	accordance,	this	project	aimed	to	study	the	interaction	between	B-	and	T-cells	in	the	context	of	M.tb	infection	to	determine	the	potential	 immunomodulatory	 role	 B-cells	 may	 play	 during	 TB	 disease.	 Studies	 have	 inferred	 the	importance	 of	 several	 T-cell	 populations	 during	 TB	 disease,	 in	 which	 some	 populations	 have	 been	shown	to	correlate	with	protection	(Derrick	et	al.,	2011;	Lindenstrøm	et	al.,	2009)	while	other	have	been	found	to	correlated	with	poor	disease	prognosis	(Caccamo	et	al.,	2010;	Forbes	et	al.,	2008).	Therefore,	the	 induction	 of	 specific	 T-cell	 populations	 by	 B-cells	 following	 M.tb	 challenge	 could	 ultimately	determine	the	fate	of	infection.	To	achieve	our	aims,	we	evaluated	the	effect	of	pre-stimulated	B-cells	on	T-cell	population	distribution	and	cytokine	secretion,	and	provided	insight	into	the	relative	contribute	of	these	cells	to	the	host	defense	in	combating	M.tb	infection.	In	line	with	our	hypothesis,	B-cells	were	observed	to	influence	T-cell	behavior	through	modulation	of	Treg	and	TE	phenotypic	frequencies,	as	well	
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as	via	alterations	within	the	cytokine	milieu	of	CD4+	and	CD8+	T-cells.	These	results	are	in	agreement	with	findings	within	literature,	in	which	Bregs	have	been	shown	to	modulate	MDSC	and	Treg	phenotypic	frequencies	(Carter	et	al.,	2012;	Flores-Borja	et	al.,	2013;	Kessel	et	al.,	2012),	illustrating	the	potential	immune	 modulatory	 capability	 of	 B-cells	 during	 health	 and	 disease.	 This	 emphasizes	 the	 need	 for	further	 investigation	 as	 to	 the	 potential	 role	 of	 cell	 types	 previously	 through	 to	 have	 minimal	involvement	in	protective	anti-TB	immunity.	Furthermore,	these	findings	underscore	the	prospect	that	B-cells	 play	 a	 fundamental	 role	 in	 initiating	 and	 guiding	 the	 immune	 response	 against	M.tb.	 The	physiological	 implications	 of	 this	 includes	 the	 possibility	 for	 host	 directed	 therapy	 targeting	 B-cell	function	to	induce	protective	CD4+	and	CD8+	T-cell	responses,	as	well	as	the	development	of	improved	prevention	 therapies	 that	 target	 protective	 humoral	 and	 non-humoral	 B-cells	 responses	 to	 afford	superior	 protection	 from	M.tb	 infection.	 Nevertheless,	 before	 any	 definite	 inference	 regarding	 the	efficiency	of	B-cell	 to	modulate	T-cell	 function	can	be	made,	 further	studies	aimed	at	elucidating	the	intricate	interaction	between	B-	and	T-cells	is	required.	Deeper	insight	into	the	relationship	amongst	B-cell	activation	and	T-cell	priming	regarding	the	mechanisms	involved	in	intercellular	signaling	and	the	extend	of	these	responses	are	crucial	to	understanding	how	to	target	of	B-cells	for	immunotherapy	and	why	this	would	benefit	the	host	against	M.tb-exposure.		Apart	 from	 understanding	 of	 this	 intercommunication	 between	B-	 and	 T-cells	 in	 the	 context	 of	 TB,	concerns	with	the	translation	of	this	interaction	and	response	in	whole	organism	ensued.	Isolated	cell	studies	provide	valuable	insight	into	the	various	biological	mechanisms	implemented	by	cells	to	elicit	effector	 functions	 in	 response	 to	 a	 particular	 stimulus	 devoid	 of	 external	 factors.	 However,	 partial	understanding	of	the	complex	intercellular	interactions	that	occur	within	in	vivo,	due	to	the	presence	of	additional	 cell	 types,	 may	 results	 in	 artefactual	 observations	 and	 imprecise	 analyses	 regarding	 the	function	 of	 a	 cell	 population	 during	 a	 particular	 immune	 condition.	 We	 hypothesize	 that	microenvironment	 complexity	 (i.e.	 the	 degree	 of	 cellular	 isolation)	 affects	 B-cell	 function,	 thereby	impacting	the	measured	immune	responses.	Consequently,	this	project	aimed	to	determine	the	effects	of	microenvironment	complexity	on	cell	function,	with	an	emphasis	on	B-cells,	and	the	influence	this	may	 have	 on	 the	 prospect	 of	 isolated	 in	 vitro	 cell	 studies	 to	 reflect	 accurate	 events	 within	 whole	organism.	 Additionally,	 the	 effect	 of	 cell	 isolation	 on	 the	 functional	 capacity	 of	 B-cells	 during	M.tb	infection	 was	 investigated,	 to	 determine	 the	 significance	 of	 employment	 of	 isolated	 cell	 culture	techniques	 in	 studies	 inferring	 the	 role	 of	 this	 cell	 type	 during	TB	disease.	 Presently,	 observational	findings	 inferring	 the	 physiological	 role	 of	 these	 cells	 during	 TB	disease	 utilize	 isolated	 cell	 culture	techniques	(Du	Plessis	et	al.,	2016;	van	Rensburg	and	Loxton,	2018).	Inherently,	the	results	from	such	studies	 form	 the	 foundation	 upon	which	 all	 assumptions	 regarding	 the	 importance	 of	 this	 cell	 type	during	disease	are	based.	These	deductions	in	turn	affects	the	decisions	relating	to	the	development	of	new	TB	drugs,	host-directed	therapies	and	TB	vaccines	in	terms	of	the	possible	cell	types	for	targeting.			
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Therefore,	we	evaluated	the	immune	response	of	B-cells	within	various	compartments	of	isolation	(e.g.	whole	blood,	PBMC	fraction	and	pure	B-cells)	following	antigenic	stimulation,	to	determine	whether	the	sample	 type	 had	 an	 effect	 on	 the	 resulting	 cellular	 responses.	 Evaluation	 of	 the	 resulting	immunoglobulin	 profiles	 of	 B-cells	 following	 antigenic	 stimulation	 (including	 M.tb	 infection)	 was	performed.	 To	 our	 knowledge,	 B-cells	 are	 the	 only	 immune	 cell	 type	 capable	 of	 immunoglobulin	secretion,	 thus	 immunoglobulin	 secretion	 was	 regarded	 as	 a	 direct	 measure	 of	 the	 B-cell	 function.	Additionally,	B-cell	phenotypic	frequencies	were	investigated	to	conclude	the	effect	of	sample	type	on	B-cell	development.	In	line	with	our	hypothesis,	microenvironment	complexity	was	found	to	substantial	influence	 immune	 cell	 function,	 in	 which	 impaired	 humoral	 B-cell	 function	 and	 altered	 B-cell	development	 was	 observed	 following	 successive	 isolation	 procedures.	 This	 was	 illustrated	 by	 a	hampered	ability	of	B-cells	to	secrete	various	immunoglobulin	isotypes,	namely	IgA,	IgG1	and	IgG3,	in	isolation	 -	 likely	 due	 to	 a	 lack	 of	 co-stimulatory	 signals	 from	 additional	 cell	 types.	 Furthermore,	conceded	mature	B-cell	development	following	cellular	isolation	was	observed,	illustrated	by	a	decline	in	MZ	B-cell	 frequencies	 and	 an	 increase	 in	 T2	B-cell	 levels.	 Similarly,	 dysregulation	 of	 killer	 B-cell	induction,	 shown,	 in	which	 significant	 increases	 in	 observed	 cellular	 levels,	 following	 isolation	was	found;	emphasizing	the	impact	isolation	had	on	the	capability	of	B-cells	to	elicit	an	efficient	immune	response.	In	light	of	the	above,	caution	should	be	taken	when	interoperating	observations	acquired	from	cell	isolation	studies,	as	the	in	vitro	microenvironment	may	have	considerably	influenced	the	observed	findings.	Furthermore,	these	results	accentuate	the	possibility	that	B-cells	play	a	more	prominent	role	in	anti-TB	immunity	than	currently	assumed,	and	further	enquiry	as	to	the	function	of	these	cells	during	TB	disease	is	suggested.		
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Project	limitations	and	future	research	prospective	A	short	coming	of	this	project	included	the	small	sample	sizes	used	within	each	of	the	studies.	Moreover,	all	participants	were	recruited	within	 the	same	general	demographic	area.	These	 factors	could	have	contributed	 to	 artefactual	 observations	 regarding	 the	 significance	 of	 a	 particular	 experimental	condition.	As	 such,	 assumptions	made	 from	 this	 pilot	 data	 should	 be	 interpreted	with	 this	 in	mind.	Moreover,	the	absence	of	an	active	TB	cohort	as	well	as	other	lung	disease	(OLD)	controls	within	the	co-culture	pilot	study	represents	a	drawback,	as	our	observations	were	based	solely	on	data	from	healthy	QFN	positive	and	negative	individuals.		Participants	within	our	study	are	recruited	from	highly	endemic	TB	areas	(World	Health	Organization,	2017),	where	it	is	suggested	that	more	than	50%	of	the	population	are	 exposed	 to	M.tb	 challenged	by	 the	 time	 they	 reach	adolescence.	However,	 only	10%	of	 exposed	individuals	 go	 on	 to	 develop	 active	 disease,	 underscoring	 the	 ability	 of	 their	 immune	 system	 to	overcome	infection.	In	the	current	context,	understanding	the	role	of	B-cells	during	healthy	conditions	(this	includes	M.tb-exposed	individuals)	are	more	suited	to	our	research	questions	as	it	provides	the	opportunity	to	study	cellular	responses	essential	for	the	successful	combat	of	M.tb	infection.	As	such,	the	applicability	of	these	investigated	physiological	events	is	assumed	during	TB	disease,	rather	than	authenticated.	Consequently,	these	results	should	be	regarded	as	purely	preliminary,	highlighting	the	need	for	more	in-depth	analysis	of	the	function	of	B-cells	during	M.tb	challenge	during	different	disease	states.	 Prospective	 studies	 of	 active	 TB	 disease	 cohorts	 should	 increase	 the	 sample	 size	 before	 any	conclusions	regarding	the	relative	significance	of	this	intercellular	interaction	as	a	potential	target	for	innovative	anti-TB	host	therapies	can	be	made.	Additionally,	investigation	as	to	the	function	and	inter-communication	of	the	investigated	cell	types	at	the	site	of	disease,	rather	than	in	the	periphery,	may	provide	valuable	pertaining	to	the	primary	anti-TB	immune	mechanisms	responsible	for	successful	M.tb	control	and/or	eradication.			Recently,	the	incidence	of	killer	B-cell	during	TB	disease	had	been	accentuated	(Lundy,	2009;	Lundy	et	al.,	 2015;	 van	 Rensburg	 and	 Loxton,	 2018;	 van	 Rensburg	 et	 al.,	 2017;	 Van	 Rensburg	 et	 al.,	 2017).	However,	the	function	of	these	cells	along	with	possible	mechanisms	they	employ	to	elicit	the	suggested	protective	immune	responses	during	M.tb	infection	remain	undefined.	Thus,	a	practical	future	endeavor	would	involve	full	characterization	of	these	naturally	occurring	killer	B-cells	using	a	variety	of	advance	techniques,	including	single-cell	FACS	sorting,	whole	genome	sequencing,	receptor	expression	analysis,	protein	 expression	 analysis	 and	 metabolic	 pathway	 mapping.	 This	 would	 improve	 the	 basic	understanding	we	have	of	killer	B-cell	function	and	the	physiological	impact	these	cells	may	have	on	anti-TB	immune	responses.					
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Moreover,	 limited	 research	 investigating	 the	 role	 of	 killer	 B-cells	 in	 vivo	 has	 occurred.	 The	 results	obtained	 within	 this	 study	 highlighted	 the	 significant	 effect	 microenvironment	 complexity	 has	 on	cellular	function.	Thus,	investigating	the	protective	capacity	of	regulatory	killer	B	in	vivo	may	provide	vital	 information	 as	 to	 the	 physiological	 relevance	 of	 this	 cell	 type	 in	 anti-TB	 immunity	 that	would	otherwise	be	masked/absent	during	in	vitro	culture.		This	can	be	achieved	by	induction	of	killer	B-cells	prior	and	preceding	M.tb	infection	in	murine	models,	as	well	as	pre-	and	post-	treatment.	Such	enquiry	will	 provide	 insight	 into	 efficacy	 of	 this	 cell	 type	 to	 prevent,	 control	 and	 eliminate	M.tb	 through	modulation	 of	 adaptive	 immune	 responses,	 enhancing	 host-derived	 protection	 against	 TB	 infection.	Importantly,	evaluation	of	several	sample	types,	including	the	blood,	lung	tissue	and	lymphatic	system	will	provide	a	“full”	picture	of	the	augmented	immune	response	that	occur	prior	to	establishment	of	disease	and	following	successful	infection	control.	This	“complete”	study	approach	will	provide	valuable	insight	into	the	complex	communication	between	various	systems	within	the	body	during	TB	disease,	as	well	 as	uncover	 alterations	 in	 the	 immune	profile	within	 a	 specific	 sample	 type	 that	would	 have	otherwise	gone	unnoticed	using	an	isolated	experimental	approach.	 	
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